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 1 
Summary 
 
G protein-coupled receptors (GPCRs) belong to a group of alpha-helical transmembrane 
proteins (TMPs) that are constantly involved in triggering vital biochemical responses. 
These receptors exist in all eukaryotic organisms, very diverse in nature and especially in 
humans, almost 800 varieties of genes were identified that code for these TMPs. GPCRs 
totally constitute only 1% of the total cellular proteins, but they mediate many vital 
functions of immense pharmacological significance. Almost 50% of the drugs on the 
market and in research target these receptors with therapeutic implication against many 
diseases. The major role of GPCRs is to broadcast a signal across the cellular membrane. 
GPCRs function by receiving an extracellular signal from ions, photons, small organic 
molecules, peptides, and entire proteins (for example hormones) resulting in 
conformational changes that affects the interacting G-proteins inside the cells. After 
receiving the signal G-proteins dissociate from the GPCRs, split into two subunits that 
trigger a cascade of downstream signaling events. It is important to note that the 
fundamental event triggered by ligand binding is a conformational change, which is 
exploited by many drugs. The relationship between structure and biological action is of 
great interest to tackle existing diseases or disorders because it allows designing drugs 
that will interfere with GPCR signaling. 
 
In humans, approximately 15% of all genes code for GPCRs, but the function of most of 
them has not been discovered yet. For those the function is known, structural information 
is limited. Even with the present advanced technologies, characterizing these receptors at 
atomic-resolution is extremely challenging because of some of their properties such as 
their hydrophobic nature, low natural abundance, high flexibility and the lack of finding 
an ideal membrane mimic for them.  
 
In my first chapter, I introduce the properties of these receptors and subsequently 
elaborate on the recent developments in trying to overcome low expression levels by 
using heterologous strains. I conclude the chapter by discussing the possibility to use 
different membrane mimetics that are suitable for reconstituting TMPs for biophysical 
analysis. 
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In chapter 2 and 3, I present a divide-and-conquer approach towards solution structures of 
G-protein coupled receptors. Therein the human Y4 receptor is dissected into 2-3 
transmembrane helix fragments, which are individually studied by solution NMR. I 
systematically compare various aspects of biosynthetic routes for expression of the 
fragments in E. coli and discuss purification strategies. In particular, I compare the 
production of the TM fragments in inclusion bodies using the insoluble ΔTrp leader 
sequence, with the membrane-directed expression using Mistic as the fusion partner. 
Moreover, I have developed methods for enzymatic cleavage to liberate the protein of 
interest from the fusion partner. The direct expression of 2 and 3-TM fragments into 
inclusion bodies are successful for the TMP discussed in the third chapter.  
 
Biophysical evaluation of membrane proteins using solution NMR spectroscopy 
technique has recently advanced and in the fourth chapter, I describe the expression, 
purification and subsequent NMR-spectroscopic characterization of all the C-terminal 
NPY4R fragments. I also discuss the potential in transferring chemical shifts onto larger 
fragments based on common NOESY correlations. I conclude the chapter discussing 
possible explanations for the missing or unassigned peaks.  
 
Finally, in chapter 5 I describe one particular membrane environment developed by 
Sligar and colleagues that mimics native membranes very closely. These membrane 
mimetic entities are called nanodiscs, and are made up of discoidal phospholipid bilayers 
(~ 10-12 nm large), stabilized by the enclosure with an amphipathic helical membrane 
scaffold protein (MSP). A TMP incorporated into nanodiscs is claimed to remain more 
stable and possibly mono-disperse with the ability to access both sides of the lipid bilayer. 
These properties may allow performing structural, biophysical and biochemical 
investigations in a more effective and simpler way. Nanodiscs mimic near-native 
environments, but their large particle size complicates the spectral analysis of TMPs by 
solution NMR. Recently this disadvantage was tried to overcome by developing smaller 
nanodiscs, which are obtained by truncating the MSP. However, applicability to solution 
NMR needs to be demonstrated for multi-spanning TMPs. In the last chapter, I describe 
the methodology for incorporating a 3-TM fragment (TM567) of NPY4R into nanodiscs 
of smaller diameter.  
 3 
Zusammenfassung 
 
G-Protein-gekoppelte Rezeptoren (GPCRs) zählen zu einer Gruppe von alpha-helikalen 
transmembran Proteinen (TMPs), die bei unzähligen biochemischen Prozessen der 
Signalübertragung involviert sind. Diese Rezeptoren kommen in sämtlichen 
eukaryotischen Organismen vor und weisen in der Natur und vor allem im menschlichen 
Körper, wo knapp 800 verschiedene Genarten identifiziert wurden, die für TMPs 
kodieren, eine sehr hohe Diversität auf. Obwohl GPCRs nur rund 1% der Zellproteine 
ausmachen, sind sie an vielzähligen Signalübertragungsvorgängen beteiligt und somit 
von grossem pharmakologischen Interesse. Fast 50% aller am Markt erhältlichen 
Medikamente wirken auf diese Rezeptoren, die als therapeutisches Ziel bei zahlreichen 
Krankheiten gelten. Die Hauptaufgabe von GPCRs ist es, Signale durch die Zellmembran 
zu übertragen. GPCRs erhalten dabei einen extrazellulären Reiz von Ionen, Photonen, 
kleinen organischen Molekülen, Peptiden und sogar ganzen Proteinen (wie zum Beispiel 
Hormonen). Dies führt zu einer Konformationsänderung der Rezeptoren, welche 
daraufhin wiederum mit G-Proteinen im Inneren der Zelle in Wechselwirkung treten 
können. Nach dieser Signalübertragung dissoziieren die G-Proteine vom Rezeptor, 
spalten sich in zwei Untereinheiten und lösen weiterführende Signalkaskaden aus. 
Wichtig zu erwähnen wäre hierbei, dass die meisten Medikamente auf die initiale 
Bindung des Liganden und die einhergehende Konformationsänderung abzielen. Ein 
besseres Verständnis der Beziehung zwischen Struktur und biologischer Funktion ist 
daher von höchstem Interesse, um gezielt Medikamente herzustellen, die GPCR-
Signalübertragung beeinträchtigen. 
 
Im menschlichen Körper kodieren rund 15% aller Gene für GPCRs, wobei die Funktion 
der meisten Rezeptoren noch unerforscht ist. Ausserdem sind selbst für GPCRs mit 
bekannten Funktionen  strukturelle Informationen limitiert, da sich ihre Charakterisierung 
selbst mit modernen Technologien als äusserst anspruchsvoll darstellt. Die Ursache 
hierfür kann in den Eigenschaften von GPCRs, wie ihre Hydrophobizität, ihr geringes 
natürliches Vorkommen, ihre hohe Flexibilität und die Schwierigkeit geeignete 
Membranmimetika zu identifizieren, gefunden werden. 
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Im ersten Kapitel stelle ich die generellen Eigenschaften dieser Rezeptoren sowie die 
neuesten Entwicklungen in Bezug auf die Optimierung der Expressionsausbeuten mit 
heterologen Expressionsstämmen vor. Ausserdem gehe ich auf die Möglichkeiten ein, 
passende Membranmimetika zu finden, um TMPs zu rekonstruieren und biophysikalisch 
zu analysieren. 
 
In Kapitel 2 und 3 stelle ich einen 'Divide-and-Conquer' Ansatz vor, um Strukturen G-
Protein-gekoppelte Rezeptoren in Lösung zu bestimmen. Dabei wird der menschliche Y4 
Rezeptor in 2-3 transmembran grosse Fragmente aufgeteilt, die dann individuell mittels 
NMR Spektroskopie untersucht werden können. Hierbei untersuche ich systematisch 
verschiedene Aspekte der Expression der Fragmente in E. coli sowie diverse 
Proteinaufreinigungsstrategien. Im Besonderen vergleiche ich hier die Produktion der 
Fragmente in Einschlusskörpern mit der unlöslichen ΔTrp leader Sequenz als 
Fusionsprotein oder mit Mistic, welches das Expressionsprodukt direkt in die Membran 
dirigiert. Ausserdem stelle ich Methoden vor, die es ermöglichen die Fusionsproteine 
enzymatisch von den Fragmenten abzuspalten. Die direkte Expression von 2- bzw. 3-TM 
Fragmenten in Einschlusskörpern diskutiere ich im dritten Kapitel. 
 
Die biophysikalische Analyse von Membranproteinen mittels Lösungs-NMR 
Spektroskopie ist in letzter Zeit sehr stark fortgeschritten, und im vierten Kapitel 
beschreibe ich Expression, Aufreinigung und anschließende NMR spektroskopische 
Charakterisierung aller C-terminalen NPY4R Fragmente. Ausserdem diskutiere ich die 
Möglichkeit, mit Hilfe von gemeinsamen NOESY Korrelationen, chemische 
Verschiebungen von kleineren auf grössere Fragmente zu übertragen. Am Ende des 
Kapitels behandle ich mögliche Erklärungen für fehlende oder nicht zugeordnete Peaks. 
 
In Kapitel 5 beschreibe ich ein spezielles von Sligar und Kollegen entwickeltes 
Membranmimetikum genauer, das natürlichen Membranumgebungen sehr ähnlich ist. 
Diese sogenannten Nanodiscs sind diskoidale Phospholipid-Doppelschichten mit einer 
Grösse von ungefähr 10-12 nm, die durch ein amphipathisches helikales Gürtelprotein 
(membrane scaffold protein - MSP) stabilisiert werden. In Nanodiscs eingebaute TMPs 
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sind somit wahrscheinlich stabiler, vermutlich monodispers und von beiden Seiten der 
Lipid-Doppelschicht zugänglich. Diese Eigenschaften könnten es erlauben, biochemische 
und biophysikalische Untersuchungen einfacher und effektiver durchzuführen. Obwohl 
Nanodiscs die natürliche Membranumgebung sehr gut imitieren, bedeutet deren 
erhebliche Partikelgrösse ein nicht triviales Problem bei der Lösungs-NMR 
spektroskopischen Untersuchungen der TMPs. In letzter Zeit wurde daher versucht, durch 
die Verkürzung von MSP kleinere Nanodiscs herzustellen. Die Anwendbarkeit dieser 
kleineren Nanodiscs für NMR spektroskopische Untersuchungen von mehreren 
Transmembranhelices enthaltenden TMPs muss jedoch noch demonstriert werden. Im 
letzten Kapitel beschreibe ich daher die Methodik zur Insertion eines 3-TM grossen 
Fragments (TM567) von NPY4R in Nanodiscs mit kleinerem Durchmesser. 
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Chapter I: Heterologous Expression Systems for Eukaryotic Transmembrane 
Proteins (TMPs) and their Reconstitution into Membrane Mimetics 
 
1. Introduction 
Transmembrane Proteins (TMPs) are considered to perform a diverse range of crucial 
biological functions and thus are of significant pharmacological importance. TMPs 
comprise only 1% of the total cellular proteins but pharmacologically TMPs are the 
targets for approximately 50% of drugs in the market and in research1, 2.  Structural 
characteristics of alpha-helical (as in contrast to beta-barrel TMPs) TMPs resemble a 
single transmembrane helix or a bundle of transmembrane helices existing independently 
or interacting with other partners within the host cell membrane environment. TMPs act 
as intermediary signaling networks by interacting with broad range of extracellular 
ligands and subsequently undergoing conformational changes that generate wide variety 
of stimuli directing intracellular responses. Thus from a human curiosity point of view, it 
is obvious to conquer their structural implications for understanding biological 
mechanism3, 4. In both Prokaryotes and Eukaryotes, approximately 25% of all genes code 
for TMPs and especially in humans 15% of these TMPs is G-protein coupled receptors 
(GPCRs) 2, 5. Out of the vast majority of TMPs identified, function for most of them has 
not yet been assigned and for those the function has been assigned they lack high-
resolution structural information. It shouldn’t be construed that the minimum availability 
of high-resolution structures of TMPs meant lack of efforts by the scientific community 
but it’s because of the tremendous challenges displayed by their hydrophobic nature, low 
natural abundance, high flexibility and the lack of an ideal membrane setup. 
 
Again from all the issues mentioned above for studying TMPs in detail, especially 2 of 
them are very critical: Obtaining sufficient quantities and selecting an ideal membrane 
mimetic. Thus in this chapter, I shall address the progress in troubleshooting 
developments or the alternatives available in overcoming the above 2 critical challenges. 
 
2. Recombinant expression of proteins: After the development of recombinant 
technology in the 1960’s, in vitro studies on all types of proteins have drastically 
increased and there is a surge on the number of crystal structures being deposited into the 
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PDB. But the number of entries for TMPs compared to soluble proteins is insignificant 
because of the unavailability of a perfect expression system that can deliver sufficient 
quantities. However, during the course of exploring new expression systems or new 
methodologies/procedures for expressing TMPs, many host systems have come up with 
distinctive characteristics solving the problem of ‘protein yields’ to a promising extent 
(Fig 1). 
 
Figure 1. Development progress of different TMP expression systems. Well-known TMP 
expression systems are compared with regards to their emerging applications for protein 
expression (yellow), initial applications to TMP production (light green), improvement 
for preparative-scale TMP production (dark green) and first appearance of TMP 
structures (blue)6. 
 
These host systems should be amenable for large-scale production resulting in at least 
milligram quantities of purified, homogenous TMPs for high-resolution structure 
determination (X-ray, NMR or EM). A heterologous system chosen to express TMPs 
again has certain limitations7 and some of them are: Toxicity to the host, low-levels of 
expression, short half-lives before degrading8, failure to produce properly folded states 
and lack of certain post-translational modifications (Fig 2).  
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Fig 2. Glycosylation of TMPs when expressed in different hosts9. In E.coli, N-
Glycosylation of TMPs is completely absent, while in mammalian cells TMPs are 
completely glycosylated.  
 
Recombinant protein overexpression requires 3 crucial elements: Suitable vector, 
expression host and ideal expression conditions (adding inducer at the correct cell 
density, inducer concentration and post-induction temperature). Mix and match of the 
suitable above combinations maximize the quantity and quality of the protein. In any 
experimental setup for the overexpression of TMPs in a heterologous host, it’s difficult to 
predict a standard combination because of the diverse nature of TMPs having distinct 
physico-chemical properties. Even after overexpression of TMPs, it’s difficult to predict 
if they can be purified or if they are in the active state or even if they are suitable for 
high-resolution (X-ray, NMR) structure determination. Thus for a better end result, it’s 
always good to test diverse heterologous systems. In this chapter the focus is mainly on 4 
aspects:  
1. Recent techniques developed for high-throughput cloning strategies  
2. E.coli as expression system  
3. Heterologous expression systems other than E.coli for TMP overexpression and 
purification  
4. Reconstitution of purified TMPs in an ideal membrane mimetic. 
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3. Cloning Strategies: 
The first step when overexpressing TMPs in a heterologous system is cloning. Traditional 
cloning of the gene of interest (GOI) using restriction enzymes and ligase into multiple 
expression vectors is time consuming. Thus, alternative cloning strategies have come up 
in the last few years that allow for quick cloning of hundreds of genes generating 
multiple constructs simultaneously10. Some of these cloning technologies are: Gateway 
cloning, Creator and the fragment exchange (FX) cloning11-16. These cloning strategies 
also take into account addition of various fusion tags that could be effective in 
overexpression, folding and purification. Fusion tags can be placed at either the N- or the 
C-terminus of a target protein depending on the purpose it serves and most often it is 
difficult to know in advance, but can be determined experimentally both the position and 
the type of fusion.  
 
Once the design of the expression vector is ready, overexpression of the TMPs can be 
tested in suitable prokaryotic and eukaryotic systems, keeping in mind the pros and cons 
of each of them towards functional protein expression12, 17-22.  
Prokaryotic expression systems are: 
a) Escherichia Coli 
b) Lactococcus lactis 
c) Rhodobacter sphaeroides 
 
Eukaryotic expression systems are: 
d) Yeast 
e) Insect cells 
f) Mammalian cells 
 
4. Prokaryotic expression systems 
 
4.1.  Escherichia Coli 
To date, E.coli is the most extensively used expression host for producing recombinant 
proteins. It’s ideal characteristics such as ease of use, low cost and short generation times 
resulted in expressing almost all types of recombinant soluble and TMPs. However, 
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expression of TMPs in E.coli presents many disadvantages: Many TMPs such as GPCRs 
often are not expressed to sufficient quantities: In most cases, expressed TMPs are not 
properly folded or result in formation of insoluble aggregates such as inclusion bodies, or 
they lack post-translational modifications. Since the E.coli system has been well-
characterized, recent developments showed significant improvement in TMP 
expression23, 24. Strains such as C43, C41 & Lemo 21 emerged as tolerant strains for toxic 
TMPs in E.coli7, 25. Also, TMP production can be enhanced by incorporation of various 
fusion tags such as GFP26, MBP, GST, NusA6, ΔTrp or Mistic27, etc. and their influence 
on TMP expression is as follows:  
 
Fusion tag Size Function in E.coli cells 
His(6-10) - tag 1 kDa Most common affinity purification tag 
Maltose binding protein (MBP) 43 kDa Enhances solubility and folding 
N-utilization substance (NusA) 54.8 kDa Enhances solubility and folding 
Thioredoxin (Trx) 12 kDa 
Enhances solubility and avoids 
inclusion body formation 
IgG domain B1 of streptococcus 
Protein G (GB1) 
6 kDa 
Enhances solubility and usually used in 
protein preparations for NMR 
Trp leader sequence (ΔTrp) 14 kDa Diverts TMPs into inclusion bodies 
GST 26 kDa 
Enhances solubility and acts as a 
purification tag 
Small ubiquitin modifier (SUMO) ~11 kDa Enhances solubility and stability 
Mistic 13 kDa 
Enhances overexpression and solubility 
of TMPs. 
Ketosteroidoisomerase (KSI) ~15 kDa Diverts TMPs into inclusion bodies 
 
A special emphasis shall be put on Mistic, a 13 kDa protein originally from Bacillus 
subtilis. Mistic, when produced recombinantly in E.coli, was postulated to directly 
associate with the inner membrane without the need for recognition by the Sec translocon 
machinery. Mistic’s unusual nature to spontaneously associate with the membrane 
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facilitated successful insertion of various TMPs into E.coli membranes when fused to 
Mistic as an N-terminal fusion tag27-31.  
 
Tags might not be suitable or even necessary for TMP expression in certain strains.  
During the reconstitution process, some of the fusion tags can interfere with the active 
site that can result in altered structure and function of the target protein. Thus cleavage 
recognition sites (enzymatic or chemical) can be engineered into the expression construct 
to cleave the fusion tags at different stages of purification. Few commonly used 
recognition sites are: 
Protease/chemical 
recognition site 
Recognition 
Sequence 
Enterokinase DDDDL| 
Factor Xa I D/E GR| 
TEV protease ENLYFQ|G 
C3 protease LEVLFQ|GP 
Thrombin LVPR|GS 
CNBr X M|X 
Signal peptidase AXA| 
 
 
4.2 Lactococcus lactis 
L. lactis is a non-invasive, non-pathogenic, Gram-positive bacterium, which is similar to 
food-grade lactic acid fermenting bacteria. Because of the wide-ranging developments in 
genetic engineering tools, L. lactis is also extensively used for the large-scale production 
of recombinant TMPs32. TMP expression in L. lactis is done with the Nisin-Inducible 
Controlled gene Expression (NICE) system where Nisin, an antimicrobial peptide, acts as 
an inducer for the genes positioned under the control of promoter PnisA. Several 
eukaryotic TMPs have been expressed using the NICE system in L. lactis33-35. The main 
advantage of using L. lactis over E. coli is that the TMPs expressed were always directed 
into membranes and not into inclusion bodies36, 37. The other advantage is the presence of 
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a single membrane that can help in performing activity studies by directing ligands or 
inhibitors on the whole cells.  
 
 
4.3 Rhodobacter sphaeroides 
 R. sphaeroides belongs to the class of purple, non-sulphur photosynthetic bacteria. The 
main advantage of this expression system is the presence of an increased membrane 
surface area, which is a major limitation for most of the hosts. It consists of 
chromatophores in the photosynthetic apparatus made up of the pigment-protein complex 
(light-harvesting complex and reaction centers), situated in the projections of the 
cytoplasmic membrane. These bacteria synthesize large amounts of photosystems on 
exposure to light and/or reduced oxygen availability resulting in the production of more 
chromatophores that leads to the increase in membrane surface availability38. This 
property of increase in intracytoplasmic membrane surface can be exploited for the 
production of TMPs, which was already being implemented39.  
 
5. Eukaryotic expression systems 
 
 5.1 Yeast 
In general, yeast has numerous advantages as host system for the production of 
eukaryotic TMPs. Similar to bacteria, yeast systems are well characterized, can be 
inexpensively cultured in large volumes, their plasmids can be straightforwardly 
genetically engineered but unlike bacteria, yeast systems have an additional advantage of 
possessing protein processing machinery for adding post-translational modifications 
(PTMs) to the expressed proteins that are similarly observed in mammalian cells. Many 
yeast systems have been tested and engineered for eukaryotic protein production but 
Saccharomyces cerevisiae and Pichia pastoris are the two main yeast systems, which are 
widely used for TMP production. Yeast system S. cerevisiae is the most extensively 
characterized strain for TMP production and in general has vast variety of sub-strains to 
work with, whereas the yeast system P. pastoris mediates a stringently coordinated 
inducible expression system18. From an NMR point of view it is worth to mention that 
perdeuterated proteins can be produced in Pichia Pastoris. 
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5.1.1  P. pastoris: It has the capability to utilize methanol as an exclusive carbon source. 
Methanol metabolism occurs in peroxisomes and the first reaction is the conversion of 
methanol to formaldehyde and hydrogen peroxide by alcohol oxidase40. Thus in the 
presence of methanol, peroxisomes significantly enlarge in size due to high expression 
levels of enzymes that are necessary for complete methanol metabolism (Fig 3). P. 
pastoris mainly expresses 2 alcohol oxidase genes (AOX1 & AOX2) and they assemble 
as ~600 kDa homo-octamers. While 10% of total oxidase activity is from AOX2, the 
majority is from AOX1. Thus expression levels of AOX1 increase from trace amounts to 
~30% of total intracellular protein in presence of methanol. Thus the methanol-inducible 
AOX1 promoter is tightly regulated and is an ideal system for heterologous protein 
expression. Exploiting the above concept, P. pastoris expression vectors were designed 
featuring the AOX1 promoter for producing many heterologous soluble and TMPs 
including GPCRs.  In one such high-throughput effort, 100 different types of mammalian 
GPCRs were expressed in P. pastoris, of which 52 were investigated for ligand binding 
and 20 were screened for high expression yields41. 
 
Figure 3. Electron micrographs showing morphological transformations in P. pastoris 
before (A) and after (B) methanol induced β2 adrenergic receptor protein expression41. 
(A) Medium without methanol. (B) Same clone as in (A), but induced with methanol. N - 
nucleus; M - mitochondria; P - prominent peroxisome following elevated H2O2 during 
methanol metabolism; ER - endoplasmic reticulum with expressed receptor. 
 
5.1.2  S. cerevisiae: This is the first yeast system used for the expression of recombinant 
proteins. The most frequently used promoters are GAL1 and GAL10, which are galactose 
inducible. It is observed that 3 crucial parameters should be followed for the production 
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TMPs such as GPCRs to obtain permissible yields: (i) use of a robust promoter such as 
GAL1 and co-expression of its transcriptional transactivator; (ii) tagging the N-terminal 
end with a yeast signal sequence (N-terminus of STE2 receptor) that favors insertion into 
membranes (iii) induction should be carried out in presence of an antagonist that could 
act as a structural stabilizer. However, subsequent studies showed that the above 
methodology doesn’t work for all GPCR expression. The most successful observation 
was for human β2-adrenergic receptor with yields of 115 pmol of receptor per milligram 
of total membrane protein42. On the contrary, only 20 fmol/mg of membrane protein was 
observed for the production of µ1-muscarinic receptor43. Moreover, following the above 
described conditions for human β2-adrenergic receptor, but swapping the cultures from 
lab-scale to fermenters (preparative scale) decreased the yields to 36 pmol/mg of 
membrane protein44. 
 
Recombinant TMP expression in yeast systems drives the focus on mainly towards 
PTMs. PTMs mainly comprise of the glycosylation patterns and clearly there is huge 
difference compared to those in mammalian cells. Hyperglycosylation is generally 
observed in S. cerevisiae whereas in P. pastoris PTMs are at optimum levels. Thus the 
level of glycosylation for expressed proteins in yeast can not only effect activity but also 
trafficking, folding, stability and degradation45. Recently, yeast systems have been 
engineered so that they can glycosylate recombinant proteins with the patterns observed 
in mammalian systems and these modified yeast strains could in the future become the 
potential strains of choice for all eukaryotic recombinant protein expression46. Another 
major difference to be considered when expressing TMPs in yeasts is the biochemical 
nature of the membrane environment. Both yeast systems have significant variations from 
the mammalian cells in the lipid composition that make up the membranes11, 47. 
Endogenous cholesterol found in the mammalian cell membranes is totally absent from 
yeast membranes, which might be crucial for the functionality of the expressed protein as 
is in the case of SERT1 serotonin receptor 48.  
 
5.2  Insect Cells 
In general, insect cells are easy and inexpensive systems to handle compared to 
mammalian systems like CHO, HEK 293 or COS cells, particularly for scale-up, but are 
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expensive to culture compared to yeast and bacteria. Principally, the system relies on 
baculovirus (recombinant) infection of insect cell lines (Sf9, Sf21 or High Five). Thus 
this is also called baculovirus expression system (BVES). After the viruses infect the 
insect cells (host), they multiply along with the expression of recombinant protein until 
they reach a certain viral titer. In the last decade, many improvements have been executed 
to generate recombinant baculoviruses and one of them comprises the Bac-to-Bac system 
(Invitrogen), which utilizes site-specific transposition in E. coli rather than homologous 
recombination in insect cells (fig 5)49, 50. The polyhedrin or p10 late promoter normally 
drives the gene expression (fig 4)51, 52. Recently, a similar system (BacMam, Invitrogen) 
has been established to allow baculovirus-based expression in mammalian cells. 
 
Figure 4.  Representation of a simple baculovirus transfer plasmid125. 
 
BVES is extensively used for eukaryotic protein expression in insect cells as a 
compromise between mammalian expression systems (stably or transiently transfected) 
and the bacterial expression systems. Although, BVES is more costly and laborious than 
expression in E. coli, it is better suited for eukaryotic proteins (especially TMPs) because 
of (i) similar codon usage rules, (ii) better expression levels (iii), better folding and fewer 
truncated proteins and (iv) allowance for post-translational modifications that are close to 
mammalian systems. A notable fact is that, some of the post-translational modifications 
generated are not identical to those found in mammals (for example glycosylations), but 
they are closer than those produced by bacteria, or even yeast49. 
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Figure 5. Generation of recombinant baculoviruses from vectors obtained through 
transposition between a transfer plasmid and a bacmid53. 
 
5.3  Mammalian Cells 
Mammalian cells, and in particular those of human origin, undoubtedly offer the most 
native biochemical composition for the expression of TMPs that are linked to human 
physiology and disease. Until the last couple of years, their use in structural biology had 
been limited because of the practical difficulties in culturing and transfecting large 
quantities of cells and more crucially the costs endured in maintaining them. 
Conventionally, TMP expression in mammalian system depended on obtaining stable 
transformants or on the use of viral vectors. Most commonly used viral vector for TMP 
expression is the Semliki Forest Virus (SFV) and in several cases, promising quantities of 
homogeneous, functional protein has been obtained17, 54,  55. However both, the generation 
of stable transformants and the usage of viral stocks require expensive culture media and 
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thus are technically challenging. But, in the last decade, acceptably successful and 
relatively cheaper large-scale transient transfection (LSTT) techniques have evolved with 
the development of serum-free media as an alternative expression method56-58. In recent 
years, efforts were put into increasing transfection efficiency for higher expression yields 
by optimizing various media components and culture conditions57, 58. 
 
The Structural Proteomics IN Europe (SPINE) group has carried out detailed 
investigation on expression characteristics of all kinds of proteins using LSTT and 
concluded that the highest overall expression was observed for secreted proteins relative 
to other types of proteins59. SPINE group also investigated protein expression using 
baculoviruses, and concluded that this method gave better yields for cytosolic and TMPs. 
Other investigations also revealed that the mammalian cells are best-suited systems for 
functional TMP production60.  
 
A remarkable approach comprises the use of baculoviruses as mammalian expression 
vectors61, 62. The concept of baculoviruses infecting mammalian cells was known in the 
mid 1990’s, but scientists were not able to replicate the same phenomenon with other 
viral vectors for avoiding safety concerns. Recombinant shuttle baculoviruses are 
generated using the shuttle vector pfastbacmam-1, in which the traditional polyhedrin 
promoter is substituted with a cytomegalovirus (CMV) promoter63, and this system has 
since been applied to a wide variety of cell lines, mainly for receptor binding assays64-66 
but more recently also for large-scale protein production 67. Lately, a single shuttle vector 
comprising both the CMV and pol10 promoters are under widespread usage, allowing 
expression in both mammalian and insect cells50. One of the drawbacks posed with the 
usage of induced promoters in transient transfection is that gene expression is 
constitutive, and that protein overexpression could easily cause cell death due to toxicity. 
To overcome this, a vital development has taken place in which protein overexpression 
can be tuned to levels that avoid toxicity68-71.  
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6. Comparison of different expression systems 
The choice of selecting an expression system is highly empirical with regards to 
functional TMP production. Considering a few realistic examples:  
• Functional SERT1 a serotonin transporter is expressed at low levels in yeast and 
insect cells compared to mammalian cells 48. 
• Functional AQP4 suitable for crystallization was produced in high quantities in 
insect cells compared to yeast and CHO cells72. 
• Recombinant rhodopsin has been produced in almost all expression systems, but 
in comparison insect cells had the highest levels of functional expression while 
yeast had the lowest expression levels73-76. Moreover, only mammalian COS cells 
produced the glycosylated rhodopsin, which is analogous to the bovine rhodopsin 
and was successful in crystallization77. 
 
Generally, it’s the target protein, which determines whether a particular host is ideal or 
not for expression, and thus extensive screening is required to determine the best host 
system and its best strain under ideal conditions17. Due to the wide range of recent 
developments in all the expression systems, several potential comparative platforms have 
emerged especially for mammalian and insect-cell systems that are conventionally 
tedious and time-consuming11, 78.  
 
Table 2. Comparison of major expression systems for the production of functional TMPs 
based on the type of recombinant technique followed including the advantages and 
disadvantages32.  
 
Expression system Advantages Disadvantages 
E. coli Plasmid Low-cost Problems in folding  
Easy to culture Low yields 
Quick construct generation No PTMs 
Compatible with most media for 
labeling 
 
Yeast Plasmid Inexpensive and can be grown to a 
high density 
Non-native 
PTMs/hyperglycosylation (S. 
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cerevisiae) 
Easy to culture Non-native membrane  
environment 
 
Quick construct generation Poor expression of some 
proteins 
Eukaryotic processing Poor folding 
Insect 
cells 
General More native membrane environment 
than yeast 
Costly 
Somewhat robust culture requirements Non-native PTMs 
Good track record in producing 
functional proteins 
Non-native membrane 
environment 
Baculovirus Well-established protocols Time needed to generate virus 
Easier titration of viruses Cell lysis, safety concerns 
Transient 
transfection 
Quick construct generation Costly 
Amount of DNA required 
Bacmam Cross-over Necessity for two different 
types of cells 
Lysis in insect cells 
Mamma
-lian 
cells 
General Native membrane environment Costly 
Native secretory/post-translational 
pathways 
Technical requirements 
Good track record in producing 
functional proteins 
 
Stable 
integration 
Consistent expression levels Time needed to establish 
No need to generate a vector Instability in integration 
Semliki 
Forest 
Virus (SFV) 
Successful in expression-screening 
studies 
Necessity for helper RNA 
Efficient infection Technically demanding 
Transient 
transfection 
Rapid 
 
Amount of DNA required 
Price of reagents at large scale 
Bacmam Lack of degradation in mammalian 
cells 
Necessity for two different 
types of cells 
Cross-over  
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7. Cell-free expression system (CFES) 
CFES for analysis of various proteins has been used for several decades79, 80. The main 
drawback of this system during its early days was the low yield of target proteins. 
Reticulocyte lysate or wheat germ extract was the first mode of medium used for CF 
protein synthesis, especially for analyzing specific antibodies that are radiolabelled by 
autoradiography or by western blotting80. In the late 1990s, significant improvements 
were made for obtaining higher expression yields in the medium composition of both an 
E. coli and wheat germ derived cell-free systems. In the last decade, CFES for especially 
TMP production has undergone significant progress due to the advances made in the CF 
ingredients by several marketing companies (e.g. Novagen, Roche, Qiagen, Invitrogen)81-
84. Thus several commercial cell-free extracts are available in the market based on E. coli 
strains and wheat germ lysates for preparative production of proteins. Some of the 
advantages of CFES over cell-based systems are: 
• Expression of cell-toxic proteins 
• Production of difficult-to-express proteins on preparative scales quickly and 
economically. 
• Simultaneous expression of multiple proteins in one reaction 
• Easier incorporation of non-natural aminoacids 
• Easier isotopic labeling, in particular amino-acid specific labeling with less 
scrambling 
• Feasibility to use suitable membrane mimetics for TMP production 
• Other additives that could be added are metal ions, cofactors, binding 
partners/ligands, etc. 
• In some cases, PCR amplified product with the gene of interest is sufficient to act 
as template for protein synthesis. Thus doesn’t require cloning into vectors. 
 
Cell-free Reaction: It works in two different ways: First is the batch mode82 in which 
the translation reaction is allowed to undergo in a vessel that has all the necessary 
ingredients. This type of reaction can only last for 2-3 hrs as the initially supplied 
energetic sources, nucleotides, metal ions and cofactors start to get either depleted or 
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degraded.  This mode of reaction can produce up to 500 µg/ml protein and sometimes up 
to 1 mg/ml protein in exceptional cases with proper optimization. 
 
The second method is the dialysis mode cell-free reaction85. Here, the translation 
reaction is performed in a reaction compartment that is separated by a dialysis membrane 
from the reservoir chamber (10-20x larger than reaction compartment) consisting of 
lower molecular weight ingredients. In this setup, reactions usually last for 20-24 hrs 
resulting in higher protein yields. Protein yields up to 5 mg/ml were reported with the E. 
coli system for both the marketed (Roche, Invitrogen) and as well as with the self-
prepared ingredients according to published protocols. With the wheat-germ system, 
protein yields reported were less, usually 1 mg/ml but this system provides stable 
reactions that can run for several days86, 87. 
 
Basic ingredients required for a cell-free reaction are E. coli strain’s cytosolic extract 
(BL21DE3, BL21 CodonPlus, A19, etc.), buffers such as Tris-acetate (pH 8.2), HEPES-
KOH (pH 7.5) and other chemical compositions such as KOAc, Mg(OAc)2, K-glutamate, 
NH4OAc, DTT, NaN3, PEG8000, β-ME, NTPs (ATP, GTP, CTP, UTP), 20 amino acids, 
3',5'-cyclic AMP (cAMP), Folinic acid, creatine phosphate, phosphoenol pyruvate (PEP), 
creatine kinase, pyruvate kinase, T7 RNA polymerase and total tRNA mix from E. coli. 
In addition to the above components, TMP production in active form requires membrane 
mimetics such as detergents, lipids and nanodiscs84, 88-90. Extensive optimization is 
required for the translation reaction to take place as excess membrane mimetics could 
affect the activity of enzymes in the reaction mix. Recent studies have shown efficient 
production of functional TMPs including GPCRs91-95. 
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8. Membrane Mimetics 
Although obtaining sufficient quantities of TMPs has progressed drastically by using 
tailored heterologous systems, their incorporation into membrane mimetics in functional 
form is still a major bottleneck. Lipids in cell membranes not only act in embedding 
TMPs but also regulate their function by their dynamic rearrangements96. TMPs 
sometimes are embedded in unique lipidic environments native to certain cells97-99 and 
thus in vitro experiments carried out should satisfy the following properties to support 
comprehensive biological characterization: 
• The selected membrane environment should support ideal folding of TMPs 
• Membrane environment surrounding TMPs should provide appropriate access to 
its binding partners (peptides, cofactors, metal ions, ligands)  
• Membrane environment should regulate oligomeric state of TMPs based on 
functional significance 
Although detergent micelles, liposomes (artificial lipid bilayers, bicelles) and nanodiscs 
are reported to provide native-like environments for TMPs, none of them fulfill all the 
above-enlisted criteria. For understanding the incorporation of TMPs into membrane 
mimetics, we will first consider the most common types available for functional 
reconstitution in vitro and then will analyze their advantages and disadvantages100. 
 
Basically, there are 5 types of membrane mimetics widely used by most labs. These are:  
i. Detergent or mixed micelles  
ii. Bicelles  
iii. Unilamellar lipid vesicles 
iv. Nanodiscs 
v. Amphipols 
 
An imaginary view of each membrane mimetic with the TMP integrated is depicted in the 
following figure (Fig 6).  
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8.1  Detergent or mixed micelles: These are the most common membrane mimetics used 
for in vitro studies of purified TMPs101, 102. Micelles or mixed micelles are formed by 
adding a single type of detergent, a mixture of detergents or a combination of detergents 
and lipids in water at certain levels of concentration (Figure 6a). Because the TMPs 
consist of both hydrophilic and hydrophobic regions, a stable environment is provided to 
them by the detergents, which are amphipathic molecules. Thus detergents prevent 
precipitation of TMPs in water. Wide ranges of detergents are available for solubilizing 
TMPs, but a selected detergent is considered ideal if it is mild enough to prevent instant 
denaturation of the protein. For example, sodium dodecyl sulfate (SDS) solubilizes TMPs 
effectively but often in a denatured mode, and thus SDS is not the best choice. On the 
contrary, n-octyl-β-d-glucopyranoside (OG)103, cholate and dodecyl-β-d-maltoside 
(DDM)104 act as mild detergents and are used with greater success. Crystal structure of 
one of the TMP rhodopsin was first solved in presence of the mixed micelles composed 
of heptanetriol and nonyl-β-d-glucoside105, 106. 
 
 
6a. TMP in a detergent micelle  6c. TMP in unilamellar lipid vesicles 
6d. TMP in nanodiscs 6b. TMP in bicelles 
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Micelle formation is a thermodynamically driven process to shield the hydrophobic tail of 
detergents from getting exposed to water while maintaining the interactions of polar head 
groups with water. When a detergent is added to water, they disperse as monomers upto 
certain concentrations and when these concentrations are exceeded, they tend to 
aggregate forming micelles. The concentration at which the detergent monomers tend to 
aggregate is called as the Critical Micelle Concentration (CMC). Depending on the type 
and length of the hydrophobic tail and to a certain extent the type of head group involved, 
CMC values change. The number of detergent monomers that associate to form the 
micelle is called as the Aggregation number. This also depends on the type of detergent 
monomer based on similar properties such as the length of the hydrophobic tail and the 
head group involved. Most commonly used detergents in structural biology are illustrated 
in table 3. 
 
Basically, detergents that solubilize TMPs and suitable for NMR fall into two categories: 
(a) Detergents with apolar tails – dodecylphosphocholine (DPC), sodium dodecylsulfate 
(SDS), N-lauroylsarcosine, lauryldimethylamine oxide (LDAO), decyl- and dodecyl-
maltoside (DM, DDM) and octylglucoside (OG). Most commonly used tailed detergents 
suitable for NMR are dihexanoylphosphatidylcholine (DHPC) with two short tails and 
lyso-glycerophospholipids (phospholipids without their sn-2 acyl chain). Tailed 
detergents with uncharged headgroups were not used extensively on TMP studies using 
NMR because they yield poor-quality spectra. It is speculated that the micelle 
monodispersity with these detergents is not well preserved at high concentrations suitable 
for NMR studies, resulting in longer correlation times for the TMP- detergent complexes. 
Tailed detergents with charged head groups were extensively used in studying TMPs 
using NMR because they yield high-quality spectra. Some of these detergents such as 
DPC, SDS, LDAO and N-laurylsarcosine should be used carefully as they have the 
tendency to destabilize folded TMPs. Widely used detergents in this category are the 
those with short-chained phospholipids (DHPC)126 and lysophospholipids127 (LMPC, 
LMPG, LPPG – table 3).  These are zwitterionic in charge, resulting in high water 
solubility and the micelles mostly exist in monodisperse form. A minor disadvantage is 
that these detergents are very mild in nature to solubilize TMPs. (b) These are rigid 
amphipathic molecules similar to bile salt-derived detergents or amphipathic peptides. 
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Most common example is CHAPS128. In addition to solubilizing TMPs, CHAPS is also 
capable of stabilizing small exposed hydrophobic patches present in few water-soluble 
proteins.  
 
 
Table 3. Most widely used detergents for structural biology purpose and their 
properties129. ND – not determined. 
 
8.2  Bicelles:  Upon removal of detergent from an incorporated TMP present in a mixture 
of lipid/detergent micellar environment made-up of both short- and long-chain lipids, a 
bicellar environment is formed (figure 6b)130. Bicelles are nothing but fragments of lipid 
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bilayer with the outside border stabilized by short-chain lipid or detergent molecules 107-
109. It is interesting that the size of the bicelle can be adjusted depending on the ratios of 
short- to long-chain constituents. The resulting sizes could range from 10-30 nm and 
sometimes up to 80 nm is possible upon adjustments for reconstituting multiple GPCRs. 
Important point to be noted here is, specific lipid ratios should always be maintained for 
the bicelle entity to persist. Khorana and his coworkers were successful in using the 
bicelle system to study kinetics of opsin-retinal interactions that results in forming the 
GPCR rhodopsin110. Opella and his coworkers successfully incorporated the CXCR1 
chemokine receptor into bicelles, and obtained encouraging NMR spectroscopic 
results108, 111. Recently, the Y2 receptor (GPCR) has been successfully reconstituted into 
bicelles for solid-state NMR studies112. 
 
8.3  Unilamellar lipid vesicles: It was observed for TMPs such as GPCRs that they 
could be reconstituted into unilamellar lipid vesicles from the detergent-solubilized form. 
These vesicles are generally prepared by solubilizing TMPs and phospholipids in 
presence of cholate (detergent), followed by detergent removal with the help of bio-beads 
or by SEC and eventually collecting the separated vesicles (figure 6c). The best-studied 
TMP that has been successfully reconstituted in unilamellar lipid vesicles is the β2-
adrenergic receptor along with its Gs-subunit113. These vesicles are considered to be more 
advantageous than micelles because of their resemblance towards native-like 
environment. Recently, Grisshammer and his coworkers reconstituted neurotensin 
receptor into lipid vesicles and successfully carried out solid-state NMR studies114.  
 
8.4  Nanodiscs: These are also denoted as high-density lipoprotein (HDL) particles or as 
nanoscale apolipoprotein bound bilayers (NABB) and present a perfect example of how 
creative scientists considered using HDLs to incorporate TMPs. Basically a nanodisc is a 
precisely structured bicelle entity stabilized by 2 molecules of membrane scaffold protein 
(MSP). The bicellar/bilayer entity in a nanodisc is a lipid bilayer that can incorporate 
TMPs in its center. MSPs are helical repeat proteins with a hydrophilic and a 
hydrophobic surface, which can wrap around the lipid bilayer’s hydrophobic surface 
entity resulting in a sturdy bicellar unit called the nanodisc (figure 6d). Because of the 
nature of MSP function, it is also referred to as a belt protein. 
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In 2009, Sligar and his coworkers were successful in designing nanodiscs of defined 
diameter by manipulating the number of helical repeats in the MSP. This resulted in discs 
with varied sizes ranging from 9-13 nm115, 116. Reconstitution of TMPs into nanodiscs 
offers numerous advantages: 
• Major advantage is the absence of a detergent that is responsible for generating a 
dynamic system. 
• Since the lipid bilayer within the nanodisc is not dynamic, free or excess lipid 
molecules in the solution do not distort the folded TMP in the compact nanodisc. 
• In most cases, nanodiscs with TMPs incorporated are considered to be stable for 
weeks to months whereas it is only days for micelles or bicelles. 
• Because of the absence of an enclosed topology, intracellular and extracellular 
sides of the receptor are easily accessible and amenable for ligand binding studies. 
• Because TMPs within nanodiscs have limited conformational flexibility, they act 
as promising vehicles for structure determination by NMR. 
• These entities can be implemented into cell-free expression systems for the direct 
co-translational reconstitution of TMPs131. 
 
Some of the successful illustrations with the usage of nanodiscs are: 
• Sligar and his coworkers were able to incorporate purified β2-adrenergic receptor 
into nanodiscs117. 
• Kobilka and his coworkers revealed that the above incorporation could activate 
G-proteins118, 119. 
• Rhodopsin incorporated into nanodiscs showed light-induced activation of the 
receptor and also activation of the G-protein transducin or arrestin120-123. 
• Recently, Sakmar and his coworkers successfully incorporated purified CCR5 
chemokine receptor into nanodiscs124. 
The size of nanodisc entities with the presence of reconstituted TMP is estimated to be 
around 150-200 kDa. These large sizes have in the past, discouraged NMR structural 
biologists, but recently this system has regained hope after showing promising results 
with encouraging NMR spectra for medium-sized TMPs132-133. Many TMPs using 
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nanodiscs are at the moment under investigation by NMR, which shows the likely interest 
of structural biologists to study TMPs in genuine membrane mimetics. 
 
8.5  Amphipols: These are one of the novel classes of model membranes used for 
studying TMPs by NMR. Chemically, these are amphipathic polymers that can act as 
alternatives to detergents by keeping the TMPs soluble in water under mild conditions. 
These are first used as a medium to study OmpA, which gave high-quality NMR 
spectra134. In this example, amphipol A8-35 was added to the detergent solubilized 
OmpA, following which the detergent was removed using polystyrene bio-beads. OmpA 
remained in solution trapped by A8-35, which on NMR analysis gave convincing spectra 
for backbone determination. This study proved that amphipols could replace detergents to 
study TMPs using solution-state NMR. 
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Chapter II: Biosynthesis and spectroscopic characterization of 2-TM fragments 
encompassing the sequence of a human GPCR, the Y4 receptor 
 
1. Abstract 
This paper presents a divide-and-conquer approach towards solution structures of G-
protein coupled receptors. The human Y4 receptor is dissected into 2-3 transmembrane 
helix fragments, which are individually studied by solution NMR. We systematically 
compare various aspects of biosynthetic routes for expression of the fragments in E. coli 
and discuss purification strategies. In particular, we have compared the production of the 
TM fragments into inclusion-bodies using the ΔTrp leader sequence, with the membrane-
directed expression using Mistic as the fusion partner, and developed methods for 
enzymatic cleavage. In addition, direct expression of 2-TM fragments into inclusion 
bodies is a successful route in some cases. With the exception of TM13, we could 
produce all fragments in isotope-labeled form in quantities sufficient for NMR studies.  
 
 
Complete to nearly complete backbone resonance assignments are obtained for the first 
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two helices as well as for helix 5 and 7 and a high degree for those of TM6, while 
conformational exchange processes result in disappearance of many signals from TM4. In 
addition, complete assignments are obtained for all residues from the N-terminal domain, 
the extracellular as well as the cytosolic loops (with exception of a undecapeptide 
segment in EC2) and for the complete cytosolic C-terminal tail: In total backbone 
resonances of 78% of all residues have been assigned for the Y4 receptor. Predictions of 
secondary structure based on backbone chemical shifts indicate that most residues from 
the TM regions occupy helical conformations with exceptions around polar residues or 
Pro sites. However, the domain borders are often slightly different from what is predicted 
from homology models. We suggest that the obtained chemical shifts may be useful in 
assigning the full-length receptor. 
 
 
2. Introduction: 
Our knowledge of structural biology of G-protein coupled receptors has advanced 
significantly in the last decade. High-resolution structures determined from single crystal 
diffraction now are available for the ground states of a number of receptors, e.g. bovine 
rhodopsin,[1] the turkey β1[2] and human β2[3] receptors, the human adenosine A2A 
receptor,[4] the human dopamine D3 receptor,[5] the human CXCR4 receptor[6] and the 
human histamine H1 receptor.[7] Mostly, these structures were determined in the presence 
of inverse antagonists, or for mutants that display little basal activity. Moreover, recent 
structures of GPCRs allow deciphering the mechanism of activation. To this end 
structures of GPCR in the agonist-bound state[8-11] or for mutants with constitutive 
activity[12] have been determined. Moreover, the ternary complex of the β2-receptor, its 
ligand and G-protein bound has been investigated.[13] In case of rhodopsin, the structure 
of its ground state,[1] its state when bound to all-trans retinal (metarhodopsin II) and in 
retinal-free opsin[14,15] allowed mapping the pathway of activation. 
 
To allow crystallographic studies GPCRs had to be stabilized biochemically, either by 
inserting the sequence of T4 lysozyme into the third cytosolic loop, or by selecting for 
temperature-stabilized mutants (for a review see Bill et al.[16]). In principle, NMR 
spectroscopy is capable of studying structure and dynamics of proteins in solution. In 
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particular this is also the case for proteins that contain partially unstructured parts or 
longer loops, features that usually hamper crystallization. The high-quality structure of 
sensory rhodopsin[17,18] and the recently published NMR structure of proteorhodopsin,[19] 
although not true GPCRs, but also of other integral membrane proteins[20-22] indicate that 
structure determination is possible by solution NMR methods once spectra of sufficient 
quality can be recorded. While progress in this area can be expected, to our knowledge 
presently in the particular case of true GPCRs spectral quality is not sufficient to follow 
this approach. Moreover, biosynthesis, purification and refolding of isotope-labeled entire 
GPCRs are very challenging.  
 
Herein we study large fragments of the human Y4 receptor, a class A GPCR, to learn 
about structural features of these entities, to develop methods for assigning entire GPCRs 
and to investigate folding of GPCRs. Previously, we determined the structure of a 
fragment corresponding to the first two transmembrane (TM) helices of the yeast Ste2p 
receptor.[23] That fragment could be expressed in good yields in all flavors of labeling, 
and was shown to adopt tertiary structure in detergent micelles. Moreover, we previously 
reported on the structure and ligand binding of the isolated extracellular domain of the Y4 
receptor (N-Y4).[24] Furthermore, we described the biosynthesis and backbone assignment 
of the N-TM12 fragment.[25] 
 
In this work we present a comprehensive overview on our efforts at studying a series of 
2-3 TM fragments spanning the entire sequence of the Y4 receptor. We report on the 
biosynthesis of the fragments in E. coli comparing both direct expression methods as well 
as fusions that direct expression products into inclusion bodies or membranes. We 
present fingerprint spectra for the fragments, and demonstrate that backbone assignments 
are possible to a large extent. We discuss the results with respect to GPCR folding and 
speculate on the future use of the data for supporting assignments of entire receptors.  
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3. Results 
 
3.1 Biosynthesis:  
A biosynthetic method that proves useful for NMR studies needs to accomplish several 
tasks: expression yields should be such that an NMR sample (at least 200 but preferably 
300µM in concentration) can be made from 1-2 L of culture. Perdeuteration is absolutely 
necessary in order to facilitate backbone assignments, unless a large set of selectively 
labeled proteins is made. The method must also be capable for producing the protein in a 
form from which it can be refolded, and from which formation of precipitates or high-
molecular weight oligomers is unlikely.  
 
Yields for direct expression of helical integral membrane proteins are often 
unsatisfyingly low. Several methods have been proposed to increase yields. The most 
popular method is the use of fusion proteins, and both soluble as well as insoluble fusions 
have been advertised. In case of entire GPCRs conceptually the best method clearly is 
direct expression into membranes, but the low yields essentially prevent this method from 
being useful for NMR studies. A promising strategy to direct expression into membranes 
is the use of Mistic, a membrane protein from B. subtilis that bypasses the translocon-
mediated insertion into the membrane and therefore allows much higher yields.[26] An 
alternative strategy is clearly the direction into inclusion bodies followed by a refolding 
step (see Figure 1). The requirement for full deuteration is incompatible with most 
expression system, and essentially precludes the use of sf9 insect cells despite the fact 
that most of the GPCRs that were recently determined by crystallography were expressed 
in that host. To the best of our knowledge deuteration can only be achieved in vivo in E. 
coli,[27] and in the methylotrophic yeast Pichia Pastoris[28] or in vitro with cell-free 
expression methods.[29] In this work we have used E. coli for the reason of ease of use, 
and because comparably high expression levels can be achieved in this host. 
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Figure 1: Overview of the constructs and the two strategies used for expression and 
purification. 
 
With the aim of improving direct expression into inclusion bodies, we have compared the 
expression levels using the original cDNA coding for the human Y4 receptor and the 
same sequence devoid of rare codons and optimized for the GC content of E. coli. We did 
not observe any significant improvement in expression when using the codon-optimized 
sequence. The regions of the Y4 receptor used in this study are spanning residues M1-
Q155 (here referred to as TM13), E138-L267 (TM45), I179-N301 (TM56) and R239 –
I375 (TM67) (Sup. Mat. Figure S2). Direct expression into inclusion bodies was possible 
for N-TM13, N-TM45, TM45 and TM56 using minimal medium, although with variable 
yields. We could demonstrate that spectra derived from samples refolded after the Ni-
NTA purification usually do not display good quality, which we attribute to the presence 
of residual lipids that result in micro-heterogeneity and conformational exchange[25]. In 
contrast, a second step of purification using a C4 reverse-phase HPLC step resulted in 
more homogeneous protein that displayed improved spectra. Final yields of purified 
protein per liter of culture differed, depending on the exact construct, and was observed 
to be in the range between 0.4 (N-TM13), 0.8 (TM45) and 0.7 (TM56) mg (for a gel of 
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the purified proteins see Figure 2). An advantage of this procedure is that at the end of the 
purification and following lyophilization the protein is available in powder form and can 
be simply dissolved in any detergent, thereby avoiding a detergent exchange step - a 
particular advantage when using deuterated detergents. 
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Figure 2: Coomassie-stained SDS-page of the fragments directly expressed into 
inclusion bodies and purified under denaturing conditions: M (marker), lane 1 TM13, 
lane 2 N- TM45, lane 3 TM45, lane 4 TM56. 
 
In our experience, backbone assignments of membrane proteins of this size require highly 
deuterated proteins, in particular for experiments that relay magnetization onto the Cβ 
carbons. Given the high content of some amino acids and the reduced signal dispersion of 
helical membrane proteins, knowledge of Cβ chemical shifts is important for sequential 
assignments. Typically, expression yields drop by more than 50  % when growing cultures 
in deuterated water, even after extensive optimization. In our case TM56 and TM45 
could not be expressed directly in perdeuterated form, while for the other constructs 
deuterated proteins sufficient for one NMR sample were obtained from 1  L of culture. 
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Some of the constructs could not be directly made, and therefore they were expressed as 
fusion proteins. Following earlier work of the Naider group we expressed TM67 as the 
fusion to the ΔTrp leader peptide (ΔTrp-LE). The ΔTrp-LE sequence is highly 
hydrophobic and results in accumulation of the expression product in inclusion bodies. In 
our experience this method is generic and usually results in reasonable quantities. An 
obvious problem with this (or most of the other fusions) is that the fusion partner must be 
removed. When working under denaturing conditions this can be achieved chemically 
using a CNBr cleavage step, with the limitation that only a single N-terminal Met residue 
is tolerated in the target protein. We also frequently encountered problems with the 
cleavage when Cys residues were present. Since the TM67 construct contains both Met as 
well as Cys residues we decided to utilize enzymatic cleavage as an alternative method. 
The particular problem with the latter is that the fusion protein must be soluble under 
conditions under which the protease is still active. We performed initial cleavage trials 
using the TEV or the 3C protease. Both enzymes are reported to be active in presence of 
low concentrations of denaturant or detergent. In a first approach we have solubilized the 
ΔTrp-TM67 fusion from inclusion bodies in a detergent buffer containing 1% 
dodecylphosphocholine (DPC). Although the purification using the IMAC was efficient 
and the 3C cleavage was almost 70%, we have experienced problems in completely 
removing cleaved ΔTrpLE and uncleaved ΔTrpLE-TM67 during the IMAC step. 
Although we have been able to produce a sample suitable for NMR using this method, 
the difficulties of detergent exchange, mostly due to the low CMC of DPC, precluded its 
further use. In order to increase cleavage efficiency, to improve solubility in denaturant at 
concentrations compatible with the enzymatic cleavage, and to improve binding to the 
Ni-NTA column, we have modified the original construct in the following way: i) a 
second deca-His tag was inserted prior to the 3C cleavage site. Since this tag is present in 
the part that is removed from the construct it does not cause further complications and 
even (slightly) increases solubility. ii) A 20 residue hydrophilic linker was inserted prior 
to the 3C site containing the sequence AKQFVEDNAENDEAEKLFNQ. The fusion 
protein was solubilized in 6M GdmCl, subjected to a Ni-NTA purification step and 
dialyzed against cleavage buffer in the presence of 3C protease.  At sufficiently low 
concentrations of GdmCl the 3C protease refolds while the ΔTrp-TM67 fusion still 
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remains in solution. Under these conditions the cleavage was more than 80% efficient. 
Following dialysis, the precipitate material was redissolved in 6M GdmCl and was 
directly injected into the C4-HPLC. Using this methodology we were able to obtain 2 or 
3 mg of purified protein from 1L of culture using M9 minimal medium in light or heavy 
water, respectively.  
 
We noticed that yields for direct expression of N-TM12 were substantially higher than 
for the other 2-TM proteins. N-TM12 additionally contains the N-terminal 41-residue 
extracellular domain. The latter was investigated before in isolation, and low-affinity 
binding of the ligands was demonstrated.[24] We tested whether this small domain itself 
can serve as a fusion partner for some of the 2-TM proteins that we could not express 
directly, in particular for those not expressing in perdeuterated form. An attractive feature 
of this fusion is the very limited size, which even allows leaving it attached. Moreover, 
the fusion can be easily recognized because we assigned its resonances previously. We 
propose here to use this fusion to produce the perdeuterated form of a 2-TM protein that 
cannot be expressed in deuterated water directly, assign this protein, and then transfer the 
assignments from this protein onto the directly expressed. We have tested this approach 
for a smaller version of the construct TM45 (T147-H259), for which we failed to observe 
expression in deuterated water (data not shown). We were able to purify this construct in 
15N/13C/2H labeled form in sufficient yields (2 mg/liter of culture). Although we have not 
yet tested the use of the N-terminal domain systematically for the production of other 
truncated forms of the Y4 receptor, the use of N-terminal domain of the Y4 receptor 
represents an interesting alternative to the commonly used larger fusion proteins.  
 
3.2 Expression and purification of Mistic fusions  
All the fragments were initially tested for expression into the membrane of E. coli using 
Mistic fused at the N-terminus and the green-fluorescent protein (GFP) at the C-terminus. 
GFP fusions have proven valuable tools for evaluating expression levels of folded 
membrane proteins due to the fact the fluorescence levels are directly related to the 
amount of expressed protein.[30] All the fragments were well expressed into the 
membrane of E. coli, although the expression level of TM56 was lower (Figure 3). TM56 
is the only fragment with an expected N-out-C-out topology (Figure 1) that should result 
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in a lower fluorescence signal due to misfolding of GFP in the periplasm.  The total 
expression level of TM56 was confirmed to be lower from both an in-gel His-tag 
detection and a Coomassie-stained SDS-page gel (Figure 3). The expression of TM13 
without any fusion directly into inclusion bodies resulted in low yields in comparison to 
other fragments. For this reason we have directed the expression of TM13 into the 
membrane of E. coli using the N-terminal Mistic fusion. Initial expression screenings 
revealed that Mistic-TM13 was better expressed in Rosetta pLysS cells at 16 °C, 
resulting in overall yields of the fusion construct after the IMAC purification in the range 
of 2 to 4 mg from 1 liter of LB culture. A solubilization assay[31] showed that the 
construct could not be extracted from the membranes using the detergent LDAO (Figure 
S1), a detergent that was suggested previously to efficiently solubilize Mistic on its 
own.[26] Other detergents suitable for NMR were tested, and DPC and LPPG proved to be 
most efficient. Finally, large scale purification and 3C protease cleavage were performed 
in presence of DPC, conditions under which the fusion was stable for several days at 4 
°C. Following this procedure it was possible to purify 0.5 mg of target protein from 1 
liter of LB culture and the final DPC concentration was ∼ 15 mM as determined by NMR 
(Figure 4).  
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Figure 3: Expression of the fragments into the membrane of E. coli using Mistic at the 
N-terminus and GFP at the C-terminus. Left: in-gel fluorescence. Right: Coomassie 
stained SDS-page. On both gels lane 1 denotes Mistic-TM13-GFP, lane 2 Mistic-TM45-
GFP, lane 3 Mistic-TM56-GFP and lane 4 Mistic-TM67-GFP. 
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Figure 4: Cleavage and purification of Mistic–TM13 from membrane vesicles (left) and 
of ΔTrp-TM67 from GdmCl-solubilized inclusion bodies (right). Left: Lane 1: Mistic-
TM13 before cleavage; lane 2: Mistic-TM13 after cleavage; lane 3: TM13 after reverse 
IMAC. Right: lane 1: ΔTrp-TM67 after IMAC, lane 2: after 3C cleavage, lane 3: after 
RP-HPLC. 
 
3.3 Detergent screening and sample preparation 
Spectra quality is of prime importance, and the extent to which resonances can be 
assigned very much depends on the latter. Detergent optimization therefore usually is the 
first step once a strategy for protein expression and purification has been established. 
Others and we are using 15N,1H correlation spectroscopy to evaluate the quality of spectra 
in a variety of detergents. The pros and cons of detergents have been extensively 
discussed in literature.[32-36] While certain classes of detergents have been advocated for 
use in solution NMR so far no particular detergent that in general is better than others has 
been identified, and detergents therefore need to be optimized for the protein in question. 
We have in our systems, however, observed that spectra in lyso-phosphocholine 
detergents generally behave better than detergents from the simple FOS series (e.g. DPC 
(FOS-12)). The group of Nietlispach observed superior spectra in C-7 DHPC.[18] 
 
In the following we will describe the procedure used for TM67. Spectral quality in terms 
of signal dispersion and line-width as well as completeness of signals of TM67 was very 
good in 5% DHPC (C-7), but the sample started to precipitate after 4 hours of 
measurements at 47 °C. Other detergents screened were LMPC (70 peaks), LMPG (120 
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peaks) and LPPG (125 peaks) (see Supp. Mat. Figure S3). For diagnostic purposes we 
monitored the 7 glycine backbone and the 2 tryptophan sidechain peaks. Since all 7 peaks 
due to Gly residues were observed in LMPG and LPPG spectra with similar linewidths 
and peak intensities LPPG was selected as the detergent of choice since we were able to 
purchase the perdeuterated form of it. Representative spectra of 15N labeled proteins of all 
investigated fragments are depicted in Figure 5. 
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Figure 5: 15N,1H correlation spectra of TM1-TM2 (upper left), TM4-TM5 (upper right), 
TM5-TM6 (lower left) and TM6-TM7 (lower right). For annotation of cross peaks see the 
Supp. Mat. 
 
3.4 Backbone Assignments 
NMR spectroscopy of perdeuterated proteins is usually done with out-and-back type 
experiments.[37,38] Backbone assignments were determined with standard procedures by 
matching amide moieties via Cα and Cβ resonances in the HNCACB and HN(CO)CACB 
experiment, via CO frequencies in the HNCO and HN(CA)CO experiments, and via 
sequential amide protons NOEs in the [15N,1H]-NOESY experiments. The procedure used 
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for assignments in TM67 is briefly described in the following. Since the extent of peak 
overlap was unknown at the outset of the analysis we have started to adjust peak 
positions based on HNCO strips. The latter displayed good signal-to-noise peak for all 
peaks observed in the proton-nitrogen correlation map. Often correlations in HNCACB 
and HN(CO)CACB spectra were incomplete and in those cases HNCA and HN(CO)CA 
spectra were helpful to at least obtain common Cα frequencies. Assignments were 
straightforward for residues of segments that are not micelle-embedded as well as for 
residues of the putative TM7, resulting in unambiguous assignments for 24, 14 and 48 
residues in the ICL3, ECL3 and C-terminus, respectively, as well as for 21 out of 24 
residues of TM7. A representative plot of strips from the HNCACB spectrum for a 
segment of TM7 is displayed in Figure 6 (next page). Although, peaks could generally 
also be mostly observed for residues of the hydrophobic TM6, the repetitive occurrence 
of Val residues (e.g. VNVVLVVMVVA) did not allow connecting observed fragments 
unambiguously. Overall, possible assignments were observed for more than 90% of 
residues of TM67, and in 80% unambiguous annotations were made.  
 
As TM45 could not be expressed directly in perdeuterated form, we decided to instead 
use the C-terminal fusion to NY4, the extracellular N-terminal domain of the Y4 
receptor, which we could obtain from cultures grown in heavy water. Although a strategy 
similar to the one described above for TM67 was used, we encountered serious problems 
for assignments in TM4. While TM5 and the C-terminal tail could be completely 
assigned, only 2 out of 25 residues from TM4 were observed. In addition, large fractions 
from the sequence N-terminal to TM4 as well as from the loop connecting TM4 and TM5 
were missing. Altogether unambiguous backbone assignments were possible only for 
59% of the residues. For more details see the Supp. Mat. (shown in Tables S3-S6; for 
annotated spectra see Figures S4-S6) We would like to note here that we were able to 
completely assign all peaks with reasonable intensity. Accordingly, all peaks from 
missing residues are likely to be exchange-broadened. In addition we have also expressed 
[15N13C]-TM45, a truncated version in which the fusion to the N-terminal domain is 
removed. While this protein displays lower-quality triple-resonance spectra due to the 
lack of deuteration the quality of the 15N-NOESY was much better.  
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Figure 6: Plot displaying strips from the HNCACB spectrum of TM67 in a segment 
encompassing residues Asn-301 to Leu-310, that is part of TM7. 
 
Most peaks from the TM segments did superimpose very well and peak positions could 
be adjusted using [15N,1H]-NOESY strips or common Cα, Cβ and C’ shifts from the 
triple-resonance spectra. For this construct 75% of all backbone resonances were 
assigned. In particular further assignments in the putative TM4 and E2 loop were 
obtained (shown in Table S4). 
 
Obviously, many peaks from residues in the TM segments were weak or missing. We 
speculate that this is due to conformational exchange processes. To gain insight into the 
details of this process we decided to measure a second data set for the protein N-TM45 in 
trifluoroethanol (TFE):water. This mixture has recently been used by the Naider lab to 
determine the structure of the TM12 fragment of the Ste2p GPCR.[39] Although tertiary 
structure is likely absent in this solvent mixture we hoped that these spectra might be 
useful to discover the missing signals. Due to the high quality of the triple-resonance 
spectra in this solvent we could rapidly obtain 90% backbone and side assignments. 
Nearly complete assignments were possible except for residues of the E2 loop segment 
and three residues from TM5 (see Supp. Mat. Table S5 and Figure S7), while gaps 
remained in the E2 loop. [15N,1H]-HSQC spectra of N-TM45 in LPPG detergent and in 
TFE/water are rather different, indicating that tertiary structure is altered in these two 
environments (see Figure S7). We are presently investigating whether assignments can be 
transferred from TFE:H2O to LPPG spectra using comparisons of strips from 15N-
resolved NOESY spectra.  
 
To investigate whether the presence of certain residues in central parts of TM4 is 
responsible for the observed line-broadening a number of point mutants such as W164A/ 
W164F or S171A/S171C was produced in 15N-labeled form and evaluated based on the 
quality of their 15N,1H-correlation spectra. We reasoned that the polar Ser residue, for 
which no interaction partner exists in this fragment, may introduce flexibility in 
TM4.[40,41] Trp164 was further chosen for mutagenesis since Trp residues prefer to be 
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located in the interface rather than in the center.[42] Moreover, different Trp sidechain 
rotamers may induce a large effect on chemical shifts. We monitored signal intensity of 
Gly-159, that is clearly visible as a distinct single peak, and whose assignment can be 
readily adapted from the spectrum of the wild-type protein. In the wild-type protein this 
signal is significantly broadened indicating the presence of more than one state. In both 
the Ala and the Phe mutant Gly-159 is observed as a rather sharp peak with higher 
intensity (see Figure S8). While this mutant study is far from being complete and will be 
continued in our lab it indicates that much signal intensity for residues of TM4 may be 
recovered when a few residues are exchanged. 
 
Backbone assignments of N-TM12 have been reported by us previously.[25] The triple-
resonance spectra in that case were generally of much higher quality than for any other 
fragment described in this report, and almost complete backbone assignments could be 
obtained. In total backbone assignments for 281 out of 369 Y4 residues are made 
accounting for 78% of all residues (see also Figure 7).  
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Figure 7: Snake plot of the Y4 receptor displaying secondary structure predictions based 
on backbone chemical shifts, as well as the present status of backbone assignments. 
Residues predicted to adopt helical or no secondary structure are displayed as orange or 
yellow spheres, respectively. 
 
For a more detailed account of the status of assignments in all fragments see the Supp. 
Mat. Table S2. From the missing assignments 25 are due to residues from TM3, and 
hence from a fragment that we could not produce in deuterated from in sufficient 
amounts up to now. 
 
4. Discussion 
The intention of this work was to provide tools for structural studies of large fragments of 
GPCRs using solution NMR spectroscopy, with the aim of improving our knowledge on 
their folding and to obtain spectroscopic data that may help in tackling the entire 
receptors. 
 
Structural studies of membrane proteins are usually hampered by low expression levels 
and by the difficulties in finding conditions under which the protein of interest is stable 
and displays spectra of sufficient quality.[43] The use of NMR spectroscopy needs 
additional prerequisites, such as that the requirement for isotope labeling at reasonable 
cost and for perdeuterated detergents as membrane mimicking environments. The 
presence of rare codons is one important factor that can reduce heterologous expression 
levels in bacteria.[44] This problem can be overcome using strains of E. coli that produce 
increased levels of rare tRNAs (Rosetta, Codon plus), or by synthesizing genes optimized 
for the E. coli codon usage. In our case, however, we did not observe any significant 
improvement in expression using the codon-optimized gene.  
 
We have compared two methods for expressing and purifying the fragments in E. coli. 
The fragments were expressed in insoluble form by directing expression into inclusion 
bodies or in folded form by directing it into the inner membrane, where quantification of 
expression was greatly facilitated by the use of the C-terminal GFP tag.[45] Both methods 
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have been widely applied to membrane proteins and represent viable strategies for 
obtaining the target proteins in amounts compatible with structural studies.[35] The 
expression of a membrane protein into inclusion bodies usually requires refolding into a 
functional form, a step that involves careful optimization of the refolding buffer. Often 
only a small fraction of the target protein can be functionally refolded, especially in the 
case of alpha helical membrane proteins.[46-51] The large GPCR fragments used in this 
study are devoid of function, and we have therefore exploited the alternative route of 
directing them into inclusion bodies (IB). The possibility to purify the protein from these 
in absence of detergents allows to finally solubilize the lyophilized protein in the 
detergent of choice. This procedure thereby avoids difficult detergent exchange steps, and 
hence is particularly suitable when screening a larger number of detergents. Several 
proteins have been suggested as N-terminal fusions in order to enhance expression of 
GPCRs and direct them into IB[52]. In this study we used the ΔTrp-LE[53-55] for increasing 
the expression in IB for a fragment that could not be expressed directly. In addition, we 
presented a protocol for highly efficient cleavage from the ΔTrp-LE in detergent.  
 
As an alternative expression method the fragments were directed into the membrane 
using the fusion to Mistic, and GFP added as a C-terminal fusion was exploited as an 
indicator for both expression level and protein folding. The presence of the GFP offers 
the additional advantage of directly detecting the target protein in standard SDS-page gels 
avoiding the use of immunoblot systems. The expression of TM13 into the inner 
membrane of E. coli with the help of Mistic represents a viable alternative to the 
expression into inclusion bodies. Presently, however, we prefer to use the IB directed 
methods because the yields are higher, and only a minimal amount of (expensive) 
detergent is required. Nevertheless, we suspect that the membrane-directed method may 
be useful for longer constructs that cannot be refolded with good efficiency.  
 
A comparison of the expression levels of the various fragments described in this study 
reveals that it is difficult to know a priori which strategy will give the best results. 
Clearly, optimization of overexpression can be achieved only after extensive screening 
for several constructs and conditions. Provided that sufficient expression levels are 
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obtained direct expression into inclusion bodies is the method of choice. Unfortunately, 
protein quantities are often too low, and then the insoluble expression of suitable fusions 
into IBs is the more promising route to obtain these fragments. Whether biophysical 
properties of refolded protein and protein that is obtained from direct expression into the 
inner membrane is different in the case of fragments is subject to future studies.  
 
The present study has demonstrated that a set of fragments comprising almost the 
complete sequence of the human Y4 GPCR can be obtained from expression in E. coli in 
isotope-labeled form. The corresponding 15N,1H correlation spectra display reasonable 
signal dispersion. Assignment of the backbone resonance was possible for 78% of all 
backbone resonances. However, we have also encountered serious problems with 
assignments of TM4 and TM6. While most of the problems in TM6 were related to 
repetitive sequences, no or weak peaks corresponding to residues of TM4 were observed 
in the spectra. We attribute this fact to conformational exchange processes in the 
detergent. Why exactly TM4 suffers so much from conformational exchange rather than 
other segments, in particular TM5 that is supposed to interact with TM4, is presently 
unclear to us and subject to further studies. 
 
The knowledge of backbone chemical shifts can be used to rather reliably predict 
locations of secondary structure.[56,57] Figure 7 highlights the locations of predicted helical 
and loop regions in the secondary structure as predicted from the backbone chemical 
shifts using the program TALOS+, [56] and also summarizes the present state of backbone 
assignments. The data indicate reasonable overall agreement with the predictions. For 
both TM1 and TM2 the helical regions are longer than predicted from the homology 
model. We have previously determined the structure of the extracellular N-terminal 
domain, and observed the presence of a long rather flexible loop that is anchored on the 
micelle surface via helices at both termini.[24] A longer stretch with residues with α-
helical propensities is also observed in the EC2 loop. Moreover, the presence of a 8th, 
cytosolic helix is in agreement with the predictions.  
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Significant destabilization of internal helices is observed within all TM segments, and 
mostly occurs around polar or Pro residues. Such polar residues are often located within 
the central TM segment and usually form contacts with polar residues from other helices. 
Whenever these other helices are not included in the fragment of interest the presence of 
these residues is expected to hamper proper integration of the TM helices into the 
membrane or micelle. When comparing the content of polar residues within central 
segments of TM helices between the 7 putative TM stretches it becomes clear that TM1, 
TM2, TM3 and TM7 form a polar core, whereas TM4, TM5 and TM6 are mostly devoid 
of polar residues. A systematic study of the location of termini in N- or C-terminally 
truncated fragments of the Y4 receptor has demonstrated that the C-terminal fragments 
better integrate into the membrane.[58] Moreover, we noticed in previous studies of the 
TM7 fragment from Ste2p that the TM7 was destabilized at positions of polar residues, 
which were positioned rather in the micelle-water interface than in the micelle interior.[59] 
Preliminary results on the structure determination of N-TM1-TM2 of the Y4 receptor 
indicate that the two helices are significantly destabilized around central polar residues 
(data not shown).  
 
Recently, the structures of sensory rhodopsin[18] and of proteorhodopsin[19] have been 
determined by solution NMR methods. In both cases high-quality structures could be 
obtained, with very high degrees of backbone and considerable extent of sidechain 
assignments. In both cases assignments started from high-quality [15N,1H]-TROSY 
spectra, but both proteins despite their 7-TM bundle structure do not belong to the family 
of GPCRs since they are not coupled to G-proteins. Little is published on solution NMR 
of true GPCRs, but in the few available cases spectra are much more problematic 
displaying dramatically varying linewidths, and assignments were often only possible for 
residues from loops or the N- or C-terminal tails. We speculate that it is the inherent 
flexibility required for the mechanism of activation that results in the unfavorable 
spectroscopic properties that hamper their study by solution NMR. Crystallographers 
have conducted major efforts to stabilize either the ground or the activated state of these 
receptors,[60] and it may likely also present a viable route for NMR studies, and fragments 
may be useful to identify positions for modifications. Another interesting option of this 
approach is to obtain backbone and in particular side-chain assignments. We are 
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presently investigating to which extent such assignments can be adapted to spectra 
recorded on the entire receptor. Finally, studying fragments of GPCRs that contain a 
number (2-3) of entire TM helices therefore presents a possibility of studying folding of 
these proteins. Individual helices are believed to insert into and diffuse within the 
membrane until productive encounters between helices occur resulting in assembly of the 
tertiary structure.[61,62] We suggest that studying fragments may provide insight into the 
conformational preferences of the corresponding individual TM segments before the 7-
TM bundle has been formed successfully.  
 
5. Experimental Section 
 
5.1 Enzymes and chemicals: Phusion DNA polymerase was purchased from Finnzymes. 
All the restriction enzymes were obtained from New England Biolabs, unless specified. 
Detergents dodecylphosphocholine (DPC), 1-palmitoyl-2-hydroxy-sn-glycero-3-
phospho-(1'-rac-glycerol) (LPPG), 1,2-diheptanoyl-sn-glycero-3-phosphocholine 
(DHPC), 1-myristoyl-2-hydroxy-sn-glycero-3-phosphocholine (LMPC) and 1-myristoyl-
2-hydroxy-sn-glycero-3-phosphatidylglycerol (LMPG) were purchased from Anatrace 
(Maumee, OH) and Avanti (Alabaster, Alabama). 
 
5.2 DNA techniques: All the cloning procedures were done following standard 
methods,[63] unless specified. The cDNA sequence of the human Y4 receptor was 
obtained from the Missouri S&T cDNA Resource Center, while the same sequence 
optimized for the E. coli codon usage was purchased from GeneArt. DNA sequences 
coding for the constructs TM13, TM45, N-TM45 and TM56 were amplified by PCR 
using as templates both human and the codon-optimized cDNA. All the forward and 
reverse primers used in this study are listed in Table S1 (Supp. Mat.). The PCR products 
were gel-purified and cloned into a pLC01 vector[55] between NdeI and BamHI restriction 
sites, and into a pET15b vector (Novagen) between NdeI and XhoI sites. Both plasmids 
are under the control of a T7 promoter and contain an N-terminal octa or deca-His tag, 
respectively. The extracellular N-terminal domain of the Y4 receptor (M1-M41), here 
used as a fusion protein for enhancing the expression of deuterated N-TM45, was 
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amplified by PCR and fused to the start of TM45 by overlapping PCR and cloned into a 
pLC01 vector between NdeI and BamHI sites. The DNA sequence coding for construct 
TM67 was amplified by PCR in order to include at the N-terminus an octa-His-tag and a 
3C protease cleavage site (LEVLFQGP), separated by a hydrophilic 20 amino-acids 
linker (AKQFVEDNAENDEAEKLFNQ). The modified TM67 was then cloned into a 
pLC01 vector between HindIII and BamHI containing the N-terminal fusion TrpΔLE (a 
vector obtained from the Fred Naider Lab). The DNA sequence of Mistic was obtained 
from the Choe lab and was fused by overlapping PCR to the sequence coding for the 
cDNA of the Y4 receptor, introducing a 3C cleavage site between the two sequences. The 
PCR product was gel-purified and cloned into a pET21b vector between BamHI and 
XhoI sites, and was later on used as a template for the amplification of all the Mistic-
constructs. For expression on large scale, the DNA sequence corresponding to Mistic-
TM13 was amplified by PCR and cloned into a pET15b vector. DNA sequences 
corresponding to the constructs Mistic-TM13, Mistic-TM45, Mistic-TM56 and Mistic-
TM67 were amplified by PCR using primers extended on their 5’ and 3’ by SapI sites 
using as templates vectors constructed previously[58] and cloned into a pBAD derivative 
vector (pBX3CGH) using the FX cloning method.[64] This vector is under the control of 
an arabinose promoter and contains the GFP gene following the cloning site. 
 
Site-directed mutagenesis on the sequence coding for TM45 was done following the 
QuikChange® methodology (Stratagene). Primers for that purpose were designed using 
the QuikChange Primer Design program. Again, plasmids were sequenced and used to 
transform E. coli BL21-AI cells. 
 
5.3 Strains and growth conditions: E. coli DH5α and E. coli BL21-AI (Invitrogen) 
were used as the host for the DNA manipulations and expression, respectively, for the 
constructs TM45 and its mutants as well as for TrpΔLE-TM67, while N-TM45 and 
TM56 were expressed in the E. coli strain C41.[65] Overnight cultures were grown in 
Luria-Bertani broth supplemented with ampicillin (100  µg/ml) at 37°C under vigorous 
shaking. Cells were then diluted 1:100 in 0.5 liter flasks (usually 2 L in total) of M9 
medium supplemented with ampicillin (100 µg/ml) containing 15NH4Cl or 15NH4Cl/13C-
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glucose as the sole nitrogen or carbon sources. For expression in deuterated water, cells 
were adapted to D2O by plating them on a D2O-M9 agar plate supplemented with 
ampicillin (100 µg/ml). Cells were grown at 37°C until the OD600 reached ∼ 0.8 (TM45, 
N-TM45, TM56) or 0.6 (TrpΔLE-TM67), after which the temperature was lowered to 
20°C. Expression was induced with arabinose (0.2%) in the case of the E. coli BL21-AI 
strain or with Isopropyl-β-D-thiogalactopyranoside (IPTG, 1 mM) for the E. coli C41 
strain. Induced cells were harvested after 16 hours of growth in M9/H2O or 40 hours of 
growth in M9/D2O. Due to higher expression levels, the E. coli Rosetta pLysS strain 
(Novagen) was chosen as the host for Mistic-TM13. Cells were grown overnight while 
shaking at 37 °C, diluted to 1:1000 in LB broth supplemented with ampicillin (100 
µg/ml), and grown at 37 °C until the OD600 was ∼ 0.5. Subsequently, the temperature was 
lowered to 16 °C followed by induction with IPTG (0.5 mM). Finally induced cells were 
harvested after 24 hours. All the GFP fusions were expressed in E. coli SF100 [recA, 
Δlac, Δompt] (a gift from the Lolkema lab) in LB-broth (0.7 ml) using a 96 well plate (2 
ml capacity). Cells from an overnight culture were diluted 1:100 and grown for 1 hour at 
37 °C. After the temperature was lowered to 25 °C for 90 min, protein expression was 
induced with arabinose (0.2%) and the cells were harvested 4 hours later. 
 
5.4 Purification from inclusion bodies: Cells were centrifuged at 6’000 g for 20 min. 
and the pellet was weighed and resuspended in a volume corresponding to ∼ 4 times the 
weight of the cell pellet in Tris-buffer (50 mM Tris-HCl pH 8.0, 500 mM NaCl and 1 
mM DTT). Cells were disrupted by sonication and inclusion bodies (IB) were separated 
by centrifugation at 10’000 g for 30 min. Inclusion bodies were solubilized in 
denaturation buffer (6 M GdmCl, 50 mM Tris-HCl pH 8.0, 500 mM NaCl, 1 mM DTT) 
upon sonication (TM45, N-TM45, TM56) or by stirring at RT overnight (TrpΔLE-
TM67). The insoluble material was removed by centrifugation (15’000 g for 30 min.)and 
the supernatant was mixed with the Ni-NTA resin (SIGMA) pre-equilibrated in the 
denaturation buffer, while stirring for 1 hour. The resin was washed with five column 
volumes of wash buffer (denaturation buffer containing 30 mM imidazole) and the target 
protein was eluted using a higher imidazole concentration (300 mM). The fractions 
corresponding to the elution peaks were pooled and dialyzed against 100 volumes of 
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water (overnight at RT) using a dialysis membrane (6-8 kDa, Spectrumlabs) to obtain the 
target protein in form of the precipitate. The precipitate was then solubilized in small 
quantities (usually 1 ml) of a highly reducing denaturation buffer (6 M GdmCl, 100 mM 
DTT, 250 mM β-mercaptoethanol (BME), 20 mM Tris-HCl, pH 8.0, 200 mM NaCl), 
after which the pH was lowered to ∼ 2.0. The samples were injected into a C4 Reversed-
Phase HPLC column (VYDAC) equilibrated with an aqueous solution containing 
trifluoracetic acid (TFA, 0.1%)  and acetonitrile (ACN, 10%), operated at 55°C. The 
target proteins (TM56, TM45, TM13) were eluted at 68, 74, 90% of ACN, respectively, 
in a H2O/ acetonitrile gradient.  
 
The fusion construct TrpΔLE-TM67 was initially purified from inclusion bodies (IB) by 
solubilization in a detergent buffer (50 mM Tris-HCl (pH 8.0), 500 mM NaCl, 10 mM 
BME and 1% DPC) in a volume corresponding to 5 times the weight of the IB pellet. The 
solution was kept stirring for 12 hours at 4 oC and the insoluble fraction was removed by 
ultracentrifugation (40’000 g, 20 min.). The soluble fraction was then applied to a Ni-
NTA column pre-equilibrated with detergent buffer (50 mM Tris-HCl, pH 8.0, 500 mM 
NaCl, 10 mM BME and 0.2% DPC). The column was washed and the target protein was 
eluted with the same buffer, additionally containing imidazole (30 mM and 300 mM 
respectively). Fractions corresponding to the elution peaks were pooled and the 3C 
protease was added at a final molar ratio of 1:5 of protease to target protein. The solution 
was then dialyzed overnight against 100 volumes of detergent buffer (50 mM Tris-HCl 
buffer pH 8.0, 0.2% DPC) and successively re-loaded onto the Ni-NTA column from 
which the flow through was collected. Unfortunately, the flow-through still contained 
most of the cleaved (His-tagged) TrpΔLE, which could be separated from the solution 
containing the fragment TM67 through multiple reloading on the Ni-NTA column. The 
same construct was also purified when solubilized inGdmCl (6 M), a procedure that was 
finally used for the preparation of the NMR samples. In this case, the GdmCl-solubilized 
fusion construct was purified from the inclusion bodies using the IMAC, and the fractions 
containing the fusion protein were pooled and mixed with the 3C protease in a final 
molar ratio of 1:5 (3C : TrpΔLE-TM67). The solution was subsequently dialyzed 
overnight against 100 volumes of protease cleavage buffer (50 mM Tris-HCl, pH 7.5, 200 
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mM NaCl and 10 mM BME).  Upon removal of denaturant to sufficient levels, the 3C 
protease refolds, and cleaves the TrpΔLE fusion. Both fragments, TrpΔLE and TM67 
precipitate, while most of the 3C protease remains in solution. The precipitate was then 
solubilized in 1 ml of denaturation buffer (6 M GdmCl, 100 mM DTT, 250 mM BME, 20 
mM Tris-HCl pH 8.0, 200 mM NaCl), after which the pH was lowered to ∼2.0. This 
solution was injected into the C4 RP-HPLC column, from which TM67 eluted at 61% 
acetonitrile using conditions described above. Fractions corresponding to the desired 
protein were lyophilized.  
 
5.5 Purification of Mistic-TM13: Cells were harvested by centrifugation at 6’000 g for 
15 min. at 4°C, and the cell pellet was resuspended in ice-cold KPi (50 mM), pH 7.5, 
NaCl (150 mM) such that the OD600 was  ~150-200. After adding lysozyme (1 mg/ml 
final), DNase (20 µg/ml final) and MgCl2 (1 mM final), cells were homogenized using a 
homogenizer device while keeping the suspension on ice and the solution was stirred for 
1 hour at 4°C. Subsequently, cells were disrupted by three passes at 15kPsi (Emoulsiflex, 
cooled), and a protease inhibitor mixture (Roche) was added. After removal of unbroken 
cells by centrifugation at 15’000 g for 15 min. at 4 °C, the supernatant containing the 
membrane fraction was centrifuged at 40’000 g at 4 °C for 1 hour. The formed pellet was 
resuspended in KPi (50 mM), pH 7.5, NaCl (150 mM), glycerol (10%) using a Potter 
tube (Sigma) to a final concentration of 1 gr. of membrane/ 2 ml of buffer, and 
immediately frozen in liquid nitrogen. Membranes were solubilized by stirring for 1 hour 
at 4°C in KPi (50 mM, pH 7.5), NaCl (300 mM), glycerol (5%), DTT (1 mM) and DPC 
(1% wt). Insoluble material was then removed by centrifugation (40’000 g at 4°C for 1 
hour), and the supernatant mixed with pre-equilibrated Ni-NTA resin. The column was 
washed with ten column volumes equilibration buffer containing imidazole (50 mM) and 
DPC (2 mM). The protein was eluted using a higher imidazole concentration (300 mM). 
The fractions corresponding to the desired protein were pooled together and dialyzed 
overnight against KPi (50 mM, pH 7.5), NaCl (300 mM), DTT (1 mM), glycerol (5%) 
and DPC (1 mM), adding 3C protease to the dialysis bag in a final molar ratio of 1:5 
(protease: target). Following buffer optimization, best conditions were observed using 
KPi (50 mM), NaCl (300 mM), glycerol (2.5%), DPC (1 mM), DTT (1 mM), 4°C for 48 
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hours. The cleavage was done during the dialysis step that was necessary to remove 
imidazole from the Ni-NTA elution in the presence of DPC (1 mM). This low detergent 
concentration was chosen as a compromise for solubilizing the protein and retaining 
activity of the protease. After 48 hours, the cleavage was almost quantitative although 
part of the excised protein precipitated. The solution from the dialysis bag was then 
mixed with pre-equilibrated Ni-NTA resin, and the flow-through containing TM13 was 
collected and concentrated using an Amicon Centricon tube (Millipore, 30’000 MW cut-
off). 
 
5.6 Solubilization assay and in-gel fluorescence: Samples for the solubilization assay 
were prepared as described elsewhere.[31] Briefly, cell pellets corresponding to a total 
amount of proteins (2 mg) were resuspended in KPi (50 mM pH 7.5), NaCl (150 mM), 
glycerol (5%), a protease inhibitor mix (Roche) and glass beads (Sigma). Cells were 
disrupted by using the FastPrep device (Bio101), the supernatant containing the 
membranes was transferred to ultracentrifuge tubes and incubated with the detergents 
used in the assay (1% wt/vol of LDAO, DPC or LPPG). From these solutions small 
aliquots were taken, mixed with SDS-loading buffer, and stored until further use. These 
samples represented the total amount of protein before solubilization. Samples were 
incubated for 1 hour on ice in presence of detergents, and the insoluble material was 
removed by ultracentrifugation (100’000 g, 20 min.). Again, small aliquots from the 
supernatant were then mixed with the SDS-loading buffer. These samples represented the 
amount of solubilized protein (see Figure S1). 
Aliquots were loaded on an acrylamide (15%) SDS-PAGE that was then blotted on a 
PVC membrane with the help of a semidry electroblotting system, followed by 
immunodetection (Roche). Chemiluminescence detection was performed using the 
Western light kit (Tropix, Inc.) and the Fujifilm LAS-3000 imaging system. Samples for 
the in-gel fluorescence of the constructs Mistic-TM13, Mistic-TM45, Mistic-TM56, 
Mistic-TM67 were prepared as described elsewhere.[31] In-gel fluorescence was detected 
using the Fujifilm LA300 imaging system. The same gel was then incubated in presence 
of a Ni-NTA Atto Complex (Sigma) binding the His-tag of the GFP fusion, following 
instructions from the manufacturer. His-tagged proteins were visualized using the 
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Fujifilm LAS-3000 imaging system (λem 669, λex white light). 
 
5.7 Samples preparation and NMR spectroscopy: NMR samples (TM45, N-TM45, 
TM56 or TM67) were prepared by dissolving the lyophilized powder obtained after the 
reverse-phase C4 purification in the final NMR buffer  (200 µl of 90% H2O/D2O 
containing 50 mM KPi, pH 6.0) in presence of selected detergent (5% wt/vol. of either 
LPPG, DPC, DHPC, LMPC or LMPG). The solution was subjected to several cycles of 
water-bath sonication and vigorous shaking at 37 °C until the powder was completely 
dissolved. The solution was then centrifuged at 10’000 g for ten minutes and the 
supernatant was transferred into a Shigemi NMR tube (Shigemi Inc.) for NMR 
measurements. The final protein concentrations were 0.2 mM and 0.4 mM for the 15N and 
the [15N,13C,2H] samples, respectively.  
 
We recently discovered that the exact details of sample preparation have a substantial 
impact on the quality of spectra. Often better samples yielding superior spectra were 
obtained when using a procedure suggested by Killian et al.[66] Therein the lyophilized 
protein was dissolved in hexafluoroisopropanol (HFIP, 50 µL) resulting in a clear 
solution. To this, NMR sample buffer (200µl of 40 mM phosphate, 20 mM DTT, 10% 
D2O, 1 mM TMSP and 5% LPPG) was added. The resulting cloudy suspension was 
diluted to 1 ml with water and the solution shaken at 37 °C with sporadic sonication 
cycles until a clear solution was obtained (4-8 h). The latter was lyophilized, redissolved 
in water and sonicated at 25 °C until a clear solution was obtained, which was lyophilized 
again. This step was repeated three times. Finally, the lyophilized powder was dissolved 
in water (200 µL) containing DTT (20 mM). 
 
All spectra were recorded on Bruker AV-600 or AV-700 spectrometers equipped with 
cryoprobes at 320K. The 2D experiments utilized gradient-selected coherence selection 
(echo-antiecho) [67] in combination with sensitivity enhancement schemes. Proton-
nitrogen correlation maps were measured as [15N,1H]-HSQC [68] (non-deuterated proteins) 
or as TROSY [69] (deuterated proteins) experiments. For assignment purposes of the 
receptor resonances, TROSY-versions [70] of standard 3D triple-resonance experiments 
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were recorded, such as the HNCO, HN(CA)CO, HNCA, HN(CO)CACB or the 
HNCACB [38,71] as well as from 15N-resolved NOESY experiments. For more details on 
data acquisition see the Supp. Mat. Table S2. 
 
Raw data was processed using the Bruker Topspin software version 2.1 and transferred to 
CARA[72] for further analysis. To investigate the effect of point mutations within TM4 on 
the signal intensity of signals from residues in TM4, a few well-resolved resonances were 
integrated. To eliminate influences of different concentrations or oligomeric states all 
integrals were normalized to obtain same integrals for G258, a flexible residue from the 
C-terminal tail. 
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7. Table of Contents 
To facilitate the assignment of the entire Y4 receptor or in order to enable study of its 
folding the almost complete sequence of the GPCR is expressed in large fragments 
comprising 2-3 transmembrane helices. Solution NMR techniques reveal that secondary 
structure in these fragments to a very large extend coincides with predictions for the 
entire receptor. Challenges and prospects for further studies of GPCR by NMR are 
discussed. 
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9. Supplementary Material 
 
Table S1: Oligomers used for cloning of various receptor fragments  
 !
Name Sequence (5-¶* 
TM13CO-NdeI/His10-For aat tta cat atg cat cac cat cac cat cac cat cac atgaataccagccatctgctg 
TM13CO-BamHi-Rev aat taa gga tcc tta ctggctaatgctcggtttc 
TM13WT- NdeI-His10-For aat tta cat atg cat cac cat cac cat cac cat cac atgaacacctctcacctcct 
TM13WT-BamHi-Rev aat taa gga tcc tta ctgtgagatgctgggcttc   
TM45CO- NdeI/His10-For aat tta cat atg cat cac cat cac cat cac cat cac gaacgtcatcagctgattat 
TM45CO- BamHI -Rev aat taa gga tcc tta cagaacaacattaacctgtt 
TM45 WT- NdeI/His10For aat tta cat atg cat cac cat cac cat cac cat cac gagaggcatcagctcatcatc 
TM45WT- BamHI -Rev aat taa gga tcc tta cagcaccacattgacctg 
TM56CO-NdeI/His10-For aat tta cat atg cat cac cat cac cat cac cat cac attctggaaaatgtgtttca 
TM56CO- BamHI -Rev aat taa gga tcc tta attgccatgacaaatcggaa 
TM56WT- NdeI/His10-For aat tta cat atg cat cac cat cac cat cac cat cac atcctggagaatgtcttc 
TM56WT- BamHI -Rev aat taa gga tcc tta gttcccgtggcagatgggga 
TM67-3C-For gaa gcg gaa aaa ctg ttt aac cag ctg gaa gtg ctg ttc cag ggg ccc 
TM67-20aa-linker-For cgc gcg aag cag ttc gtg gaa gat aac gcg gaa aac gat gaa gcg gaa aaa ctg ttt aac 
TM67-HindIII-His10-for gac aag ctt cac cat cac cat cac cat cac cat cac cat gaa cgc cgcgcgaagcagttcgtggaagat 
TM67-For ctggaagtgctgttccaggggccccggcgcctgcagaggcaggg 
TM67-Rev aat taa ggatcc tta aatgggattggacctgcca 
Mistic-For tttttaa catatg ttttgtacattttttgaaa 
Mistic-Rev ttaa ggatcc ttctttttcgccttcttc                 
TM13-wt-3C-For aattggatccctggaagttctgtttcagggtccgatgaacacctctcacctcc 
Mistic-FX-For atatatgctcttctagtttctgtacattttttgaaaaacatcac 
TM13-FX-Rev tatatagctcttcatgcctgtgagatactgggtttccagcctgt 
TM45-FX-Rev tatatagctcttcatgcacccttgtgaaacacgcgcccctgcct    
TM56-FX-Rev  tatatagctcttcatgcgcagatggggatggcctcatggtgc 
TM67-FX-Rev tatatagctcttcatgcaatgggattggacctgccacttagcct 
 
*Restrictions sites used for cloning of PCR products are depicted in red; octa-His tag introduced via forward primers is 
depicted in blue; 3C protease site used for constructs 'TrpLE-TM67 and Mistic-TM13 is depicted in purple; the 20 aa 
linker used for 'TrpLE-TM67 is depicted in green. 
 
 
 
!
!
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Figure S1: Solubilization assay: 15% acrylamide SDS-page, blotted on a PVC membrane 
and detected via anti-His antibody. Lysed cells were incubated with 1% (wt/vol) of 
LDAO (1), DPC (2) or LPPG (3). Lanes 4-6 correspond to TM13 solubilized by LDAO 
(4), DPC (5) or LPPG (6).  
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Figure S2: Locations of segments of the Y4 GPCR investigated in this work. Residue 
numbering is indicated a certain positions, and the first and last TM helix residues are 
encircled in bold black. Both full-sequence numbering as well a numbering according to 
the Ballesteros-Weinstein system (J. Ballesteros, H. Weinstein, Methods Neurosci. 1995, 
25, 366-428)  (in brackets) is used. The location of position 50 is highlighted by bold red 
circles. 
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Table S2: Spectroscopic details of NMR experiments: 
 
TM45 
experiment # of data points spectral width scans Remarks 
F3 F2 F1 F3 F2 F1 
[15N,1H]-HSQC  2048 256  16 32 128  
HNCO 2048 40 128 14 27 22 16  
HN(CO)CACB 2048 40 128 14 30 70 16  
HNCA 2048 40 128 16 30 32 16  
HN(CO)CA 2048 40 128 16 30 32 16  
15N-NOESY 2048 40 200 14 27 10 16 100ms mix 
NTM45 
 Data points Spectral width NS  
F3 F2 F1 F3 F2 F1 
[15N,1H]-HSQC  2048 300  16 33 32  
HNCO 2048 44 140 14 33 22 8  
HN(CA)CO 2048 48 128 16 25 16 8  
HNCACB 2048 44 140 18 25 70 16  
HN(CO)CACB 2048 44 140 18 25 70 16  
HNCA 2048 128 40 18 32 24 16  
HN(CO)CA 2048 40 128 18 24 32 16  
15N-NOESY 2048 42 180 14 24 10 16 150ms mix 
TM45TFE 
 Data points Spectral width NS  
F3 F2 F1 F3 F2 F1 
[15N,1H]-HSQC  2048 256  16 36 8  
HNCO 2048 40 128 14 24 22 4  
HNCACO 2048 40 128 14 24 22 16  
HNCACB 2048 40 140 14 24 70 8  
HN(CO)CBCA 2048 40 128 14 24 70 8  
15N-NOESY 2048 50 200 14 30 10 16 120ms mix  
TM67 
 Data points Spectral width NS  
F3 F2 F1 F3 F2 F1 
[15N,1H]-HSQC  2048 256  18 33 32  
HNCO 2048 40 128 18 22 22 8  
HNCACO 2048 40 110 18 22 22 16  
HNCACB 2048 40 124 18 22 70 32  
HN(CO)CACB 2048 40 128 18 22 70 16  
HNCA 2048 40 92 18 22 20 32  
HN(CO)CA 2048 40 97 18 22 18 32  
15N-NOESY 2048 40 161 14 22 10 16 120ms 
TM12 
Expt Data points Spectral width NS  
F3 F2 F1 F3 F2 F1 
[15N,1H]-HSQC  2048 256  18 25.7 16  
HNCO 2048 40 128 18 26 22 8  
HNCACO 2048 40 128 18 25 22.6 16  
HNCACB 2048 40 150 18 26 60 32  
HN(CO)CACB 2048 40 128 16 25 65 32  
HNCA 2048 40 128 16 25 32 8  
HN(CO)CA 2048 40 128 16 25 32 16  
15N-NOESY 2048 40 200 14 24 10 16 100ms 
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Table S3: Assignment statistics of [15N13C2H]-NTM45 in LPPG.  
NTM45 Amino acids number Assignment in sequence Assign 
Assign 
% 
N-term 
50 
(8 Histag, 4 
Proline) 
MHHHHHHHHMNTSHLLA
LLLPKSPQGENRSKPLGTP
YNFSEHCQDSVDVM 
 23   60%  
Half-I2 
loop 9 (1 Proline)  GWKPSISQA 3  37%  
TM4  22 (1 Proline) YLGIVLIWVIACVLSLPFLANS 2 1% 
E2 loop  38 (1 Proline) 
ILENVFHKNHSKALEFLAD
KVVCTESWPLAHHRTIYT
T 
 15  40% 
TM5 22 (1 Proline) FLLLFQYCLPLGFILVCYARIY 21 100% 
Half-I3 
loop 24  
RRLQRQGRVFHKGTYSL
RAGHMKQ   24  100% 
Total 165 (8 Histag, 8 Proline) 
MHHHHHHHHMNTSHLLA
LLLPKSPQGENRSKPLGTP
YNFSEHCQDSVDVMGWK
PSISQAYLGIVLIWVIACVL
SLPFLANSILENVFHKNHSK
ALEFLADKVVCTESWPLA
HHRTIYTTFLLLFQYCLPL
GFILVCYARIYRRLQRQG
RVFHKGTYSLRAGHMKQ 
 88  59% 
 
Table S4 Assignment statistics of [15N13C]-TM45 in LPPG.  
TM45 Amino acids number Assignment in sequence Assign 
Assign 
% 
I2 loop 28 (8 Histag, 2 Proline)  
MHHHHHHHHERHQLIINPTG
WKPSISQA 12  67%  
TM4  22 (1 Proline) YLGIVLIWVIACVLSLPFLANS  8  38% 
E2 loop  38 (1 Proline) ILENVFHKNHSKALEFLADKVVCTESWPLAHHRTIYTT  25  67% 
TM5 22 (1 Proline) FLLLFQYCLPLGFILVCYARIY  21 100% 
I3 loop 29  RRLQRQGRVFHKGTYSLRAGHMKQVNVVL  29  100% 
Total 139 (8 Histag, 5 Proline) 
MHHHHHHHHERHQLIINPTG
WKPSISQAYLGIVLIWVIACV
LSLPFLANSILENVFHKNHSK
ALEFLADKVVCTESWPLAH
HRTIYTTFLLLFQYCLPLGFI
LVCYARIYRRLQRQGRVFH
KGTYSLRAGHMKQVNVVL 
95  75%  
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Table S5 Assignment statistics of [15N13C]-NTM45 in TFE:H2O.  
NTM45 Amino acids number Assignment in sequence Assign 
Assign 
% 
N-term 50 (4 Proline) 
MHHHHHHHHMNTSHLLALL
LPKSPQGENRSKPLGTPYNFS
EHCQDSVDVM 
 45   100%  
Half-I2 
loop 9 (1 Proline)  GWKPSISQA 8  100%  
TM4  22 (1 Proline) YLGIVLIWVIACVLSLPFLANS 21 100% 
E2 loop  38 (1 Proline) ILENVFHKNHSKALEFLADKVVCTESWPLAHHRTIYTT  26  70% 
TM5 22 (1 Proline) FLLLFQYCLPLGFILVCYARIY 18 85% 
Half-I3 
loop 24  
RRLQRQGRVFHKGTYSLRAG
HMKQ  24  100% 
Total 165 (8 Proline) 
MHHHHHHHHMNTSHLLALL
LPKSPQGENRSKPLGTPYNFS
EHCQDSVDVMGWKPSISQAY
LGIVLIWVIACVLSLPFLANSI
LENVFHKNHSKALEFLADKVV
CTESWPLAHHRTIYTTFLLLF
QYCLPLGFILVCYARIYRRLQ
RQGRVFHKGTYSLRAGHMK
Q 
 142  90% 
 
Table S6 Assignment statistics of [15N13C]-TM67 in LPPG.  
TM67 Amino acids number Assignment in sequence Assign 
Assign 
% 
I3 loop 
26 (1 Proline, 1st 
Gly not 
observed)  
GPRRLQRQGRVFHKGTYSL
RAGHMKQ 22  92% 
TM6  22 (1 Proline) VNVVLVVMVVAFAVLWLPLHVF 12 57% 
E3 loop  17 (1 Proline) NSLEDWHHEAIPICHGN  17  100% 
TM7 24 (1 Proline) LIFLVCHLLAMASTC VNPFIYGFL  20 87% 
C-terminus 50 (3 Proline) 
NTNFKKEIKALVLTCQQSAP
LEESEHLPLSTVHTEVSKGS
LRLSGRSNPI 
 47  100% 
Total 139 (7 Proline) 
GPRRLQRQGRVFHKGTYSL
RAGHMKQVNVVLVVMVVA
FAVLWLPLHVFNSLEDWHH
EAIPICHGNLIFLVCHLLAM
ASTCVNPFIYGFLNTNFKKEI
KALVLTCQQSAPLEESEHLP
LSTVHTEVSKGSLRLSGRSN
PI 
118 90%  
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Figure S3: Detergent screen of TM67 using [15N,1H]-HSQC spectra and 300 µM 15N-
labeled TM67. Spectra are shown for samples in 5% DHPC (top left), 5% DMPG (top 
right), LMPC (bottom left) and LPPG (bottom right). 
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Figure S4: [15N,1H]-TROSY spectrum of NY4-TM1-TM2 
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Figure S5: [15N,1H]-HSQC spectrum of TM4-TM5 
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Figure S6: [15N,1H]-TROSY spectrum of TM6-TM7 
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Figure S7: Prediction of secondary structure of TM45 in TFE/water based on backbone 
chemical shifts using the program TALOS+. Residues predicted to be helical are colored blue, 
those without secondary structure in orange. 
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Figure S8: Expansions of [15N,1H]-HSQC spectra from TM45 (top), S171C and S171A 
(middle) and W164F or W164A (bottom) displaying the cross peak for G159 part of TM4. 
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Chapter III: Expression of C-terminal NPY4R fragments in inclusion bodies (IBs) 
and their purification 
 
1. Abstract 
Nowadays, transmembrane proteins (TMPs) are generally overexpressed by utilizing 
solubility-enhanced fusion tags such as SUMO, MBP, TRX, etc., which are easily 
cleaved by site-specific proteases and then followed by a simple affinity chromatographic 
purification. Alternatively, there are many other fusion protein tags existing for insoluble 
protein expression such as TrpΔLE, PurF, ketosteroid isomerase (KSI), and PagP, which 
require different conditions for cleavage like chemical cleavage, metal ion-catalyzed 
peptide bond cleavage etc., in presence of harsh denaturing conditions, followed by 
purification steps that require refolding. Expressing TMPs directly is widely practiced 
heterologously in non-native host systems such as E.coli, which often directs the TMP 
expression product into inclusion bodies due to the absence of ideal refolding machinery 
(such as chaperones), an overloading of the translocon machinery, and also because of 
the absence of a natural membrane environment that is capable of integrating multi-
spanning hydrophobic domains. This last approach is many-a-times disadvantageous 
because of the total lack of overexpression, and thus the reason for choosing a fusion tag. 
As an advantage, it has to be noted that IBs are relatively homogenous and mostly 
comprise only negligible impurities1. 
In this chapter, we describe the successful expression and purification of a number of C-
terminal fragments of NPY4R, in the form of inclusion bodies in E.coli either with or 
without the utilization of the fusion partner. Basically the fragments are 2-3 
transmembrane in length with complete loops or termini in most cases. We describe one 
specific expression and purification protocol, which was suitable for purifying TMPs 
expressed as inclusion bodies in E.coli strain.  
2. Introduction 
Expression of heterologous proteins in Escherichia coli frequently results in forming 
masses of insoluble aggregates known as inclusion bodies.  Although mechanisms behind 
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formation of inclusion bodies is not well understood, there are several reasons that could 
explain this phenomenon1: Solubility limitations, improper disulfide bond formation, the 
need to escape from protease sensitive enzymes, recombinant protein production at non-
optimal pH and temperature especially during unfavorable conditions such as drought, an 
N-terminal aminoacid sequence that hampers rapid membrane integration, expression of 
protein at rates too fast for subsequent folding and membrane integration, and the lack of 
essential chaperones. Recent findings suggest that the formation of IBs can be compared 
to that of an amyloid fibril polymerization. This specificity was demonstrated by in vitro 
studies with the triggering of nucleation cores between protein monomers and then as 
microaggregates to form bigger IBs2-5.  
The biochemical and biophysical properties of IBs in E. coli have been comprehensively 
studied in the last 3 decades. They exist as porous ovoids or cylinders with diameter 
about 1 µm6,7. IBs of recombinantly expressed proteins are considered relatively pure. 
Proteomic investigations revealed that the IB aggregates are relatively homogenous to 
>95%8-13. Components that have been seldom detected bound to IBs are phospholipids, 
nucleic acids 11 and a small background of host cellular proteins that are co-isolated from 
inadequate cell disruption. Cytoplasmic proteins rarely observed bound to IBs are small 
heat shock proteins IbpA and IbpB and minor amounts the chaperones DnaK and 
GroEL9,10,14,15. Occasionally E.coli membrane components exist as contaminants because 
of unspecific attachment during the purification process16. Most commonly identified 
membrane proteins bound to IBs are plasmid encoded proteins and OmpT that are 
responsible for antibiotic resistance (kanamycin resistance protein and β-lactamase)10,13.  
Transmembrane proteins (TMPs) when expressed in heterologous systems such as E.coli 
have a natural tendency to aggregate into IBs. When expressed in E.coli membranes, they 
are still most subsequently extracted into detergents that are suitable for biophysical 
characterization. Thus in both cases, TMPs are extracted or are refolded into detergents, 
and in most cases activity of the protein is assessed based on ligand binding. If the 
activity of the protein is regained when refolded from native membranes or from IBs, the 
method is useful. Parameters such as quantities of expressed protein, the purification 
strategy, ease of isotope labeling, and other biochemical parameter are accounted in 
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identifying the best method. Thus from an NMR point of view, TMPs expressed as IBs in 
enhanced quantities and their reconstitution into detergent micelles when possible, is 
advantageous, because it allows the more efficient synthesis of isotope-labeled proteins.  
Generally not all TMPs are expressed as IBs directly in E.coli. Reasons for directing a 
particular TMP into IB is not yet understood. When there is completely lack of 
expression of a particular type of TMP, insoluble fusion tags that direct proteins to IBs 
such as TrpΔLE, PurF, ketosteroid isomerase and PagP could help in TMP expression. 
Purifying IBs and reconstituting them into a membrane-type environment require special 
procedures, which are different from those used for soluble proteins. Protocols involving 
reconstitution take into account solubilizing the IBs in a strong denaturant such as 
Guanidinium Chloride (GdmHCl) or Urea, and then removing the denaturant through 
dilution, dialysis, or by chromatographic separation. This is followed by a refolding step 
into detergent micelles, bicelles or nanodiscs for NMR analysis. 
In this chapter we discuss the production of various TM fragments of the neuropeptide 
Y4 receptor (NPY4R), which is a human GPCR (Fig.1) in the heterologous expression 
system  Escherichia coli. Procedures involve direct expression or the usage of a fusion 
tag. Although we made attempts to use a soluble fusion tag such as SUMO for expressing 
the fragments, we were not successful in obtaining sufficient yields. When direct 
expression was possible, it was always directed into inclusion bodies. If the direct 
expression was not successful, we used the insoluble fusion tag, which is the TrpΔLE 
sequence that has already been discussed in the previous chapter.  Basically, in the 
previous chapter we explained the constructs TM12, TM45 and TM67. In this chapter we 
focus on constructs of truncated TM67, TM56 with N- or C-terminal His-tag, TM567 and 
a Cys-free mutant of TM567.   
Since all of the constructs were expressed as inclusion bodies both in LB (Luria Broth) 
and minimal medium, their purification strategy has been standardized to obtain high-
quality protein for biophysical analysis. The standardized methodology explained in this 
chapter includes cloning, expression tests both in LB and minimal medium and the 
purification strategy.  
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Figure 1. Schematic representation of a human NPY4R. The locations of 
extracellular, transmembrane and intracellular parts are depicted based on homology 
models of the receptor. Numbering refers to total receptor numbering (residue 1 refers to 
the N-terminus) or the Ballesteros-Weinstein nomenclature (in brackets). 
3. BL21AI E.coli strain for expressing complex TMPs 
E.coli BL21-type strains are mostly used because of useful features for producing 
eukaryotic TMPs. Some of the widely used BL21-type E.coli strains for recombinant 
protein expression are BL21(DE3), BL21(DE3)-pLysS, BL21 Star-pLysS, BL21AI, 
BL21 CodonPlus, C41(DE3) and C43(DE3). C41 and C43 E.coli strains are derivatives 
of BL21(DE3) strains. Although each strain has specific modification and has unique 
purpose, BL21AI stands out as the most suitable strain for us in expressing our TMP 
fragments. 
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Distinctive features of BL21AI strain compared to other E.coli strains are the lack of 
certain proteins such as Ion protease, outer membrane protease and OmpT. Absence of 
these proteases reduces the degradation of complex recombinant proteins. Additionally, 
the strain carries a chromosomal insertion of the gene encoding for T7 RNA polymerase 
(T7 RNAP) in the araB locus of the araBAD operon, enabling expression of T7 RNAP to 
be controlled by the araBAD promoter (PBAD) 17-19. Thus T7 RNAP can be regulated by 
the sugar L-arabinose. Because T7 RNAP concentration is tightly regulated, the BL21AI 
strain is particularly useful in expressing recombinant proteins that may be toxic. In other 
E.coli strains that display leaky basal expression of T7 RNA polymerase (e.g. BL21 
(DE3)) this would hamper cell growth.  
4. Materials and methods 
4.1  Cloning: The pLC01 plasmid was obtained from Prof. Fred Naider (College of 
Staten Island – CUNY, NY, USA). This plasmid originally contains a TrpΔLE gene 
cloned between Nde1 and HindIII restriction enzymes, and an Ampicillin resistance gene. 
The plasmid map of the pLC01 plasmid (without TrpΔLE) is presented in figure 2. 
Although the multiple cloning site contains more than 10 restriction recognition sites, the 
figure displays only 3 restriction sites that were used by us for most of our cloning 
purposes. The NPY4R fragment part of the gene that is to be inserted into pLC01 plasmid 
was amplified by polymerase chain reaction (PCR) from the wt-cDNA with the 
corresponding matching primers containing the restriction sites at the ends. Primers were 
ordered commercially from the supplier Microsynth AG.  
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Figure 2. Schematic representation of the pLC01 plasmid containing the Ampicillin 
resistance gene and the restriction sites utilized for cloning. 
For direct expressions, the gene of interest (TM fragment) is PCR amplified, purified and 
then double digested with Nde1 and BamH1, which subsequently is inserted into the 
plasmid pLC01 that is similarly doubly digested using the same restriction enzymes 
(figure3a). For introducing fusion tags such as SUMO or TrpΔLE, an overlapping PCR 
was performed between the fusion tag gene and the gene of interest (TM fragment) and 
then ligated into the Nde1 and BamH1 doubly digested plasmid. Alternatively, we 
generally maintained a pLC01 plasmid, which already contains the TrpΔLE fusion tag. In 
this case we just double digest the plasmid with HindIII and BamH1, and later ligated 
with the amplified TM gene of interest. For introducing the SUMO tag, we removed the 
TrpΔLE fusion gene by double digesting it with Nde1 and HindIII and later ligating it 
with the SUMO tag (figure 3b). 
 
 
Figure 3. Schematic representation of the pLC01 plasmid after introducing the TM 
fragment’s gene of interest between Nde1 and BamH1 restriction sites (3a). In 3b is the 
representation of pLC01 plasmid after introducing the fusion tag between Nde1 and 
HindIII restriction sites and the TM fragment gene of interest between HindIII and 
BamH1 restriction sites. 
3a. 3b. 
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For all the fragments of NPY4R, the target gene of interest was amplified from the wt-
cDNA present originally in pcDNA 3.1, which is a mammalian expression vector. 
Almost all constructs are designed by introducing a hexa or a octa His-tag through 
cloning. For the Cys mutants, the constructs were generated from a synthetic gene of 
NPY4R devoid of Cys residues. The synthetic gene of NPY4R was commercially ordered 
from the company GeneArt. Sequences of all generated clones (table 1) were confirmed 
by sequencing. Gene and protein sequence analysis was done using CLC Main 
workbench software and EXPASY tools available online. 
Sl.No. Construct Short Name Primers (5’-3’) 
1. His-NPY4R HisY4 
Fwd: ATA CAT ATG CAT CAC CAT CAC 
CAT CAC AAC ACC TCT CAC CTC CTG GCC 
Rev: AAT TAA GGA TCC TTA AAT GGG ATT 
GGA CCT GCC A 
2. NPY4R-His Y4His 
Fwd: ATA CAT ATG AAC ACC TCT CAC CTC 
CTG GCC Rev: ACG GGA TCC TTA ATG GTG 
ATG GTG ATG GTG ATG GTG AAT GGG 
ATT GGA CCT GCC 
3. 
ΔTrp-3C-w/o ICL3-
TM67-w/o Cter 
ΔxTM67x 
Fwd: GAC AAG CTT CTG GAA GTG CTG 
TTC CAG GGG CCC ATG AAG CAG GTC 
AAT GTG GTG CTG Rev: AAT TAA GGA TCC 
TTA AAT GGG ATT GGA CCT GCCA  
4. 
ΔTrp-3C-ICL3-TM67 
w/o Cter 
ΔTM67x 
Fwd: CTG GAA GTG CTG TTC CAG GGG 
CCC CGG CGC CTG CAG AGG CAG GG Rev: 
TCT AGA CTC GGA TCC TTA CAG GGC CTT 
GAT CTC CTT CTT 
5. 
SUMO-3C-ICL3-
TM67 w/o Cter 
S-TM67-x 
Fwd: ATT CAT ATG GGC AGC AGC CAT 
CAT CAT CAT CAT CAC GGC Rev: ATT AAG 
CTT ACC ACC AAT CTG TTC TCT GTG  
6. 
SUMO-3C-w/oICL3 -
TM67-Cter 
S-x-TM67 
Fwd: ATT CAT ATG GGC AGC AGC CAT 
CAT CAT CAT CAT CAC GGC Rev: ATT AAG 
CTT ACC ACC AAT CTG TTC TCT GTG 
7. 
ΔTrp-3C-ECL2-
TM56-ECL3 
ΔTM56 
Fwd: GTG CTT TTC CAA GGC CCA GAG 
AAT GTC TTC CAC AAG AAC Rev: AGA CTC 
GGA TCC TTA GTT CCC ATG GCA GAT 
GGG GAT GGC 
8. 
His-ECL2-TM56-
ECL3 
HisTM56 
Fwd: AAT TTA CAT ATG CAT CAC CAT CAC 
CAT CAC CAT CAC ATC CTG GAG AAT GTC 
TTC Rev: AAT TAA GGA TCC TTA GTT CCC 
GTG GCA GAT GGG GA 
 92 
9. 
ECL2-TM56-ECL3-
His 
TM56His 
Fwd: ATT CAT ATG ATC CTG GAG AATGTC 
TTC Rev: CCT GGA TCC TTA ATG GTG ATG 
GTG ATG GTG GTT CCC ATG GCAGAT GGG 
10. 
ECL2-TM567-Cter-
His 
TM567His 
Fwd: ATT CAT ATG ATC CTG GAG AAT 
GTC TTC Rev: ACG GGA TCC TTA ATG GTG 
ATG GTG ATG GTG ATG GTG AAT GGG 
ATT GGA CCT GCC 
11*. 
ECL2-TM567-ECL3-
His (Cys free) 
TM567His 
(Cys-free) 
C201S-Fwd: GCA GAT AAG GTG GAC AGT 
ACC GAG TCC TGG Rev: CCA GGA CTC GGT 
ACT GTC CAC CTT ATC TGC 
12*. 
ΔTrp-3C-ICL3-
TM67-Cter (Cysfree) 
ΔTM67-
Cys-free 
C298N-Fwd: GAG GCC ATC CCC ATC AAC 
CAT GGG AAC CTC ATC Rev: GAT GAG GTT 
CCC ATG GTT GAT GGG GAT GGC CTC 
C307F-Fwd: AAC CTC ATC TTC TTA GTG 
TTC CAC TTG CTT GCC ATG GCC Rev: GGC 
CAT GGC AAG CAA GTG GAA CAC TAA 
GAA GAT GAG GTT  
C316F-Fwd: CTT GCC ATG GCC TCC ACC 
TTT GTC AAC CCA TTC ATC TAT Rev: ATA 
GAT GAA TGG GTT GAC AAA GGT GGA 
GGC CAT GGC AAG  
C340K-Fwd: AAG GCC CTG GTG CTG ACT 
AAG CAG CAG AGC GCC CCC CTG Rev: CAG 
GGG GGC GCT CTG CTG CTT AGT CAG CAC CAG 
GGC CTT 
* These constructs/mutants were generated using the quick-change protocol as illustrated 
by the commercial supplier Stratagene.  
Table 1. Different fragments of NPY4R generated by cloning into the pLC01 vector. 
Primers of each construct are listed. 
 
4.2  Expression tests: After confirming the clones by sequencing, initial tests were done 
by transforming the plasmids into various E.coli expression strains. Protein 
overexpression was tested by small-scale screening, in which cells were grown in 1-3 ml 
of LB medium containing the appropriate antibiotic at 37oC, and by using different 
inducer concentrations at different cell densities, and also by lowering temperatures after 
induction. In most cases, the BL21AI strain was used as the expression strain, requiring 
arabinose as its inducer. Best expression yields were obtained with 0.2% arabinose as the 
inducer at 20oC in the BL21AI strain. Once overexpression was observed, LB medium 
was switched to minimal medium with 15N-labeled NH4Cl on a 1-liter scale. Based on the 
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protein overexpression levels per liter of medium, 1-3 liters of cultures were used for the 
subsequent purification steps. Basic ingredients in an M9 medium are listed below. 
4.3  Minimal Medium Components 
The following is the recipe for 1 liter of M9 minimal medium: 
M9-salts: 
• KH2PO4 -------------- 4 g/l 
• K2HPO4 -------------- 4 g/l 
• Na2HPO4 * 2 H2O -- 3.5 g/l 
• NaCl ------------------ 1 g/l 
• NH4Cl ---------------- 1 g/l 
Note: Normal NH4Cl was replaced with 15NH4Cl if 15N labeling was desired. 
 
To the above ingredients, 960 ml of deionized water was added to dissolve the salts and 
then the mixture was autoclaved. To the autoclaved 960 ml M9 salts solution, the 
following components were added to complete the M9 medium: 
 
• 1 M MgSO4 solution (autoclaved separately): 10 ml 
• 20% (w/v) Glucose (filter sterilized): 25 ml, which gives final concentration of 5 
g/l of M9 medium. For 13C-labelling the final concentration of 13C-Glucose was 
between 3-5 g/l. 
• 150 mM Thiamine HCl (Vitamin B1; sterile filtered): 1 ml 
• Antibiotic of choice: 1 ml 
• Trace metal stock (sterile filtered): 1 ml 
• pH of medium in the end was adjusted to 7.2 
 
Trace metal stock composition: 
FeSO4 * 7H2O ----------- 4 g/l 
CaCl2 * 2H2O ----------- 4 g/l 
AlCl3 * 6H2O ------------ 1 g/l 
MnSO4 * nH2O ---------- 1 g/l 
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CoCl2 * 6H2O -----------  0.4 g/l 
ZnSO4 * 7H2O ----------- 0.2 g/l 
CuCl2 * 2H2O ------------ 0.1 g/l 
H3BO3  -------------------- 0.1 g/l 
Caution: One must be careful while dissolving these salts, as some may react vigorously 
with water. Better is to dissolve them in a wide-open container (e.g. in a beaker) and not 
in a narrow vial (such as a Falcon tube). Some precipitate will be observed but this can be 
dissolved by drop wise addition of concentrated HCl. After the precipitate 
disappears/dissolves solution was sterile filtered.  
 
4.4  Protein purification: The basic methodology for purifying proteins that are 
expressed in inclusion bodies was explained in the previous chapter. In brief, IBs isolated 
from sonicated cells were solubilized in 6 M GdmHCl, subjected to Ni-NTA purification 
and further purified on C4 RP-HPLC column. Wherever a fusion protein was involved, 
enzymatic cleavage was performed after affinity purification by adding the 3C precision 
protease to the elute obtained from affinity column. Subsequently, the denaturing buffer 
was removed by dialysis, resulting in precipitation of TM protein and fusion partner. The 
precipitate was re-solubilized in GdmHCl and further purified by C4 RP-HPLC using a 
water-acetonitrile gradient. All fragments of NPY4R overexpressed as IBs were 
subjected to the above standard purification method.  
 
5. Results 
 
5.1  Cell growth and protein expression: Once the cloned constructs were sequence 
confirmed, they were transformed into BL21AI E.coli cells for testing protein 
overexpression. The results of the expression tests are summarized in Table 2, and 
indicate that few of them showed very good and few absolutely no expression. 
Expression was initially screened on whole cells by looking at the cell lysates on SDS-
page.  Once expression occurs, it was investigated whether they accumulate in the soluble 
or in the insoluble fractions. In almost all cases the overexpressed protein was observed 
in the inclusion bodies.  
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Sl.No. Construct Short Name Fusion Expression Can be purified 
1. His-NPY4R HisY4 ---- No ------ 
2. NPY4R-His Y4His ---- No ------ 
3. 
ΔTrp-3C-w/o ICL3-
TM67-w/o Cter  
ΔxTM67x TrpΔLE Yes No 
4. 
ΔTrp-3C-ICL3-TM67 
w/o Cter 
ΔTM67x TrpΔLE Yes No 
5. 
SUMO-3C-ICL3-
TM67 w/o Cter 
S-TM67-x SUMO No ----- 
6. 
SUMO-3C-w/oICL3 -
TM67-Cter  
S-x-TM67 SUMO No ----- 
7. 
ΔTrp-3C-ECL2-
TM56-ECL3 
ΔTM56 TrpΔLE Yes No 
8. 
His-ECL2-TM56-
ECL3 
HisTM56 ---- Yes Yes 
9. 
ECL2-TM56-ECL3-
His 
TM56His ---- 
Yes (No in 
D2O) 
Yes 
10. 
ECL2-TM567-Cter-
His 
TM567His ---- Yes Yes 
11. 
ECL2-TM567-ECL3-
His (Cys free) 
TM567His 
-(Cys free) 
---- Yes Yes 
12. 
ΔTrp-3C-ICL3-
TM67-Cter (Cysfree) 
ΔTM67-
Cysfree 
TrpΔLE Yes Yes 
Table 2. Expression yields and success of purification for different fragments of NPY4R. 
 
Note: As the discussion progresses, I would be using the symbol ‘Δ’ in denoting ΔTrp 
and the symbol ‘x’ in denoting the removal of N- or C-terminus. 
Expression of the full-length receptor with either N- or C-terminal His-tag was not 
possible. Although few of them such as ΔTM67x and ΔxTM67x were expressed as IBs 
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with the help of a fusion-tag, the enzymatic cleavage and its subsequent purification 
proved to be very difficult. To bypass the difficulties related to poor solubility we also 
used the soluble SUMO fusion instead, but this resulted in a total loss of protein 
expression. A new construct of ΔTM56 was made with the fusion to TrpΔLE, which gave 
identical problems as in the case of ΔTM67x and ΔxTM67x. Subsequently, direct 
expressions were tested for TM56 with a His-tag on either N- or C-terminus, which both 
(TM56His and HisTM56) gave positive results with respect to expression and 
purification. Finally, TM7 was added to the TM56 construct to test direct expression of 
longer fragments. Surprisingly the new 3-TM construct TM567His displayed even better 
expression than the 2-TM constructs of TM56 (HisTM56 & TM56His). Since the 3-TM 
construct was also a direct expression in the form of IBs, no cleavage was required and 
purification was straightforward.  
 
In the following table the yields are summarized for proteins that were subjected to more 
detailed biophysical analysis (table 3). 
 
Sl.No. Construct LB 
(mg/l of culture) 
M9-H2O 
(mg/l) 
M9-D2O 
(mg/l) 
1. HisTM56 2 4 0.75 
2. TM56His 1 1.5-2 0 
3. TM567His 3 10 0.8 
4. TM567His  (Cys-free) 4 10 * 
5. ΔTM67 (Cys-free) 3 5 * 
* Not tested yet 
Table 3. Protein yields of different NPY4R fragments in 3 different media.  
It is also interesting to note the growth parameters such as pH and the cell-densities of 
BL21AI E.coli strain under different labeling conditions at the start and the end of cell 
cultures (table 4). In general it is assumed that the cells stop growing if they are unable to 
express the recombinant proteins, but I have observed the contrary with the BL21AI cells 
as they always were growing irrespective of the TMP was expressed or not. Growth 
parameters indicated in the below table was a standard phenomenon for the BL21AI 
strain for all expressions attempted on the C-terminal NPY4R fragments. 
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Factor LB M9-H2O M9-D2O 
pH 
Start 7.2 7.2 7.2 
End 6.4 5.8 6.8 
Time required to reach 
induction OD600 of 0.8 
2hrs 5-6hrs 20-24hrs 
Maximum cell density (OD600) 
reached after 24hrs of induction 
at 20oC (48hrs in case of M9-
D2O) 
1.8 4.2 1.8 
Table 4. Factors fluctuating while growing BL21AI strain in different media. 
It is interesting to note that the yields are comparably high in M9-H2O, which might be 
correlated to high cell densities as observed in table 4. Another aspect is the drastic 
reduction of protein yields in M9-D2O, which might be correlated to extremely slow 
growth rate as observed from the induction times in table 4. 
If we consider the availability of various factors/nutrients for the growth of BL21AI 
E.coli strain in LB and M9 minimal medium, cells were not able to grow beyond a cell 
density of 1.8 in LB but to high densities of above 4 in M9-H2O. Changing from H2O to 
D2O with the same M9 components, growth had been reduced drastically from 4.2 to 1.8 
even after considering their slow nature of growth. 
5.2  Protein Purification: Since all fragments expressed into IBs, they were solubilized 
using 6M GdmHCl containing Tris buffer (20 mM Tris - pH 8.0, 150 mM NaCl and 10 
mM β-mercaptoethanol) for overnight. Solubilized IBs were loaded onto a Ni-NTA 
column pre-equilibrated with the above denaturing buffer, washed sequentially each time 
with three column volumes of the same buffer additionally containing 10 mM, 20 mM 
and 30mM imidazole. His-tagged protein was eluted with 200 mM Imidazole containing 
denaturing buffer, which was further purified using C4 RP-HPLC column (VYDAC). 
Before loading into the C4 column, pH of the Ni-NTA elute was reduced to 2, which 
allows binding to the hydrophobic column which is pre-equilibrated with the solvent 
mixture – 90% water and 10 Acetonitrile (both contain 0.1% TFA). Acetonitrile 
concentration was gradually increased allowing the column bound protein to be 
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completely soluble at certain water-acetonitrile gradient. The gradient concentration, at 
which the protein separates from the column, depends on its hydrophobicity. 
Attempts were made to purify all the expressed proteins. Fragments such as ΔTM67x, 
ΔxTM67x, ΔTM56, HisTM56, TM56His, TM567His, TM567His (Cys-free) and ΔTM67 
(Cys-free) of NPY4R had shown expression and thus we will discuss the purification of 
each fragment of NPY4R separately. Each fragment will be denoted with a snakeplot-
type schematic representation, exact sequence taken from the protoparam file format and 
their chromatographic purification followed by analysis on SDS-PAGE. 
 
5.2.1  Construct 1. ΔTrp-3C-w/o ICL3-TM67-w/o Cter (ΔxTM67x): 
xTM67x Sequence after cleavage:  
 
Residues: 79; Molecular weight: 8.91 kDa 
From the previous chapter, NMR characterization of a TM67 fragment containing ICL3 
and the C-terminal domain was near to 80%, but the assignments of the TM regions 
(TM6 & TM7) were difficult because peaks were either weak or absent. Most of TM6 
was only partially assigned. The reasons might be attributed to the redundancy of valines 
in the sequence (VNVVLVVMVVA) resulting in peak overlap or extensive line 
broadening due to conformational exchange effects. To at least overcome the peak 
overlap problem, the following construct was designed by removing the complete ICL3 
loop and nearly 70% of C-terminus while keeping the soluble helix 8 intact. This 
construct was well expressed as a fusion in the IBs but the enzymatic cleavage of the 
fusion partner was reduced by 50% compared to the original construct that contained the 
full loops (fig 4c and fig 4d). Although a small peak of xTM67x was observed at 74% 
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water- acetonitrile gradient, SDS-PAGE analysis showed large contamination from the 
uncleaved fusion.  
Additional feature of this construct was its very high hydrophobicity, which might not be 
suitable to work with C4 RP-HPLC purification. I observed that there is considerable 
amount of protein loss on injecting the cleaved products into the hydrophobic column and 
alternatively the xTM67X product would very easily aggregate with its partners 
rendering the purification process altogether difficult. Thus this fragment was not 
analyzed further primarily because of the very low efficiency of the enzymatic cleavage 
of the fusion and its difficulty to handle in solubilizing it in monodisperse form. 
 
Figure 4. Snake plot of the Y4 receptor with the ΔxTM67x region highlighted in yellow 
(4a and 4b). RP-HPLC chromatogram of ΔxTM67x after performing the precision 
protease cleavage (4c) and the purity of each observed peak was analyzed by SDS-PAGE 
(4d). 
   M     80%    74%  68%   55% 
Fusion 
xTM67x 
4a. 4b. 
4c. 4d. 
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5.2.2  Construct 2. ΔTrp-3C-ICL3-TM67 w/o Cter (ΔTM67x): 
TM67x Sequence after cleavage:  
 
Residues: 100; Molecular weight: 11.42kD 
We reasoned that the cleavage site might be not accessible because it is too close to the 
hydrophobic TM segments. Accordingly, ICL3 was re-introduced (fig 5a and 5b). When 
tested, the enzymatic cleavage improved compared to ΔxTM67x, but the TM67x 
fragment obtained from the cleavage of fusion construct (ΔTM67x) tends to aggregate on 
the column as the peak of interest was of very low intensity while eluting with the water 
– acetonitrile gradient (fig 5c). We observe strong peak for the ΔTrp which normally 
elutes at 55% of water-acetonitrile gradient and thus conclude that this construct was 
good for C3 protease cleavage but not for hydrophobic purification. The cleaved TM67x 
product tends to be very hydrophobic that is resulting in strong interactions the 
hydrophobic tails of the column or could be co-aggregating and precipitating in the 
column.  
We speculate that the long C-terminus (nearly 45 residues) is necessary to keep the 
fragment in the monomeric state. Although the cleavage yields are better than for the 
previous construct, they were not as reproducible as in the original TM67 fragment 
discussed in the previous chapter.  
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Figure 5. Snake plot of the Y4 receptor with the TM67x region highlighted in yellow (5a 
and 5b). Purification of TM67x fragment by reverse-phase HPLC after performing the 
precision protease cleavage (5c). Since the peaks obtained were of very low intensity, I 
didn’t analyze the fractions by SDS-PAGE.   
5.2.3  Construct 3. ΔTrp-3C-ECL2-TM56-ECL3 (ΔTM56): 
TM56 Sequence after cleavage: 
 
Residues: 123; Molecular weight: 14.32 kDa 
5a. 5b. 
5c. 
 102 
Similar to construct 1, the idea behind designing this construct was to better understand 
the reason for the observed line-broadening of resonances from TM6. We suspected that 
the broadening might be due to interactions with TM5 that take place on an unfavorable 
timescale.  Thus TM56 was designed as a fusion to TrpΔLE (fig 6a and 6b). As a fusion, 
the fragment ΔTM56 was well expressed but the cleavage efficiency was so low that the 
purified TM56 could not be identified on the SDS-PAGE (fig 6c and 6d).  
 
 
Figure 6. Snake plot of the Y4 receptor with the TM56 region highlighted in yellow (6a 
and 6b). Purification of TM56 fragment by reverse-phase HPLC (6c) after cleavage and 
SDS-PAGE of the fractions from the HPLC (6d). 
6a. 
6b. 
M  __52%B     61%B    66%B  
KDa 
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From the chromatogram (6c) and the SDS-Page gel (6d) analysis, the peak at 52% water-
acetonitrile gradient was supposed to be the cleaved TrpΔLE, the peak at 61% 
acetonitrile gradient was the uncleaved fusion and the broad peak at 66% gradient also 
shows the uncleaved fusion on SDS-PAGE due to the tailing of prior peak at 61%. I 
assume that the peak at 66%B contains TM56 at very low concentrations, which can’t be 
detected using SDS-PAGE. Since the cleavage was low and the purification didn’t show 
promiscuous outlook for more optimizations, I decided to check for direct expression of 
the same construct. 
5.2.4  Construct 4. His-ECL2-TM56-ECL3 (HisTM56): 
HisTM56 Sequence: 
 
Residues: 132; Molecular weight: 15.62 kDa 
To avoid the problems that occurred during cleavage and purification of the fusion 
proteins, HisTM56 was designed for direct expression. An octa-His-tag was introduced at 
the N-terminus of TM56 (fig 7a and 7b) for affinity purification. Following expression 
HisTM56 was observed in the inclusion bodies and a purification protocol similar to that 
used for the previous constructs was followed, except for the need for enzymatic 
cleavage.  After affinity purification, HisTM56 was loaded onto a C4 column for RP-
HPLC purification and the purified fragment eluted at 62% acetonitrile/water gradient 
(fig 7c), which is confirmed by SDS-PAGE analysis (fig 7d). As discussed in the table 3, 
this construct gave sufficient yields (4 mg/l in M9-H2O) for generating an NMR sample 
and for spectroscopic characterization. This fragment was expressed in very low 
quantities when changed from M9-H2O to M9-D2O (0.75 mg/l) and the yields were down 
to only 20% of M9-H2O expression. NMR characterization was performed with this 
fragment, which will be discussed in the following chapter. 
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This was my first construct where I was successful in identifying and purifying a NPY4R 
fragment without the usage of a fusion tag. Although reasonable yields were obtained 
from IBs, I also tested if any fraction of the protein goes into the membranes. I collected 
the supernatant or the soluble fraction from the sonicated cells and tried to extract the 
His-tag containing proteins using Ni-NTA resin. On SDS-PAGE analysis, I wasn’t able 
to see any protein at the respective molecular weight of TM56 indicating all of the 
expressed TM56 was diverted into IBs.  
 
7a. 
7b. 
7d. 7c. 
kDa 
 
 
 
 
 
30 
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20 
 
15 
M       62%B 
HisTM56 
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Figure 7. Snake plot of the Y4 receptor with the HisTM56 region highlighted in yellow 
(7a and 7b). HPLC chromatogram of HisTM56 (7c) and SDS-PAGE of the main peak 
(7d). 
5.2.5  Construct 5. ECL2-TM56-ECL3-His (TM56His): 
TM56His sequence: 
 
 
Residues: 130; Molecular weight: 15.35 kDa 
Since few of the TM residues in the previous construct were unable to be analyzed 
(assigned) by NMR, We speculated an interaction with the N-terminal His-tag resulted in 
poor spectral quality of the previous construct, and thus we designed a new construct of 
identical sequence but with the His-tag (6x) attached to the C-terminus. Expression yields 
were reduced to <50% compared to the previous construct (table 3), pointing to an 
important role of the position of the His-tag. While sufficient yields were obtained for 
biophysical analysis in M9-H2O (fig 8c and 8d) no expression was observed in M9-D2O. 
Exhaustive screening by varying temperature after induction, inducer concentration and 
inducing cell densities was done for the expression of TM56His in D2O but with no 
success. Probably this is related to the fact that expression yields were already low in M9-
H2O compared to the previous construct. 
As indicated in table 3, this construct yielded less than half of the quantities (around 1.5 – 
2 mg/l) in M9-H2O compared to the prior construct and to make things worse, it hasn’t 
expressed at all in M9-D2O. At this stage, not knowing the facts that direct expressions 
yields drop drastically in M9-D2O, I made many despairing attempts changing conditions 
(temperature and induction parameters) to check for expression on a small scale. 
Considering TM7 in TM67 behaves well (TM7 backbone was nearly completely 
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assigned), I attempted to add TM7 to TM56 generating new construct with a hope to 
obtain better yields and thus moved on to the next construct TM567His. 
 
Figure 8. Snake plot of the Y4 receptor with the TM56His region highlighted in yellow 
(8a and 8b). HPLC Chromatogram of 15N-TM56His (8c). The fraction at 63% was 
analyzed by SDS-PAGE (8d). UI – Uninduced; I – Induced. 
5.2.6  Construct 6. ECL2-TM567-Cter-His (TM567His): 
TM567His Sequence:  
 
8b 8a 
TM56His 
M       UI       I        63%B 
8d 8c 
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Residues: 206; Molecular weight: 23.76 kDa 
One of the project’s goal was to investigate to which extend chemical shifts can be 
transferred from the shorter to the longer fragments. Moreover, we were interested to 
learn how additional helices may stabilize secondary or tertiary structure, and whether 
they improve integration into the membrane. To this end the following fragment 
TM567His was designed with an octa-His-tag attached to the C-terminus for direct 
expression (fig 9a and 9b).  
Considering the low expression yields of the previous fragment (TM56His), we assumed 
the larger fragment to be expressed in extremely low yields. Surprisingly, this fragment 
expressed much better than any of the previously described fragments. Protein was 
directed into inclusion bodies, purified by Ni-NTA in denaturing buffer (GdmHCl) and 
subsequently refined by C4 RP-HPLC (fig 9c). The fragment TM567His eluted at 64% 
acetonitrile gradient in a pure form, which was analyzed by SDS-PAGE (fig 9d).   
 
9b 9a 
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Figure 9. Snake plot of the Y4 receptor with the TM567His region highlighted in yellow 
(9a and 9b). HPLC chromatogram of TM567His (9c). SDS-PAGE of the 64% water-
acetonitrile fraction as well as with cell-lysates (9d). UI – Uninduced; I – Induced. 
5.2.7  Construct 7. ECL2-TM567-Cter-His w/o Cys (TM567His Cys-free): 
TM567His-Cysfree Sequence:
 
Residues: 206; Molecular weight: 23.87 kDa 
Broad lines in the previous construct lead us to suspect that aggregation occurred through 
formation of intermolecular disulfide bonds. Accordingly, we designed a construct, 
which is free of Cys amino acids. Moreover, a Cys-free mutant would be required for 
attaching MTSL spin labels to unique sites to allow for PRE experiments. The mutated 
residues are underlined in red in the above sequence, and the nature of the replacement 
was decided based on a sequence alignment of NPY receptor homologues. The most 
conserved residues were selected as Cys replacement. Thus we ordered a synthetic gene 
9d 9c 
kDa 
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of NPY4R, which is completely free of Cys residues. From the synthetic gene, the 
TM567 construct was generated by adding a His-tag (8x) to the C-terminal end.  
Expression was followed similar to the wild type fragment, which was purified initially 
using affinity chromatography and then followed by C4 RP-HPLC purification (10c). The 
major peak, which is the purified TM567His Cys-free protein, was confirmed by SDS-
PAGE analysis (10d). 
 
 
Figure 10. Snake plot of the wild type TM567His (10a) and of TM567His-Cysfree 
mutant (10b) with the replaced Cys-residues highlighted in red. HPLC chromatogram of 
TM567His (10c) and SDS-PAGE of the main HPLC peak at 64% ACN (10d).  
10b 10a 
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6. Discussion 
Excluding rhodopsin, all GPCRs exist in their native membranes at moderately low 
levels, and thus for structural investigations the only practical way in obtaining them in 
milligram quantities is by recombinant expression in heterologous hosts. Heterologous 
hosts used for GPCR expression are bacteria, yeast, mammalian cells, insect cells 
infected by baculoviruses, and using host extracts for cell-free synthesis. Recently, most 
of the GPCR structures analyzed were obtained by expressing them in insect cells, which 
provide milligram quantities of protein for crystallization purposes20-25. However, host 
systems such as mammalian- or insect cells cannot be adapted for the synthesizing 
isotope labeled proteins required for NMR because of the complexity and high costs 
associated with the nutrients involved.  
Eukaryotic transmembrane proteins can sometimes be expressed in very simple to handle 
heterologous systems such as bacteria, but post-translational modifications and proper 
refolding remains as an ongoing issue. However, many trials proved that the detergent 
reconstituted TMPs from bacterial membranes26-28 or refolded proteins from IBs29-33 have 
native folding mimicking the activity when present in native environments. In general, 
expression of heterologous proteins in bacterial strains is not generally possible. Protein 
expression levels depend on amino acid sequence, the type of bacterial strain as well as 
on details of expression conditions (temperature, availability of protein folding 
machinery and their sustaining environments). Many a times these factors could be 
circumvented by using fusion tags that help in folding, directing to bacterial membranes 
or to inclusion bodies. Usage of a fusion tag could give good protein yields or good 
quality protein but the purification processes involving cleavage are most of the times 
complicated resulting in unnecessary time-consumption. To understand the nature of 
widely used fusion tags, we shall examine the N-terminal amino acid sequence of first 30 
residues.  
 Protein Aminoacid sequence of soluble fusion tags 
1. Ubiquitin MQIFV KTLTG KTITL EVEPS DTIEN VKAKI 
2. SUMO MSDQE AKPST EDLGD KKEGE YIKLK VIGQD 
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3. MBP MKIEE GKLVI WINGD KGYNG LAEVG KKFEK 
Table 5. First 30 residues of the most commonly used soluble fusion-tags. Charged 
aminoacids are highlighted in red; polar aminoacids in blue and the remaining are the 
hydrophobic aminoacids. 
These soluble fusion tags are dominated by charged and polar residues, which could also 
help in solubilizing or proper folding of certain proteins. On the other hand fusion tags 
(few examples shown below), which direct the proteins into insoluble IBs, contain equal 
amounts of hydrophobic residues spread over the sequence.    
 Protein Aminoacid sequence of insoluble fusion tags 
4. TrpΔLE MKAIF VLKGS LDRDL DSRIE LELRT DHKEL 
5. KSI MREYS SRQTR RGCSP PCRRI EAKVI DGRNY 
6. PagP MNVSK YVAIF SFVFI QLISV GKVFA NADEW 
Table 6. First 30 residues of the most commonly used insoluble fusion-tags. 
Sometimes a TMP is expressed in the E.coli expression system even in absence of a 
fusion tag, and will most of the time be observed in the insoluble inclusion body fraction. 
Reasons for few of the protein expressions directed to membranes and few of them into 
inclusion bodies are again not known. But it is interesting to compare the N-terminal 
sequences of our fragments with those of both the widely used soluble and insoluble 
fusion protein sequences. Another interesting fact observed in NPY4R fragments is the 
expression of TM56His in very low quantities compared to TM567His, which is contrary 
to the fact that in E.coli expression of shorter TMPs should be easier than larger multi-
helical TMPs.  
 Protein Aminoacid sequence of NPY4R fragment constructs Yields 
7. TM67 RRLQR QGRVF HKGTY SLRAG HMKQV NVVLV 0 
8. HisTM56 MHHHH HHHHI LENVF HKNHS KALEF LADKV 4 mg/l 
9. TM56His MILEN VFHKN HSKAL EFLAD KVVCT ESWPL 2 mg/l 
10. TM567His MILEN VFHKN HSKAL EFLAD. ………+TM7 10 mg/l 
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Table 7. First 30 residues of different NPY4R fragments used in the study. 
A comparison amino acid occurrence of all the sequences mentioned above is shown in 
table 8. A few interesting points can be noted such as  
• Arg, Cys and His residues are not observed at the beginning of soluble fusion-
tags. 
• Met if present is not found at any other position than the first one.  
• Presence of a His-tag at the N-terminus improves expression as observed from the 
fragments HisTM56 and TM56His. 
Amino
acid 
1 
Ubq 
2 
SUMO 
3  
MBP 
4    
ΔTrp 
5  
KSI 
 6 
PagP 
7 
TM67 
8          
His- 
TM56 
9   
TM56-
His 
10 
TM567
-His 
Natural 
occurrence 
(%) 
R 0 0 0 3 7 0 5 0 0 0 5.4 
D 1 4 1 4 1 1 0 1 1 1 5.4 
E 3 4 4 3 2 1 0 2 3 3 6.6 
H 0 0 0 1 0 0 2 10 2 2 2.4 
K 4 5 6 3 1 2 2 3 3 3 6.1 
Charged  25.9 
C 0 0 0 0 2 0 0 0 1 1 1.7 
N 1 0 2 0 1 2 1 2 2 2 4.9 
Q 1 2 0 0 1 1 3 0 0 0 4.2 
S 1 2 0 2 3 3 1 1 2 2 8.4 
T 5 1 0 1 1 0 1 0 1 1 5.6 
Y 0 1 1 0 2 1 1 0 0 0 3.1 
Polar  27.9 
G 1 3 5 1 2 1 3 0 0 0 6.0 
A 1 1 1 1 1 3 1 2 2 2 6.9 
I 4 2 3 2 2 3 0 1 1 1 5.6 
L 2 2 3 6 0 1 3 3 4 4 9.3 
M 1 1 1 1 1 1 1 1 1 1 2.2 
F 1 0 1 1 0 4 1 2 2 2 4.0 
P 1 1 0 0 2 0 0 0 1 1 5.2 
W 0 0 1 0 0 1 0 0 1 1 1.2 
V 3 1 2 1 1 5 5 2 3 3 6.0 
Others  46.4 
Table 8. Comparison of the first few (30) N-terminal residues in commonly expressed 
soluble proteins, IBs and NPY4R fragments. Charged aminoacids are highlighted in red; 
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polar aminoacids in blue and the remaining are the hydrophobic aminoacids. The last 
column displays the frequency of each aminoacid occurrence within a protein sequence 
as observed in eukaryotes34.  
In this chapter we have also established a generic purification method, starting from 
GdmHCl-solubilized inclusion bodies. We note that the enzymatic cleavage must be 
improved, e.g. by fine-tuning the dialysis rate that competes with the enzymatic cleavage, 
varying the concentration of GdmHCl to have a good compromise of enzyme activity, 
determined by the concentration at which the precision protease folds with full activity 
and the point at which the enzymatic cleavage site becomes accessible to the refolded 
enzyme.  
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Chapter IV: Biophysical Characterization of the C-terminal NPY4R Fragments by 
NMR 
 
1. Abstract 
 
Structural characterization of membrane proteins is often dependent on the availability of 
sufficient amounts of purified protein and the type of membrane mimetic used. Until 
now, the best method for structure determination of TMPs has been X-ray 
crystallography, but not all TMPs (especially a few G-Protein Coupled Receptors - 
GPCRs) are amenable for structure elucidation by this method. Inherent characteristics of 
GPCRs such as their hydrophobic nature make the expression and purification difficult. 
Their flexibility, and the requirement for membrane-like environments to insure proper 
folding are limiting steps in structure determination. Also, NMR is more suitable to study 
dynamics, conformational equilibria and ligand interactions than X-ray crystallography.  
 
In the last 2-3 decades, solution NMR spectroscopy technique has evolved and 
diversified significantly from its applications for small molecules to biological 
macromolecules, and is widely used for structure determination of proteins, DNA and 
RNA. Nowadays, NMR is persistently being used even on molecules amenable to 
crystallography because of its tremendous advantages for functional investigations that 
include protein dynamics, conformational equilibria and ligand interactions. Application 
of NMR spectroscopy on TMPs is again challenging, and presents a very active field of 
research advancing with new methods. The main difficulties when using NMR on TMPs 
are large sizes of TMPs (taking into account the membrane environment), intrinsic 
dynamic properties and the low sensitivity of the technique.  
 
In this chapter, we discuss details of the NMR sample preparation of all the C-terminal 
NPY4R fragments and the related assignment strategies. I also discuss the usage of 
chemical shifts in transferring assignments onto larger fragments based on NOESY 
peaks. I conclude the chapter discussing possible reasons for the missing peaks and the 
peaks, which could not be assigned.  
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2. Introduction 
Solution NMR has been used for almost three decades to gain insights into the structural, 
conformational and interactive dynamics of TMPs in the presence of non-native 
membranes. Major developments on NMR instruments have taken place only in the last 
decade by the emergence of high-strength magnets, which improve the signal dispersion 
as well as the signal-noise ratio. These advancements helped scientists to transfer their 
expertise from small peptides to larger proteins. But the ability to replicate the same 
proficiency from even small TM peptides to small TMPs is until today though exciting 
and stimulating still challenging, arduous and costly with very few successful 
exceptions1-9. The main advantage of working with NMR over crystallography on TMPs 
is the diversity of environments that it can support: from native cell-membrane 
environment (in solid-state NMR) to different membrane mimetic environments such as 
micelles4,7, bicelles10, planar bilayers1, nanodiscs11, and organic solvents12 at different salt 
concentrations, temperatures, and pH values. These days, solution NMR technique is also 
being used to study proteins in intact cells by in-cell NMR13,14. Adding to the advantages 
of NMR spectroscopy over crystallography, NMR is an indispensible tool in drug 
screening for crucial proteins involved in diseases15,16. 
 
Recently, a number of novel NMR methods have been developed, and in combination 
with specialized labeling patterns for proteins have helped to gain assignments. Even 
though much advancement has been made, an NMR study of TMPs present in their 
native membranes is only possible if large amounts (mg) of the protein can be expressed 
and purified and this is true only in very few cases like bacteriorhodopsin. Solution NMR 
techniques applied today on TMPs involved basically the methodologies originally 
developed for large soluble proteins. These techniques were applied not only for TMP 
structure determination but also for dynamics, and interactions with partners17. There are 
very few reviews describing the techniques and practical challenges involved in the 
application of NMR spectroscopy of TMPs18-20. Despite the difficulties related to the 
preparation of protein samples and the interpretation of the complicated spectra that 
mostly are of poor quality, some studies focused on structural characterization of TMPs 
by NMR have been reported, providing useful knowledge in structure-based drug 
discovery21,22.  
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In the last decade, studies on several intact GPCRs have significantly advanced because 
of the technical developments witnessed in crystallizing the proteins especially in lipidic 
cubic phases (LCP)23-25. Many techniques are under development for crystallizing intact 
GPCRs and there still exist many challenges to study them at atomic resolution. We 
herein propose an alternative approach, in which folding and structure of these receptors 
is understood by using smaller segments, allowing the transfer of knowledge onto larger 
fragments, and ultimately onto the full intact protein. Working with smaller fragments 
will help in establishing and standardizing experimental procedures required to 
investigate more complicated systems, especially concerning protein-detergent or 
protein-lipid interactions. In most cases, production of intact GPCRs results in limited 
quantities of purified protein, which restricts the scope of screening diverse factors like 
membrane mimetics, ligand interactions, pH and temperature.  Thus, to overcome the 
above limitation, we decided to understand the behavior of various NPY4R fragments 
comprising 2-3 TM in size and transfer their knowledge onto larger or full-length 
proteins. 
 
In this chapter we report the NMR spectroscopic analysis of three C-terminal fragments 
of NPY4R  - TM67, TM56 and Cys-free TM567His mutant (including wild-type). 
Synthesis of all fragments was explained in detail in the previous chapter. NMR spectra 
acquisition and backbone analysis of TM67 was explained in the second chapter and 
published in the ChemBioChem journal26.  Here, we report the progress on the side chain 
assignment of TM67 and the backbone assignments of TM56 and the Cys-free variant of 
TM567 in presence of the detergent 1-palmitoyl-2-hydroxy-sn-glycero-3-[phospho-rac-
(1-glycerol)] (LPPG ). 
 
3. Materials and methods 
 
3.1  Chemicals 
All chemicals and solutions such as 15NH4Cl, 13C-D-Glucose, 13C-d7-D-Glucose and D2O 
were bought from Spectra Stable Isotopes (Andover, MA). 1-palmitoyl-2- hydroxy-sn-
glycero-3-[phospho-rac-(1-glycerol)] (LPPG) was purchased from Anatrace products 
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(Maumee, OH). Remaining chemicals were acquired from Sigma-Aldrich (Buchs, 
Switzerland). 
 
3.2.  Sample preparation and NMR Spectroscopy 
Biophysical characterization of TMPs or fragments of TMPs by solution NMR 
spectroscopy primarily involves production and purification of 15N labeled protein, which 
has been discussed in detail in the previous chapter. Purified fragments were 
reconstituted into different detergent micelles, allowing collection of 2D 1H-15N 
correlation NMR spectra, which were initially analyzed with respect to signal to noise, 
chemical shift dispersion, line-widths and the number of observed peaks. In our 
experience LPPG displays the most favorable properties for multi-TM GPCR fragments, 
resulting in spectra with better signal dispersion and more homogenous line-widths26-28. 
After identifying the most suitable detergent and the appropriate conditions for NMR 
measurements, a 3D NOESY-HSQC spectrum was recorded. Although also sequential 
NOEs are found in these spectra most peaks stem from intra-residual correlations helping 
to identify the nature of the amino acid. Subsequently, a uniformly labeled 15N, 13C and 
2H protein was expressed and purified. Sample was prepared using the optimized 
conditions, which allowed measuring a series of standard 2D and 3D triple-resonance 
experiments, followed by respective peak picking of correlated resonances. NMR 
experiments measured and required for protein backbone assignment are TROSY, 
HNCO, HNCACO, HNCA, HNCOCA, HNCACB and HNCOCACB. All triple-
resonance spectra relied on TROSY-type magnetization transfer except those required for 
side-chain assignment. With the help of strip matching, assignment of backbone 
resonances specific to the aminoacid sequence was achieved. Attempts for the 
identification of the missing assignments were made either by designing new constructs 
or by using alternative NMR experiments that involved shorter coherence transfer 
pathways, e.g. using the HNCA instead of the HNCACB. Once backbone assignment was 
at a point when no more correlations were found, a uniformly labeled 15N and 13C protein 
was expressed and purified, and spectra for side-chain assignments were recorded in 
deuterated d36-LPPG.  
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All NMR measurements were done at 320 K on a Bruker AV700 spectrometer equipped 
with a triple-resonance cryoprobe. NMR samples contained approximately 0.4 mM 
protein in 40 mM phosphate buffer, pH = 5.4 with 40 mM DTT and 5% LPPG as 
described in chapter 226. Proton chemical shifts were referenced using the water line at 
4.48 ppm at 320 K. 
 
3.3  Construct 1. ICL3-TM6-ECL3-TM7-Cter (TM67): 
 
The cloning, expression and backbone assignment of TM67 was explained in chapter 226. 
The final status of the backbone assignment is represented in figure 1 and figure 2 on the 
following page. Almost 80% of the sequence was assigned unambiguously and the 
missing assignments were mostly from TM6. We speculated that some weak signals 
(ambiguous assignments) of the missing residues may be attributed to Val repeats in the 
TM6 sequence (VNVVLVVMVVA), and missing peaks to extensive line broadening or 
peak overlap. To overcome some of these effects and to assign the missing residues, we 
attempted to design and purify shorter fragments eliminating the long N- and C-terminal 
tails. Although we were able to express the fusion constructs, their purification attempts 
were unsuccessful likely due to the more hydrophobic nature of these proteins. The 
biochemistry of the shorter versions of TM67 has been explained in the previous chapter. 
 
Since we had more than 80% backbone assignment of TM67, we progressed to obtain its 
side-chain assignment. For this purpose, we expressed and purified a uniformly labeled 
15N and 13C fusion protein and purified the TM67 fragment as described in the previous 
chapter26. Similarly, we prepared a 0.4 mM NMR sample solubilized in phosphate buffer 
containing 5% d36-LPPG detergent. This deuterated detergent helps in eliminating the 
intense residual signals emerging from the detergent that would otherwise obscure the C-
α and methyl resonances of aminoacid residues in the protein. 
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Figure 1: [15N,1H]-TROSY spectrum of TM67 with the assigned resonances. Numbers 
indicated on top of each resonance represents the corresponding aminoacid residue 
present in the full-length NPY4R.  
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Figure 2: Snakeplot of TM67 with the completed assignments in orange and the missing 
assignments in green. Most of the unassigned region falls in TM6.   
 
Unfortunately we noticed significant shifts of peak positions in [15N, 1H]-HSQC spectra, 
along with a large inhomogeneity in line-widths between spectra measured using 
deuterated and non-deuterated detergent and between deuterated and non-deuterated 
proteins (figure 3).  
 
All the NMR data acquisition parameters are summarized in table 1. All spectra were 
initially processed using the Bruker spectrometer software Topspin 2.1 and the chemical 
shift assignment was performed using the CARA software tool (Keller 2004).  
 
TM7 TM6 
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Figure 3: [15N, 1H]-TROSY spectra of TM67 when labeled differently. Spectrum (3a) 
was used for backbone assignment on a uniformly labeled 15N, 13C and 2H protein 
dissolved in protonated LPPG and spectrum (3b) was used for side-chain assignment on a 
uniformly labeled 15N and 13C protein dissolved in deuterated LPPG. 
 
TM67 
Experiment # of data points Spectral Width 
(ppm) 
Scans Remarks 
F3 F2 F1 F3 F2 F1 
[15N,1H]-HSQC  2048 256  18 33 32  
HNCO 2048 40 128 18 22 22 8  
HNCACO 2048 40 110 18 22 22 16  
HNCACB 2048 40 124 18 22 70 32  
HN(CO)CACB 2048 40 128 18 22 70 16  
HNCA 2048 40 92 18 22 20 32  
HN(CO)CA 2048 40 97 18 22 18 32  
15N-NOESY 2048 40 161 14 22 10 16 120ms mix 
[13C,1H]-HSQC  2048 256  13 70 32  
HCCH-TOCSY 2048 48 120 13 25 70 32  
13Cali-NOESY 2048 40 120 13 33 10 24 100ms mix 
 
Table 1: Spectroscopic details of NMR experiments used for measuring TM67 
 
Before starting the peak-picking from the 13C-edited spectra, Cα and Cβ chemical shifts 
generated from the backbone assignments were first adjusted using hCCH-TOCSY 
spectrum to correct for the isotope shifts. Chemical shifts were ultimately correlated to 
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the peak positions in [15N, 1H]- and [13C, 1H]-HSQC spectra. Side-chain resonance 
assignment of TM67 was accomplished using the following spectra: hCCH-TOCSY29,30 
in combination with [13C,1H]-HSQC and 13C-resolved aliphatic-NOESY31 experiments. 
The start of the side-chain assignment is by using the known Cα and Cβ chemical shifts 
obtained from the backbone assignments.  
 
 
Figure 4: [13C,1H]-HSQC spectrum of TM67. The area in the box corresponds to Cα 
chemical shifts and on enlarging (right) we see significant overlap of peaks. The blue 
crosses indicate the Cα peak positions from the backbone assignment. These assignments 
are initially made using the protein labeled with 15N, 13C and 2H. When transferred onto 
[13C,1H]-HSQC spectrum, some of the labels are distant to the resonances denoting a shift 
in peak positions with the new NMR sample or when labeled differently. Alternatively, 
the peaks may be attenuated by very efficient T2 relaxation. 
 
In CARA, by using 13C-hCCH-TOCSY spectrum in systemscope [rotate: D1-Y(1H):D2-
X(13C):D3-Z(13C)], we obtain the C-C-H chemical shifts, i.e. Hα and Hβ from Cα and Cβ 
respectively. This is followed by rotating to D1-Xaxis(H):D2-Zaxis(C):D3-Yaxis(C) for 
obtaining the H-C-C chemical shifts, i.e. Cγ, Cδ and Cε. Once the C-spin system is 
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assigned, using the procedure applied to obtain Hα and Hβ, protons of γ, δ, and ε are 
assigned. Assigned protons were further confirmed using the 15N-resolved NOESY data. 
More detailed explanation on side-chain assignment is explained exclusively on the 
CARA wiki page. Although, I have extensively used the 13C-resolved and 15N-resolved 
NOESY spectra data to overcome heavy overlap of peaks from the same type of 
aminoacid, we were not able to assign few of the isolated peaks observed in the [13C, 1H]-
HSQC spectra (figure 4). Probably, these unassigned peaks could be attributed to the 
unidentified residues in the backbone assignment. Due to high overlap of the peaks as 
observed from the [13C, 1H]-HSQC spectra, I have not attempted to progress assigning 
the proton chemical shifts of –CONH2 amides corresponding to Asn and Gln and the 
aromatic side-chains of Tyr, Trp and Phe. At this stage, I stopped working on the side-
chain assignment of TM67 and progressed onto different fragments. 
 
3.4  Construct 2: His-ECL2-TM56-ECL3 (HisTM56): 
 
The main idea behind designing this construct was to locate the resonances of unassigned 
residues of TM6 in TM67. Fortunately, HisTM56 construct could be directly expressed 
without the requirement of a fusion tag. Expression and purification procedures are 
explained in detail in the previous chapter. NMR sample conditions were following the 
procedures for optimization as explained for TM67. HisTM56 protein was solubilized in 
40 mM phosphate buffer consisting of 5% LPPG and 40 mM DTT. For backbone 
assignments, a uniformly labeled 15N, 13C and 2H protein was produced and purified. A 
[15N, 1H]-TROSY spectrum and triple-resonance spectra such as HNCO, HNCACO, 
HNCA, HNCOCA, HNCACB and HNCOCACB were recorded for backbone 
assignments. NMR acquisition parameters for each experiment were reported in a table 2. 
Spectra were processed within the Bruker Topspin software and converted to XEASY 
format to perform chemical shift assignment using the software CARA (Keller 2004). 
 
 
HisTM56 
 Data points Spectral width NS  
F3 F2 F1 F3 F2 F1 
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[15N,1H]-HSQC  2048 256  18 22 32  
HNCO 2048 40 110 18 22 20 8  
HN(CA)CO 2048 40 110 16 22 20 16  
HNCACB 2048 40 128 15 22 70 16  
HN(CO)CACB 2048 40 128 15 22 70 16  
HNCA 2048 40 128 16 22 30 16  
HN(CO)CA 2048 40 128 16 22 30 16  
15N-NOESY 2048 40 160 14 22 10 32 100ms mix 
 
Table 2: Spectroscopic details of NMR experiments used for measuring HisTM56 
 
Unfortunately, only 72 out of the expected 132 could be assigned (figure 5 & 6). 
Originally, HisTM56 construct comprises of 132 residues starting with a Met followed by 
an 8x His-tag and includes 4 Pro’s. We again attribute the missing assignments to either 
line broadening or peak overlap but unlike the previous construct we still find strong 
peaks that are not assigned.  
 
 
Figure 5: Snakeplot of HisTM56 with the assigned residues in orange and the unassigned 
in green. In total 72 residues were assigned out of the 132 residues present in HisTM56 
construct.       
     TM5   TM6 
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Figure 6: [15N,1H]-TROSY spectrum of HisTM56 with the assigned resonances. 
Numbers indicated on top of each resonance represents the corresponding aminoacid 
residue present in the full-length NPY4R.  
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The signal to noise ratio for a few triple resonance experiments was very low due to their 
measurements with lesser number of scans, causing difficulty in peak-picking close to the 
strong resonances observed in the [15N, 1H]-TROSY spectrum. This also resulted in 
identifying the succeeding or preceding residue matches difficult. A noteworthy 
observation in HisTM56 assignment was that the HNCACO spectrum allowed picking 
only half of the signals because of poor S/N. Thus we eliminated matching of carbonyl 
chemical shifts and relied only on Cα and Cβ chemical shifts. Although protein 
concentration was sufficient (0.4 mM), we believed that the presence of the His-tag on 
the N-terminus resulted in conformational exchange, possibly causing line-broadening 
effects leading to a decrease in signal to noise. 
 
Matching peak-picked resonances in TM67 for assignment was pretty straightforward 
unlike HisTM56. Difference between the two constructs apart from the NPY4R 
aminoacid sequence is the presence of a His-tag in TM56. Probably, this was causing 
conformational changes and thus line-broadening resulting in missing of few resonances 
in HisTM56. To verify the effect of the N-terminal His-tag, we designed a new construct 
with the same aminoacid sequence but with a His-tag at the C-terminus. This new 
construct was expressed in very low quantities in light water and gave absolutely no 
expression in deuterated water. Because of the limitations in expression of TM56His, we 
were only able to compare the [15N,1H]-TROSY spectrum with that of HisTM56 (figure 
7). On comparison, we observed a significant shift changes for few peaks, but most 
resonances remained the same. We noticed that TM56His resulted in better signal to 
noise ratio with more homogeneous line-widths compared to the prior construct 
HisTM56. The [15N,1H]-TROSY of TM56His displayed 105 out of the expected 130 
peaks in total. We were not able to go any further because of the lack of expression in 
deuterated water. 
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Figure 7: [15N,1H]-TROSY spectra of HisTM56 (left) and TM56His (right) solubilized in 
5% LPPG. 
 
3.5  Construct 3: ECL2-TM567-Cter-His without Cysteines (Cys-free TM567His): 
 
Before working on the Cys-free mutant of TM567, I have expressed, purified and 
analyzed the wild-type TM567His by NMR. Expression of this larger construct was 
possible directly without the need for a fusion tag. Wild-type TM567His had 4 Cys 
residues, which were later mutated to avoid aggregation due to disulfide bond formation. 
Significant yields of purified protein were obtained for both the wild-type and the Cys-
free variants of TM567 in light water, while only for the Cys-free form sufficient 
quantities could be obtained from the cultures grown in deuterated water. A 0.34 mM 
NMR sample (15N, 13C and 2H labeled) of wild-type was prepared and an attempt was 
made to analyze the assignment using the triple-resonance spectra.  
 
Some of the NMR experiments such as the [15N,1H]-TROSY, HNCO, HNCA and 
HNCOCA resulted in good spectra, other experiments such as HNCACO, HNCOCACB 
and HNCACB contained only a subset of the expected peaks. Initially, I tried to match 
7a 7b 
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resonances using just the HNCA and HNCOCA but the strip matching was too 
complicated since too many ambiguities remained. A little progress in assignment (30 out 
of 206 residues) was made with the wild-type TM567His construct. At the same time, the 
Cys-free mutant of TM567His was designed to facilitate recording of PREs. The Cys 
mutant could be obtained in sufficient quantities in deuterated water, and an NMR sample 
was prepared using the same procedures applied to the previous constructs. A [15N,1H]-
TROSY measurement on the mutant sample displayed peaks with better signal to noise 
and more homogenous line-widths when compared to the spectrum of wt-TM567(figure 
8).  
 
 
Figure 8: [15N,1H]-TROSY spectra of wt-TM567His (left) and Cys-free TM567His  
(right) solubilized in 5% LPPG. 
 
For the backbone assignment a [15N, 1H]-TROSY spectrum and triple-resonance spectra 
such as HNCO, HNCACO, HNCA, HNCOCA, HNCACB and HNCOCACB were 
recorded. NMR acquisition parameters for each experiment were reported in a table 3. 
8a 8b 
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Spectra were processed within the Bruker Topspin software and converted to XEASY 
format to perform chemical shift assignment using the software CARA (Keller 2004).  
 
Cys-free TM567His 
 Data points Spectral width NS  
F3 F2 F1 F3 F2 F1 
[15N,1H]-HSQC  2048 256  18 30 32  
HNCO 2048 40 100 18 22 16 16  
HNCACO 2048 40 90 16 22 18 32  
HNCACB 2048 40 128 16 22 69 32  
HN(CO)CACB 2048 40 140 18 22 69 16  
HNCA 2048 40 90 18 22 30 32  
HN(CO)CA 2048 40 90 18 22 30 32  
15N-NOESY 2048 44 140 14 22 10 24 100ms mix  
 
Table 3: Spectroscopic details of NMR experiments used for measuring Cys-free 
TM567His. 
 
A procedure for backbone assignments was followed as described for TM67. All triple 
resonance spectra gave reasonable correlations. Around 120 aminoacids were assigned 
out of a total of 206 in the Cys-free TM567His construct (figure 9 & 10). Most 
assignments stem from resonances from the soluble loops and the termini. Almost the 
complete N- and C-termini have been assigned. A significant region in TM7 and a small 
stretch in TM6 are also assigned. None of the residues from the TM5 have been assigned. 
Apart from the assigned resonances, there exist many unassigned strong peaks in the 
[15N,1H]-TROSY spectrum (figure 9). These unassigned strong resonances show 
correlations in triple resonance spectra, but could not be assigned because no confident 
succeeding or preceding matches were found. 
 
 133 
 
Figure 9: [15N,1H]-TROSY spectrum of Cys-free TM567His with annotated assignments. 
Numbers indicated on top of each resonance correspond to numbering in full-length 
NPY4R. 
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Figure 10: Snakeplot of Cys-free TM567His with the assigned residues in orange and the 
unassigned in green. In total 110 residues were assigned out of the 206 residues present in 
the construct.       
 
Finding matches to the unassigned peaks was complicated both for the remaining strong 
and weak peaks. In a few instances, matches for these peaks were found with the already 
assigned peaks. In few cases, isolated strong resonances were assigned by comparing 
their 15N, 1H chemical shifts and 15N-NOESY correlations with the assigned peaks in 
spectra’s of TM67 and HisTM56. One another strategy where assignments were 
identified to the unassigned strong peaks was by finding its succeeding or preceding 
partner on matching all strips in stripscope and identifying the labels that were either not 
picked or picked wrongly.   
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The central region of [15N,1H]-spectrum shows poor signal dispersion and the peak 
picking process in this region was performed based on the HNCO correlations. The 
HNCO experiment is very sensitive and sometimes we found more peaks than observed 
in the [15N,1H]-TROSY spectrum or recognized peak overlap. These extra peaks 
identified in the HNCO correlations don’t show any connections in the other triple-
resonance spectra.  
 
Similar to the previous cases, most of the missing assignments were due to absence of 
resonances as an effect of line-broadening or because of peak overlap. Peak overlap in 
the [15N,1H]- spectrum could in principle be overcome by observing the correlations 
obtained in HNCO or in any other triple-resonance spectrum, but the problem still 
persists for repetitive sequences of the same aminoacid type. This problem exists for 
example in TM6, which comprises repetitive Val stretches. In some cases, identifying 
Gly or Ala based on their unique chemical shifts provided anchor points for short 
additional stretches of assignments. 
 
All permutations and combinations were tried for assigning as many residues as possible 
with the use of 15N-NOESY as a verification tool.  
 
4. Discussion 
 
Apart from the quantities of TMPs required and the sensitivity of NMR technique, other 
factors that are critical for the biophysical analysis of TMPs by NMR are (1) the sample 
preparation and (2) signal overlap due to repetitive aminoacid residues present in the TM 
region and (3) absence of signals due to signal broadening due to the size of the protein-
detergent complex or due to conformational exchange. The former is due to the large size 
of a complex of polytopic TMP within detergents or lipids, together with the inherent 
mobility of TMP's helical bundle that causes fast relaxation and strong non-uniform 
broadening of NMR signals and, as a result, several problems with the assignment, 
spectra analysis, and identification of long-range interactions. The weight limitations can 
only be bypassed with the invention of new methods suitable for such large entities. 
Some recent technological developments in cell-free protein synthesis, specific selective 
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isotope labeling, systematic paramagnetic labeling and data analysis, have already made 
the elucidation of many polytopic α-helical TMP structures possible2,3,32, but many more 
are necessary. Generally, it is the tendency of α-helical TMPs to result in overlapping or 
crowded spectra due to the presence of repetitive hydrophobic aminoacids, which have 
analogous chemical shifts. Maybe in future development of high-field magnets could help 
in signal dispersion solving crowded spectra problem. 
 
Problems and their troubleshooting associated with membrane protein NMR can be 
interpreted using 3 major considerations: 
1. Labeling strategies: Selective labeling, segmental labeling and high deuteration 
2. Membrane mimetics: Conformational exchange processes, generating stabilized 
receptor mutants or optimizing detergents/lipids for suitable membrane 
environment. 
3. NMR experiments: Due to large size of TMPs, shorter T2’s don’t display 
necessary correlations in triple resonance spectra 
4.1  Labeling Strategies: To achieve almost complete backbone assignments of the 
fragments despite the presence of substantial signal overlap, aminoacid type selective 
labeling schemes might be helpful, but so far we did not do so because of sub-optimal 
yields of our fragments in deuterated water. In future, we aim to optimize the yields by 
taking advantage of cell-free expression system, which could help in assigning the 
missing residues because it allows selective labeling on amino acids. Selective labeling in 
cell-free expression is considerably cheaper allowing labeling of residues - AFGILV, 
which predominantly occur in the TM regions. 15N and 13C labeling strategies of the three 
specific aminoacids (ILV) primarily found in the transmembrane parts of TMPs can be 
achieved by using aminoacid precursors33. Although segmental labeling techniques are 
popular in case of soluble proteins and ideal for our divide and conquer approach, it is 
hardly implemented for TMPs. Other strategies for the labeling of TMPs have been 
developed for specific NMR experiments that help in backbone assignments34.  
4.2  Membrane mimetics and TMP sample preparation for NMR: I believe NMR 
sample preparation should be a standardized process as preparing samples with 
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differently labeled proteins always resulted in chemical shift changes. This needs 
chemical shift adaptations, which is a tedious process. Sometimes also inhomogeneous 
line-widths were observed, especially in the case of doubly labeled TM67 compared to 
the triply labeled sample. This might also be a result of different protein-detergent 
interactions, which is deuterated in the sample preparation of doubly labeled protein and 
protonated in the later case. I note here that deuterated compounds are slightly more 
hydrophobic when compared with the protonated counterparts. The result of 
inhomogeneity in line widths could be attributed to the conformational changes as a 
result of protein-detergent interactions within the micelle. This affects the overall protein 
stability, and the conformational exchange involving a few residues or regions leading to 
exchange broadening. Also the protein interactions with the deuterated detergent 
molecules could give rise to variations in TMP packing leading to chemical shift changes.  
4.3  NMR Experiments: The sensitivity of NMR experiments used for assignment varies 
a lot with few being very sensitive and much more insensitive. This puts burden on the 
biochemists demanding more quantities of TMPs for their analysis. In the previous 
chapter, I discussed the challenges in obtaining purified TMPs and also the effects in 
protein yields, which drastically vary when changing medium from light to heavy water. 
In all the triple-resonance experiments, HNCO is the most sensitive experiment whereas 
its counter experiment HN(CA)CO is only 1/10th in sensitivity to HNCO35. Thus in most 
cases we faced difficulties when using the peaks picked from HN(CA)CO for strip 
matching because many correlations are missing. In my experience the HN(CO)CACB is 
more sensitive than the HNCACB and there were issues with the Cα and Cβ peak picking 
from HNCACB spectra because few of the resonances were at the border of noise to pick 
them unambiguously. Lack of correlations from Cα were compensated by measuring the 
more sensitive HN(CO)CA and HNCA experiments. We understand that the sensitivity 
component could be compensated on using higher concentrations of proteins, which is a 
limitation for proteins expressed in deuterated water. An alternative is to increase the 
number of scans, which sometimes doesn’t show any improvement in signal to noise 
ratio. With 16 or 32 scans measurement time for each triple resonance experiment is 
around 1.5 or 3 days. Thus, significantly improving S/N by increasing the number of 
scans significantly is not really possible. From my experience, it is only worth to measure 
 138 
triple-resonance experiment with protein concentrations is at least 0.4 mM. Any 
concentration less than the mentioned would be a significant waste of resources.     
To conclude, we imagine that the studies on fragments of GPCRs containing TM 
domains may be beneficial because they support investigation of the recruiting and 
folding processes in the membranes, as explained in the two-stage model established by 
Popot and Engelman36,37. We believe that the C-terminal fragments of NPY4R do 
integrate into the detergent micelles, but their active form and stable state could only be 
obtained in presence of their partnering helices. Possibility that the residues were unable 
to be assigned by NMR could be attributed to the instability of shorter fragments with the 
need to search for their stabilizing partners (helices), which is resulting in conformational 
exchanges and thus line broadening, causing disappearance of resonances. 
From my experience, biochemistry of purifying various NPY4R fragments or TMPs was 
though challenging, it could definitely be overcome if the protein shows expression in the 
E.coli system. Biophysical analysis of the purified fragments or TMPs by NMR needs 
further optimization either in selecting better membrane mimetic or by increasing the 
sensitivity of NMR experiments. Protein expression, membrane mimetic optimization 
and NMR techniques improvement are all at the moment transforming or advancing and 
hope in the near future these will no more pose a challenge for structural biologists.  
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Chapter V: Incorporation of TM567His Fragment of NPY4R into Nanodiscs 
 
1. Abstract 
 
Generally, Transmembrane Proteins (TMPs) perform their biological functions being 
embedded in their natural membrane environment, which are phospholipid bilayers that 
in addition contain other proteins as well as glycolipids. The natural phospholipid 
bilayers are highly dynamic and heterogeneous in composition, limiting the study of 
TMPs by standard structural and biophysical techniques such as X-ray crystallography, 
NMR, EM and CD. To provide a chemically more defined environment, TMPs are 
extracted into detergents or lipids in vitro. In these artificial environments, TMPs face 
various challenges rendering them being functionally inactive, or existing in aggregated 
form, and in addition they may be less stably folded or and solubility issues might be 
introduced. Nevertheless, some of these environments can closely mimic properties of 
native environments. One such environment recently developed by Sligar and colleagues 
is very promising, and is the incorporation of TMPs into nanodiscs. Nanodiscs are made 
up of discoidal phospholipid bilayers (~ 10-12 nm large) that are stabilized by the 
packing of amphipathic helical membrane scaffold protein (MSP) around them. A TMP 
incorporated into nanodiscs is claimed to remain stable, soluble and mono-disperse with 
the ability to access both sides of the lipid bilayer. These properties render scientists to 
perform structural, biophysical and biochemical investigations in a more effective and 
simpler way.  
 
On the contrary, although nanodiscs mimic near-native environments, their large particle 
size complicates the spectral analysis of TMPs by solution NMR. Recently this 
disadvantage was tried to overcome by developing smaller nanodiscs, which are obtained 
by truncating the MSP. However, it needs to be demonstrated yet that these are well 
suited for multi-spanning TMPs. In this chapter, we describe the methodology for 
incorporating the 3-TM fragment TM567 of NPY4R into nanodiscs of smaller diameter.  
 
* [This project was done in collaboration with my fellow colleague Mr. Philipp Ansorge. 
PhD student in the same lab] 
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2. Introduction 
To completely understand the biology of a TMP, biochemical conclusions relating to 
their functional role (e.g. signal transduction) need to be substantiated by structural 
studies (e.g. NMR or X-ray studies). Although tremendous progress in understanding the 
function of TMPs has been achieved, limitations still exist due to the difficulties 
associated with obtaining sufficient yields and incorporating them into a membrane 
mimetic environment in a functional form. To choose the best membrane mimetic, first 
we should understand the nature of native cell membranes in which the TMPs naturally 
exist. Host cell membranes are made up of phospholipid bilayers in which lipid 
molecules not only play a role in forming physiological membranes enveloping cell 
contents and embedding TMPs but also act in modulating conformational rearrangements 
of these proteins1-4. For this reason, biochemical studies of TMPs in vitro should be 
carried out with lipid molecules that closely resemble phospholipids in bilayers of cell 
membranes.  
 
Phospholipids constitute the major components in cell membranes along with many other 
minor components (cholesterol, proteins and glycolipids). They are amphipathic with a 
hydrophilic head group (negatively charged phosphate) and a hydrophobic tail (long 
hydrocarbon chain). These lipids when placed in water, line up against each other and 
also on top of each other in antiparallel fashion, resulting in bilayers with the hydrophilic 
head groups exposed to water and the hydrophobic tails buried inside the bilayer (fig 1). 
 
Figure 1. Schematic representation of a lipid bilayer indicating the arrangement of 
phospholipid molecules. Each lipid molecule is made up of a hydrophilic head group and 
a hydrophobic tail. 
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Natural lipid bilayers in cell membranes are considered to be extremely porous or 
dynamic allowing the proteins to constantly move and interact with other species present 
in the same bilayer. These movements within lipidic membranes can lead to aggregation 
and sometimes give rise to false biological outcomes in vitro5. Also, a biophysical and 
structural study on TMPs present in dynamic lipid bilayers or liposomes is extremely 
difficult. To minimize these effects one has to come up with a design of membranes 
models identical with lipid bilayers, but which are more rigid and which keep the target 
TMP in a monodisperse form. Although many artificial membranes such as micelles, 
bicelles and artificial lipid bilayers (liposomes) could satisfy the property of native-like 
membrane environment, none of these satisfy the property of rigidity or inflexibility and 
monodispersity6,7 or the requirement in terms of maximum size of the system.  
 
A new technology has been developed that relies on reconstituting TMPs in discoidal-
shaped nanometer-sized soluble phosopholid bilayer membranes termed as nanodiscs or 
nanolipoprotein particles (NLPs). These assemblies mostly satisfy the ideal properties 
mentioned above for studying the TMPs in vitro and for structural analysis. Incorporating 
TMPs into nanodiscs was first pioneered by Sligar and colleagues by taking advantage of 
the amphipathic properties of apolipoprotein A-1 (ApoA-1), which acts as a belt/scaffold 
surrounding and stabilizing the lipid bilayer8,9. Thus ApoA-1 is also referred to as the 
membrane scaffolding protein (MSP)10,11 (fig 2). Based on the amphipathic property of 
MSPs, its hydrophobic surface interacts with the long fatty acyl side-chains of the lipid 
molecules within the bilayer, and the polar surface interacts with the aqueous 
environment making the whole nanodisc entity soluble. Formation of a nanodisc with or 
without an incorporation of a TMP is a spontaneous self-assembly process regulated by 
the nature of the MSP, and the speed at which detergent is removed. Once nanodiscs are 
formed, they are highly stable entities in solution in contrast to the highly dynamic 
micelles formed by detergents. Thus incorporating TMPs into nanodiscs adds tremendous 
advantages such as more closely mimicking the natural lipid bilayer environment, and the 
fact that they possibly incorporate proteins in monodisperse form.  
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Figure 2: Model of an empty Nanodisc. Basic constituents comprise the lipid molecules 
that form the bilayer, surrounded by 2 molecules of membrane scaffold protein.   
 
The size of the nanodisc can be adjusted by using different MSP variants to either 
accommodate either large multi-spanning TMPs or TMPs with very few multi-spanning 
domains12. The most commonly used MSP, ApoA-1, is made up of 10 α-helices. For 
generating smaller nanodiscs, some of the helices can be removed to generate shorter 
version MSPs resulting in smaller nanodiscs (fig 3). The shortest version of MSP 
produces discs of approximately 10 nm in diameter with a size estimated to be 150-
200kDa.  
 
 
Figure 3. Different versions of MSPs used in generating nanodiscs of different sizes13. 
 
Today, this technique has been validated for performing biochemical experiments in 
vitro, and is increasingly used to incorporate a variety of TMPs. Some of the TMPs that 
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were successfully incorporated into nanodiscs include VDAC-114, VDAC-215, CD4mut16, 
the voltage-sensing domain of the potassium channel KvAP17, rhodopsin18, 
bacteriorhodopsin19 and cytochrome P4509. In this chapter, we describe the process of 
incorporating a Cys-free mutant of the 3-helical transmembrane fragment TM567 of 
NPY4R, which is a G-protein Coupled Receptor (fig 4a and 4b). We highlight the 
importance of selecting the best ratios of MSP to lipid for forming an empty nanodisc, 
and then the best ratio of lipid to TM protein to MSP for incorporating TM567. TM567 is 
a 23.6kDa protein with 206 residues, and its expression and purification has been 
described in chapter 3.  All the experiments were carried out using one particular lipid 
POPC (1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine) obtained from Anatrace, 
which is also a component in natural lipid bilayers. 
 
 
Figure 4. Snake plot of the Y4 receptor with the TM567His region highlighted in yellow 
(4a) and its Cys-free mutant (4b) illustrating the modified Cys-residues in red. 
 
 
 
 
 
 
 
4a 
4b 
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3. Results 
Before setting-up experiments for incorporating the TMP into nanodiscs, we had studied 
the behavior of each constituent individually that is involved in the formation of 
nanodiscs.  
3.1  Membrane Scaffold Protein (MSP): We have received MSP constructs of different 
sizes from the group of Gerhard Wagner at Harvard. Since we are interested to 
incorporate a 3-TM fragment of NPY4R, we have selected a smaller version of MSP with 
a deletion of helix 5. We name this construct MSPΔH5. This construct in vector 
harboring a kanamycin resistant gene was transformed into E. coli BL21 (DE3) tuner 
strain for expression in LB. Cells were induced with 1mM IPTG at a cell density (OD600) 
of 0.7, allowing protein overexpression for 5 hrs at 37oC. Subsequently, cells were 
pelleted, resuspended in Tris buffer (40mM Tris pH 8.0, 300mM NaCl), lysed using 
French press and the supernatant was subjected to affinity purification. All purification 
steps were carried out at 4oC. Eluted fractions from affinity purification were pooled, 
subjected to dialysis to remove imidazole, and then TEV protease was added to remove 
the His-tag attached to MSPΔH5. After allowing for cleavage over 4 hrs, the reaction mix 
was again subjected to affinity purification and the purified MSPΔH5 without a His-tag 
was collected in the flow-through, which is analyzed by SDS-PAGE (Fig 5). 
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Figure 5. Purification of MSPΔH5 analyzed on SDS-PAGE. M-Marker, UI-Uninduced, 
I-Induced and the last lane is the purified MSPΔH5 after cleaving the His-tag with TEV 
protease.  
 
3.2  TM567 fragment solubilized in detergents: The purification method was explained 
in the previous chapter. In brief, the purified and lyophilized TM567 is solubilized in an 
organic solvent (HFIP) and then mixed with the detergent (DPC) buffer. Around 3-5% 
DPC (100-150mM) was used to solubilize 1-2mg of TM567. The final volume is made 
up to 1 ml with water, subjected to sonication for 15 mins and then lyophilized. 
Lyophilized products are solubilized in plain water (200µl), subjected to sonication again 
and the behavior of the fragment was analyzed on a semi-preparative SEC pre-
equilibrated in the same buffer containing DPC. To understand the effect of sonication, a 
similar experiment was set up without the sonication step, which led to the appearance of 
a monodisperse peak.  
 
Figure 6. Behavior of TM567, analyzed by SEC, when solubilized in DPC detergent and 
its effect with (6a) and without sonication (6b).  
 
From the SEC chromatograms we understood that the TM567 fragment exists in multiple 
states if sonicated but exists in monodisperse form if the sonication step is avoided. Thus 
for all subsequent experiments, we have eliminated the sonication step. 
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3.3 Detergents binding to Bio-beads observed by NMR: There are 2 types of 
detergents that have to be removed to allow for the formation of nanodiscs. The first 
detergent is sodium cholate, which is used for solubilizing lipids (POPC or DMPC) in 
water. The second one is DPC that was used for solubilizing the TMP. Although 
detergent removal can be done via dialysis, it is an extremely slow process and 
sometimes it requires more than a day for its complete removal. A good and efficient 
strategy is the use of Bio-beads, which trap the detergent molecules specifically and 
irreversibly, but not the lipid molecules. These beads are polystyrene-based available 
commercially as SM-2 (BioRad – used in our lab)9,20 or Amberlite XAD221. An 
experiment using NMR was done to observe the rate of detergent binding to the Bio-
beads (fig 7). After incubating the detergent (100 mM DPC) for 3 hrs in presence of Bio-
beads (0.3 mg/ml) at 4oC, 50% of the signals disappeared indicating that required the 
incubation time is around 5-6 hrs. Also tested was the quantity of Bio-beads required for 
absorbing a particular quantity of detergent. In the later experiments, we used 0.6 mg/ml 
of Bio-beads to reduce the incubation time to 2-3 hrs. 
 
Figure 7. NMR spectra of the detergent DPC in presence of Bio-beads at different time 
intervals.  Detergent was dissolved in Tris buffer and a 1H NMR spectrum was recorded 
on 500 MHz spectrometer before (0’) and after the addition of Bio-beads (60’, 180’ and 
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overnight incubation). Detergent peaks completely disappeared after incubating in Bio-
beads for overnight.  
 
3.4  Identifying the best MSP/lipid ratios for generating empty nanodiscs: The basic 
methodology involves solubilizing lipids (POPC) in presence of the detergent sodium 
cholate containing phosphate buffer (10 mM sod. phosphate pH 7.4 with 150 mM NaCl). 
This is followed by the addition of MSPΔH5, after which the mixture is gently mixed at 
4oC for 2 hrs. The starting concentrations used were 0.2 mM MSPΔH5, 10 mM lipids 
(MSP/Lipid ratio was 1:50). After gentle mixing for sufficient time (2 hrs.), optimized 
quantities (0.6 g/ml) of Bio-beads were added to remove the detergent under mild 
shaking for another 3-4 hrs. As the detergent binds to the Bio-beads, lipid bilayers are 
formed which later are enveloped with 2 molecules of MSP resulting in compact 
structures – the nanodiscs. After incubation, Bio-beads are allowed to settle at the bottom 
and the supernatant is filtered, concentrated and analyzed by SEC. The nature of the 
formed nanodiscs was analyzed using SEC. Based on the elution profiles, MSP/Lipid 
ratios are adjusted and followed by SEC. From various optimizations, we concluded that 
the MSP/Lipid ratio of 1:40 gave the best elution profile for the reconstitution of empty 
nanodiscs (fig 8).  
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Figure 8: SEC profiles for the optimization of MSP/Lipid ratio. At a ratio of 1:50 (red) 
nanodiscs of different sizes/types occur, at a ratio of 1:45 (blue) larger sized nanodiscs 
disappear and at a ratio at 1:40 (green) monodisperse nanodiscs are found in the solution.   
 
At this point it was also worthwhile for us to know how a pure MSP behaves on the SEC 
(fig 9), which would be useful for comparing the chromatograms obtained while 
optimizing reconstitution of nanodiscs. As expected, free MSP remains in aggregated 
form because of its amphipathic nature. This property has been observed when we loaded 
the purified MSPΔH5 on the SEC (fig 9). Free MSP runs as multimers on the SEC and 
we assume that the detergent present along with lipids can disrupt these multimers 
allowing for nanodisc reconstitution. Although different peaks are observed on SEC, they 
run as a single band on a reducing SDS-PAGE. 
 
Figure 9. SEC profile of free MSPΔH5. 
 
3.5  Reconstitution of the fragment TM567 into nanodiscs: The basic methodology is 
similar to the one followed for nanodisc reconstitution. Here we additionally mix lipids 
solubilized in cholate and MSP with TM567 solubilized in DPC. The concentrations 
involved were 0.2 mM TM567, 0.4 mM MSPΔH5 and 8 mM POPC lipids. The ratio of 
fragment/MSP/lipid was 1:2:40. We decreased the amount of lipids compared to amounts 
used for the reconstitution of the empty nanodiscs assuming that a small portion of lipids 
will be replaced by TM protein. After incubating the mixture for around 2 hrs at 4oC, 
Bio-beads (0.6mg/ml) were added and again further incubated for 2-3 hrs under gentle 
shaking. This step removes both DPC and sodium cholate. Subsequently, Bio-beads were 
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removed by sedimentation, allowing purification of empty and TM-loaded nanodiscs. 
Nanodiscs formed were again analyzed by SEC (fig 10).   
 
Figure 10. SEC profile of TM567 reconstitution into nanodiscs, and its analysis on SDS-
PAGE. RM – reaction mix after removing Bio-beads; A, B and C are the peaks as 
observed on the SEC and TM = TM567 as a control.  
 
Three peaks were observed on the SEC chromatogram and clearly the peak A was 
identical to the free MSPΔH5 as observed previously (fig 9), peak B shows the 
incorporated TM567 fragment as analyzed from SDS-PAGE and peak C, which is of low 
intensity, may be due to empty nanodiscs. This experiment indicates that we are capable 
of reconstituting TM567 into nanodiscs.  
 
Since MSP is without His-tag and TM567 with His-tag, we decided to separate the 
loaded nanodiscs by Ni-NTA affinity purification. We followed the same procedure for 
the formation of the nanodiscs and, after removing the Bio-beads, the reaction mix was 
loaded onto a Ni2+ column. Empty nanodiscs are collected in the flow-through and the 
loaded nanodiscs are bound to the column, and eluted using 200 mM imidazole (fig 11a). 
The fractions from the affinity purification are analyzed on SDS-PAGE (fig 11c). Elute 
fractions from the affinity purification were pooled, concentrated and injected into a 
semi-preparative SEC (fig 11b).  
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Figure 11. Ni2+-NTA purification for separating the loaded nanodiscs (11a) and the Ni2+ 
elute containing the TM567 fragment from the SEC (11b). All peaks from the Ni2+-NTA 
purification and SEC were analyzed using SDS-PAGE (11c). 
 
The SEC purification confirmed the presence of loaded nanodiscs in peak B, which is the 
major peak, but peaks A and C could also contain loaded nanodiscs with different forms 
or shapes as we have loaded the Ni2+-elute into the SEC. Peaks A and C are the minor 
peaks with less intensity and thus we could not see TM567 band on the SDS-PAGE. 
Although other peaks such as D, E and F are observed on the SEC, they didn’t show any 
protein bands on the SDS-PAGE. These peaks could be related to the buffer components 
such as imidazole. We assume that peak B or peak C should contain the TM567 
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incorporated nanodiscs in monodisperse form. In our next experiments, we tried to 
change the MSP to lipid ratio to obtain Peak C as the major peak keeping the TM 
fragment concentration constant. 
 
3.6 Identifying the right fragment/MSP/lipid ratios for obtaining monodisperse 
reconstitution of nanodiscs: In the previous experiment, we used the fragment/MSP/ 
lipid ratio as 1:2:40 and the major peak observed was B. To transfer the major peak to C, 
we assumed that it requires more quantities of MSP and lipids in the solution. Thus we 
increased the MSP content by 10 times and the lipid content by ~20 times to obtain a 
final ratio of 1:20:900. After removing Bio-beads, loaded nanodiscs were separated by 
affinity purification followed by SEC (fig 12a) and SDS-PAGE (fig 12b).   
 
Figure 12. SEC profile of TM567 loaded nanodiscs obtained after affinity purification 
(12a). These nanodiscs are reconstituted at Fragment/MSP/Lipid ratios of 1:20:900. 
Observed peaks on SEC are analyzed using SDS-PAGE (12b).  M-Marker; R-reaction 
mix obtained after removing Bio-beads; F- flow-through; W-wash; E-elute; (F, W, E – 
fractions from Ni2+ -NTA purification); A, B and C are all the corresponding fractions 
obtained from the SEC. 
 
On increasing MSP and lipid by 10 and 20 times respectively, we observed a shift of 
peak A to peak B, but our goal was to increase peak C at the expense of peak B. 
Although this was not the desired effect we concluded from this that a decrease in lipid 
concentration would serve our purpose. Thus, in our next experiment we decreased the 
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lipid concentration, keeping the fragment and MSP concentration same. The new 
fragment/MSP/lipid ratio tested was 1:20:700 following the same experimental 
procedures discussed above (fig 13).  
 
Figure 13. SEC profile of TM567-loaded nanodiscs obtained after affinity purification 
(13a). These nanodiscs are reconstituted at fragment/MSP/lipid ratios of 1:20:700. 
Observed peaks on SEC are analyzed using SDS-PAGE (13b).  M-Marker; R-reaction 
mix obtained after removing Bio-beads; F- flow-through; W-wash; E-elute; (F, W, E – 
fractions from Ni2+ -NTA purification); A, B and C are all the corresponding fractions 
obtained from the SEC. 
 
By decreasing the concentration of lipids, the equilibrium has shifted to peak A and thus 
peak A is the major peak. There is also an increase in the intensity of peak C, but it is still 
a minor peak. All 3 peaks A, B and C showed the reconstituted TM567 on SDS-PAGE 
analysis. From this experiment, it is clear that the change of lipid concentration should be 
in the opposite direction and thus in the following experiment MSP was increased 2 times 
and the lipid concentration was significantly increased compared to previous 
experiments. The new fragment/MSP/lipid ratios were 1:40:1600. Again the experimental 
procedure was similar to previous experiments. Fragment-incorporated nanodiscs were 
separated using affinity purification and their nature was examined on SEC (14a), 
followed by SDS-PAGE analysis (14b).  
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Figure 14. SEC profile of TM567 loaded nanodiscs obtained after affinity purification 
(14a). These nanodiscs are reconstituted at Fragment/MSP/Lipid ratios of 1:40:1600. 
Observed peaks on SEC are analyzed using SDS-PAGE (14b).  M-Marker; R-reaction 
mix obtained after removing Bio-beads; F- flow-through; W-wash; E-elute; (F, W, E – 
fractions from Ni2+ -NTA purification); A, B and C are all the corresponding fractions 
obtained from the SEC. 
 
With fragment/MSP/lipid ratios of 1:40:1600, the equilibrium definitely shifted to peak 
C, which was our desired direction, but still peak C is not the major component. One 
positive aspect is that peak A, likely due to large-sized, distorted nanodiscs, has 
completely disappeared. Probably the increase in peak C could be a shift in equilibrium 
from peak A.  At this stage, peaks B and C are sufficiently separated allowing for 
separate biophysical analysis by NMR or electron microscopy.  
 
Currently, scale-up of the previous experiment is under progress in our lab by 
collaborators.  
 
3.7  Affect of Bio-beads on MSP and TMPs: In almost all experiments discussed above, 
we observed a decrease in protein concentration after the incubation with Bio-beads 
required for detergent removal. We speculated about binding of TM567 and MSP to the 
Bio-beads, and realized that other groups working on nanodiscs faced the same problem 
as well. Grisshamer and colleagues had also speculated the same about the adsorption of 
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neurotensin receptor (NTS1) to Bio-beads on prolonged incubation times or on excess 
usage of Bio-beads22.  We monitored protein concentration by UV before and after the 
addition of nanodiscs. Protein concentration was measured at 280 nm before the addition 
of Bio-beads and was followed at regular intervals after Bio-bead addition (fig 15). 
 
Figure 15. UV absorption profile of protein binding to Bio-beads. Protein concentration 
was measured at 280 nm in the nanodisc-forming reaction mixture that contains TM567 
solubilized in DPC detergent, MSPΔH5, lipids dissolved in sodium cholate and Bio-
beads.  
 
It is very clear from the plot that the protein is absorbed by the Bio-beads. Concentration 
was reduced to more than half on incubating the reaction mix overnight. There was 20-
30% loss of protein in 2 hrs, which is the normal incubation time followed after the 
addition of Bio-beads. The amount of added Bio-beads was chosen to match the rate at 
which they completely absorb the detergent in 2 hrs, after which they were immediately 
separated from the reaction mix to avoid further loss of the protein. It should also be 
noted that the decrease in protein concentration could be attributed to binding of TM567 
or MSP independently to Bio-beads, which needs to be tested in future.  
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4. Discussion 
 
We have described the procedure for incorporating TM567 of NPY4R into nanodiscs. 
Although more optimization is required to obtain the monodisperse peak as the majority, 
fragment/MSP/lipid ratios of 1:40:1600 gave the best results so far. From all the 
experiments mentioned above, it still difficult to predict the right combination of protein-
to-lipid ratios in order to obtain monodisperse nanodiscs, or limit the formation of 
polydisperse liposome-like particles that can incorporate multimers of TMPs. After 
picking a particular combination, three common mandatory experiments are sequentially 
followed: affinity pull-down, size exclusion chromatography and SDS-PAGE analysis. 
On successful preparations using this protocol, biophysical analysis such dynamic light 
scattering can be done to reveal the hydrodynamic/Stokes radius pertaining to the size of 
the formed nanodiscs. These values could be very beneficial especially when setting-up 
NMR experiments for structural studies or for functional studies.  
 
Incorporating TMPs into nanodiscs is a relatively simple process but to obtain 
homogenous monodisperse molecules, the process is highly determined by the type and 
combination of MSP and lipid used. The right combination for reconstituting one TMP 
may not be ideal for other TMPs. Many factors are involved in determining the right 
combination such as the size of the TMP or specifics of inter-helical or TMP-lipid 
interactions. The suitability in picking the right lipid or lipid combinations and most 
importantly the mode in which detergents used for solubilizing lipids are removed 
(dialysis or by Bio-beads) could definitely affect the folding and the nature of integration 
by TMPs into nanodiscs. Additional obvious factors that exist when working in vitro are 
pH, temperature and the choice of buffers, which contain the reducing agents. A slight 
variation in one of them could be critical and will change the equilibrium to irregularly 
shaped or aggregated or polydisperse nanodiscs (fig 16).  
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Figure 16. Schematic representation of aggregated or polydisperse nanodiscs. One of the 
helices of TMP (red) corresponding to nanodisc A is packed with the helices of TMP 
(green) in nanodisc B and in another case helices of one TMP (yellow) are packed against 
2 helices of another TMP (red) within the same nanodisc resulting in complex form of an 
aggregated polydispersed nanodisc. 
 
There could be many combinations that could be expected with regards to the packing of 
nanodiscs, but in our experiments we mainly see 3 forms on SEC corresponding to peaks 
A, B and C. As discussed above, we speculate that peak C corresponds to the 
monodisperse form of nanodiscs (fig 17a). Unfortunately, even after many optimizations 
this doesn’t represent the majority of material. At a ratio of 1:40:1600 
(fragment/MSP/lipid), peak C on the SEC profile constitutes about 40% of the total 
nanodiscs, and light scattering or NMR experiments are required to show their 
monodisperse nature. The major peak at ratios 1:2:40, 1:20:900 and at 1:40:1600 is 
always peak B on the SEC profile. Although the nature of the material corresponding to 
this peak is not entirely clear most likely it corresponds to nanodiscs incorporating 1-2 
molecules of TM567. Alternatively, it may correspond to material in which helices from 
a single TMP are incorporated into different nanodiscs (fig 17b). Again this assumption 
has to be verified by experiment. At ratios of 1:20:700 where peak A was the main peak 
polydisperse nanodiscs packed in a complex manner are likely present (fig 17c). This 
peak was the major when the lipids were decreased from 900 mM to 700 mM while 
keeping TMP and MSP concentrations constant. This indicates that there is excess TMP 
and MSP with limited amounts of lipids required to form independent nanodiscs. This 
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results in recruiting more than one fragment in the nanodiscs and also co-sharing of 
helices between nanodiscs. Fragments existing in these nanodiscs are complicated to 
analyze, and the component ratios should be optimized to avoid forming these nanodiscs. 
At a given time, it’s difficult to obtain 100% monodisperse species, as nanodisc 
formation is a self-assembly process, driven by all possible combinations (TMP, MSP 
and lipid) at different concentrations (unless perfectly defined for each component). Thus 
we have deduced a way to manipulate a crucial factor (MSP or lipid concentration) in 
obtaining nanodiscs of a distinct type. 
 
 
Figure 17. Different combinations of nanodiscs that can be formed depending on the 
MSP to lipid ratio. Obviously, monodisperse (17a) forms are desired for biophysical 
analysis.  
 
Formed nanodiscs generally range from 9-15 nm in size and these could also be analyzed 
by electron microscopy, and many groups were previously successful in doing so. We 
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have also made a few attempts with empty nanodiscs but reasonable pictures were not 
obtained. Nevertheless we could use the expertise such as sample preparation, fixing and 
observing under EM for the incorporated nanodiscs. These electron micrographs can be 
of immense advantage before starting structural analysis by NMR or X-ray 
crystallography.  
 
As discussed in the previous chapter, NMR signals for many transmembrane residues 
were missing. This could be attributed to the dynamic nature of micelles resulting in 
signal broadening. We hope that this can be overcome when the TM fragment is 
incorporated in nanodiscs, which are more rigid in nature. Hopefully we will be able to 
record NMR spectra of TM567 reconstituted into nanodiscs soon, which could be 
exciting to compare them to fragments incorporated in micelles. 
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